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1.  HEAD AND NECK SQUAMOUS CELL CARCINOMA 
(HNSCC) 
 
1.1 Incidence of HNSCC 
Squamous cell carcinoma is by far the most frequently occurring malignant 
tumor in the head and neck. More than 95 % of HNSCC originate from the mucosal 
linings of the oral cavity, the pharynx, or the larynx. Risk factors for developing 
HNSCC are smoking and alcohol consumption, oncogenic human papillomavirus 
(HPV), but also tobacco or betel quid chewing. The estimated worldwide incidence of 
HNSCC in 2000 was more than 551,000 cases, and more than 217,000 deaths (1). 
HNSCC is responsible for 12 and 7 % of male and female cancers, respectively, in the 
developing world. For the developed countries these figures are 7 and 2 %, 
respectively (2). In the USA, more than 37,000 new HNSCC cases and 12,000 deaths 
are expected for 2003 (3). A rise in incidence rates of HNSCC among males is 
noticeable in Europe and the USA (2). For oral tongue cancer an increase in incidence 
for young adults is observed over the last decades (4-6). The total incidence of 
HNSCC in the Netherlands in 1998 was 2300 cases, according to the National Cancer 
Registry (7). HNSCC was on the sixth position among the most frequent invasive 
tumors for males, and for the male age group of 45-59 years it was the fourth most 
common cancer. In total, 735 patients died of HNSCC in the Netherlands (7). Over 
the last decade, the incidence of primary tumors of the pharynx and esophagus in the 
Netherlands has increased for both sexes, due to changes in tobacco and alcohol 
habits. In contrast, a 20 % reduction over the last decade was observed for the 
incidence of laryngeal cancer for males, due to the decrease in smoking habits in 
preceding decades (8).  
 
 
1.2 Staging, treatment, and prognosis of patients with HNSCC 
 
Classification and staging of HNSCC is performed according to the TNM 
system of the International Union Against Cancer (Union Internationale Contre le 
Cancer, UICC) (9). The TNM classification system describes the anatomical extent of 
the primary tumor, the status of the regional lymph nodes, and the presence or 
absence of distant metastases. Based on the TNM classification, overall clinical stages 
I to IV can be assessed. Stage groups I and II refer to small primary tumors without 
metastatic spread to regional lymph nodes in the neck or metastases at distant sites, 
whereas stages III and IV refer to patients with large primary tumors or the presence 
of lymph node metastases or metastases at distant sites. About one third of the 
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patients present with stage I and II disease, while two third of the patients present with 
disease stages III and IV (10).  
Initial therapy of HNSCC consists of surgery and/or radiotherapy. While early 
stages I and II are generally treated with surgery or radiotherapy alone and have a 
good prognosis, the more advanced stages III and IV are treated with combined 
surgery and radiotherapy and have a high failure rate, either locoregionally or at 
distant sites. Despite improvements in locoregional control for patients with advanced 
HNSCC, the overall survival rates of HNSCC patients have not improved 
significantly over the last 25 years. For oral cavity cancer, the relative 5 year survival 





Table 1. Trends in five-year relative survival rates (%) by year of 
diagnosis, USA, 1974-1998. 
 
Site Relative 5-year survival rate (%) 
 1974-76 1983-85 1992-98 
Larynx 66 67 64 
Oral 
Cavity 
53 53 56 
 
Source: Surveillance, Epidemiology, and End Results Program, 1973-
1999, Division of Cancer Control and Population Sciences, National 




Although few HNSCC patients present with distant metastases at initial 
diagnosis, the development of distant metastases after locoregional treatment in large 
series of patients ranges between 5-25 % (11-15). In subgroups of patients with 
advanced disease, the incidence of distant metastases can be as high as 50 % (12-16). 
The most important prognostic indicator for distant metastases of HNSCC is the 
extent of metastatic spread to lymph nodes in the neck. Factors like the localization, 
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size and number of lymph node metastases, but also the presence of extranodal spread 
influence the prognosis of HNSCC patients (16-23). 
The addition of chemotherapy, either given in adjuvant or neoadjuvant setting, 
to the primary treatment of HNSCC has resulted in improved quality of life and 
considerable advances in terms of organ preservation, but not in benefit in survival of 
these patients (24-29). An effective systemic adjuvant treatment is needed in order to 
improve survival rates in HNSCC patients. 
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2. Monoclonal Antibodies 
 
2.1 History 
Among novel therapeutic approaches is the use of monoclonal antibodies 
(MAbs). The concept of developing antibodies selectively reactive with tumor cells 
dates from the early 1900s, when Ehrlich envisioned “magic bullets”, able to 
recognize specific structures on tumor cells and, when loaded with toxic agents, able 
to kill these tumor cells. The introduction of the hybridoma technology by Kohler and 
Milstein in 1975 allowed the development of uniform MAbs specifically directed 
against virtually any particular cellular antigen (30). In this way, MAbs could be 
produced for a variety of applications: selective inhibition of proliferation of tumor 
cells by blocking growth factors or growth factor receptors, induction of apoptosis, 
recruitment of immunological effector functions such as antibody-dependent cellular 
cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and the 
selective delivery of cytotoxic payloads to tumor cells such as radionuclides and 
toxins. In recent years, several MAbs have been approved by the U.S. Food and Drug 
Administration (FDA) for therapeutic application, among which are two radiolabeled 
MAbs, 90Y-ibritumomab tiuxetan and 131I-tositumomab. The first MAb for treatment 
of cancer was approved by the FDA in 1997, and since then another seven have been 
approved predominantly for treatment of hematological malignancies. As depicted in 
Table 2, several other MAbs designed for treatment of cancer are in advanced stages 
of clinical investigation, that is, in phase III trials, among which there are two 
radiolabeled MAbs. Moreover, several MAbs have been approved by the FDA for 
other therapeutic applications, such as treatment of rheumatoid arthritis, 
cardiovasvular diseases, transplantation rejection, asthma, and infectious disease. 
 
 
2.2    Characteristics of monoclonal antibodies 
Several MAbs have been developed with different characteristics and clinical 
applications. The use of enzyme digestion and recombinant-DNA technology has 
made it possible to create different types of antibodies, antibody fragments and 
constructs, with molecular weights ranging from 20 to 150 kDa. To achieve optimal 
exposition of tumor tissue, MAbs should demonstrate a high and selective uptake in 
tumor tissue, and a long tumor residence time. In general, the uptake of MAbs in 
tumor tissue after intravenous administration ranges between 0.001 and 0.01 % of the 
injected dose per gram of tissue (%ID/g). Numerous factors influence tumor uptake of 
MAbs. Among these are type, size, antigen binding (affinity), and pharmacokinetics 
of the MAb, tumor vascularity and intratumoral pressure, and the level of expression 
of antigens in tumor tissue. 
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Table 2. Monoclonal antibodies for cancer therapy. 
A.  FDA approved MAbs 
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Glioma Phase III 
Mitomomab 
(BEC-2) 






SCLC Phase III 
Pemtumomab 
(Theragyn®) 
Antisoma, Roche murine 
IgG1 









Colorectal cancer Phase III 
Ovarex® Altarex murine 
IgG 











CD22 ADCC NHL Phase III 
Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; CDC, complement-dependent 
cyotoxicity; NHL, non-Hodgkin’s lymphoma; AML, acute myelocytic leukemia; CLL, chronic 
lymphocytic leukemia; EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth 
factor; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer. 
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The most commonly used MAbs for cancer therapy, radiolabeled MAbs 
included, are intact immunoglobulins (IgG), with a molecular weight of 
approximately 150 kDa. In humans, intact MAb molecules have a long residence time 
ranging from a few days to over three weeks, with in general longer residence times 
for human than for murine MAbs. This results in high MAb concentrations at tumor 
sites, with optimal tumor-to-nontumor ratios after 2-4 days. A disadvantage is that the 
slow blood clearance also results in significant exposure to normal organs, especially 
to the bone marrow. In addition, the large size of a MAb molecule might cause 
heterogeneous uptake in the tumor because of slow diffusion from the vasculature into 
and throughout the tumor. 
For many years, the use of MAb fragments has been considered a promising 
alternative. Fragments can be produced out of intact MAb molecules by enzymatic 
digestion. The resulting fragments are called F(ab’)2 (~100 kDa), F(ab’) (~50 kDa), or 
Fab (~40 kDa). By recombinant-DNA techniques even smaller fragments can be 
made, like single chain Fv (scFv, ~25 kDa). The use of MAb fragments in patients 
makes blood clearance faster. This results in higher tumor-to-nontumor ratios at 
earlier time points, and better and more homogeneous penetration into tumor masses. 
Moreover, fragments are lacking the Fc portion and, therefore, in general are less 
immunogenic. An important disadvantage of fragments in comparison to intact MAbs, 
however, is their lower absolute tumor uptake. The aforementioned characteristics in 
general make intact MAbs first choice for use in therapeutic applications and 
fragments first choice for use in diagnostic approaches. 
 Selection of high-affinity MAbs might seem desirable for optimal tumor 
targeting, but this does not always result in improved tumor uptake. High-affinity can 
impede the penetration of MAbs deeper into the tumor by their concentrated 
accumulation at the periphery of the tumor (31,32). An intermediate-affinity, 
therefore, MAb might be more suitable for optimal tumor targeting (33). In patients 
with soluble tumor antigen in blood, high affinity of the MAbs also can affect the 
pharmacokinetics and tumor targeting of the MAb (34,35).  
 
 
2.3    Immunogenicity of monoclonal antibodies 
Most MAbs available nowadays, have been generated by hybridoma 
technology and originally were murine. One of the major limitations of using murine 
MAbs (mMAbs) in patients is immunogenicity. Development of human-anti-mouse 
antibodies (HAMA) can lead to allergic reactions like anaphylaxis, and may lead to 
rapid clearance of the antibody (36,37). Repeated administrations of mMAbs for 
multiple treatment strategies, therefore, can be limited by the development of HAMA. 
Advances in DNA technology have allowed engineering of chimeric and humanized 
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MAbs. Chimeric MAbs (cMAbs) possess murine variable domains and human 
constant domains (38,39). If the immune reaction is directed against the variable 
domain of the mMAb, however, the construction of a cMAb will not avoid 
immunogenicity. Development of human-anti-chimeric antibodies (HACA) was 
indeed noted in a considerable number of patients after administration of cMAbs (40-
44). This problem can be circumvented by engineering of humanized MAbs (hMAbs), 
where the antigen recognition part of the murine MAb, the complementarity-
determining regions (CDR), are grafted onto a human immunoglobulin framework. 
Although formation of human-anti-human antibodies (HAHA) has been observed in 
studies with humanized MAbs, a decrease or even absence of immunogenicity in 
comparison with their murine counterparts is mostly noted (45-47). Fully human 
MAbs can be produced by the use of phage display libraries (48-50), or by the use of 
transgenic mice that contain human immunoglobulin gene repertoires (51-53). 
 
 
3. Radioimmunotherapy  
 
Radioimmunotherapy (RIT) is targeted radiotherapy using tumor-selective 
MAbs labeled with radionuclides. In this way, systemically administered radiation can 
be selectively delivered to tumor sites irrespective their location in the body while 
sparing normal tissues. An important advantage of RIT as compared to for example 
chemotherapy and other MAb-based therapeutic approaches is that radionuclides are 
able to kill adjacent tumor cells. As a consequence, not every tumor cell has to be 
targeted by MAbs but can be destroyed by a “cross-fire” effect. Another advantage of 
RIT is that for effectiveness no internalization of the MAb is required. Moreover, RIT 
is not affected by multidrug resistance, and not entirely dependent on the competence 
of the immune system. Finally, RIT can be tailored by imaging and dosimetric 
evaluations. The success of RIT depends on several factors, including the type of 
MAb used, the radionuclide coupled to the MAb, and the radiosensitivity of the tumor 
and normal tissues of the patient. 
 
 
3.1 Radionuclides for radioimmunotherapy 
Selection of the ideal radionuclide for RIT is based on size and features of the 
tumor and antibody, and the physical characteristics of the radionuclide (54,55).  
Important characteristics of the radionuclide in this regard are its decay properties, 
such as physical half-life and the types of radiation (α-, β-, and/or γ-), and the 
abundance of the emitted radiation.  
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For clinical RIT with intact MAbs, β-emitting radionuclides have been most 
extensively studied. The path-length or range of β-particles is several millimeters, ~10 
to 100 cell diameters, which means that also poorly accessible or antigen-negative 
tumor cells can be efficiently eradicated. Accompanying γ-emission can be of value, 
as its opens the possibility for imaging with a gamma camera during the RIT 
procedure. The physical half-life of a radionuclide, by preference, should be matching 
with the biological half-life of the MAb used. Besides that, also its chemical 
properties play a role, e.g. the mode of labeling needed and its fate after conjugate 
catabolism in vivo. Some radionuclides are rapidly released from the cell after 
internalization and catabolism, while others are retained intracellularly and, therefore, 
are called residualizing radionuclides. 
The most widely used radionuclide for RIT is 131I, which is available at low 
costs and easy to couple to MAbs. The low β-energy and particle range of up to 2 
mm, makes 131I particularly well suited for treatment of small tumors. The γ-emission 
of 131I, however, has a relative high energy of 364 keV, which limits its imaging 
quality for a gamma camera. The physical half-life of 131I is long (8 days). In RIT 
studies that use 131I as the therapeutic radionuclide, often an imaging study (also 
called pretherapy or scouting study) with a tracer dose of 131I is performed in advance 
to confirm tumor targeting and to predict dosimetry for the individual patient. 
Alternatively, 123I can be used as it has a more suitable γ-emission of 159 keV and a 
relative short half-life. A limitation for the use of 131I in RIT is the occurence of 
dehalogenation, which requires the blocking of the thyroid with potassium iodide to 
prevent uptake of 131I. Furthermore, during treatment extensive safety measures are 
required to limit the radiation dose to medical personnel, relatives, and environment 
caused by the accompanying γ-emission. Another therapeutic iodine isotope that has 
been used in clinical RIT is 125I. This radionuclide has a long physical half-life of 60 
days and produces low-energy Auger electrons. Due to the short path length of the 
electrons, less than a cell diameter, the radionuclide needs to be internalized in order 
to damage the nuclear DNA (56). 
Another β-emitting radionuclide which has been extensively used in clinical 
RIT studies is 90Y. The physical half-life of 90Y is 64 hours and its decay is purely by 
β-emission, and, therefore, requires less extensive safety measures. Its high β-energy 
and particle range of up to 12 mm makes 90Y particularly well suited for irradiation of 
larger tumors (57). Since 90Y is a residualizing label, i.e. has a long residence time in 
the tumor cell after internalization, it can deliver a relatively large radiation dose. In 
RIT trials, it is customary to use 111In as a γ-emitting surrogate for tracing the 
biodistribution of 90Y. 
Based on its physical properties, rhenium-186 (186Re) might be another 
suitable candidate for RIT. Almost all decay (91 %) is by therapeutic β-emission with 
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an ideal energy and path length (5 mm) for irradiation of small to medium size tumors 
(54,58,59). The physical half-life of 186Re is 3.7 days, which is compatible with the 
circulating half-life of intact MAbs. Moreover, 186Re has a modest (9 %) part of low-
energy γ-emission, which has excellent imaging properties, and can be used for 
confirmation of tumor targeting as well as for dosimetric purposes (60). For imaging 
in a scouting study prior to 186Re-RIT, the pure γ-emitter technetium-99m (99mTc) 
might even be a better candidate radionuclide as it has similar chemical properties as 
186Re and delivers less radiation burden to the patient. Therapy with 186Re requires 
acceptable radiation safety measures for both patients and medical personnel, and, 
therefore, outpatient-based treatment is a realistic option for its future application. 
Another rhenium isotope, 188Re, has a relative short half-life for RIT with an intact 
MAb, while its high β-energy and particle range (11 mm) are in favor for irradiation 














 (hours) (keV)1 (%)2 (keV) (%) (mm) 
       
Iodine-131 192 333 7 364 82 
  606 89   
2.0 
Yttrium-90 64 2284 100 --  12.0 
Rhenium-186 89 939 21 137 10 
  1077 71   
5.0 
Rhenium-188 17 1965 25 155 15 
  2120 71   
11.0 
Copper-67 62 390 57 93 16 
  482 22 185 49 
  575 20   
1.8 
Lutetium-177 161 176 12 113 7 
  384 9 208 11 
  497 79   
1.5 
 






Other suitable β-emitting radionuclides for RIT have been evaluated in few 
studies, among which are copper-67 (67Cu) and lutetium-177 (177Lu). Broad scale 
application of 67Cu is still hampered by the lack of procedures for consistent 
production at high specific activities (61). 177Lu is similar in chemistry to 90Y, but has 
a considerable shorter maximum particle range of 1.5 mm, making it more suitable for 
treatment of small tumors. 
RIT with α-emitting radionuclides might be suitable for eradication of 
circulating tumor cells and micrometastases or minimal residual disease, due to their 
short path-length of 1-10 cell diameters and high linear energy transfer. Bismuth-213 
(213Bi) with a physical half-life of 0.77 hours, bismuth-212 (212Bi) with a half-life of 1 
hour, astatine-211 (211At) with a physical half-life of 7.2 hours, and actinium-225 
(225Ac) with a physical half-life of 10 days have been indicated to be suitable for RIT 
(62-64). The short physical half-life of 212Bi, 213Bi and 211At, however, makes them 
less suitable for labeling of intact MAbs. 
 
 
3.2 Dosimetry of radioimmunotherapy 
 Dosimetry is the study of energy deposition of radiation in tissue. Knowledge 
of dosimetry in tumor and normal tissues after administration of a certain amount of 
radiolabeled MAb is essential for an appropriate planning of RIT. Moreover, 
dosimetry can provide a better understanding of tumor dose-response relationships 
and the assessment of the toxicity to normal tissues, like the bone marrow. Radiation 
absorbed dose estimates can either be measured directly using mini-
thermoluminescence dosimeters or calculated from biodistribution data obtained from 
biopsies or serial gamma camera imaging. Sinve decades many sophisticated models 
have been developed to address the problem of radiation dose calculation, such as the 
medical internal radiation dose (MIRD) formalism (65) and Monte Carlo techniques 
(66-68).  
 Most knowledge about tolerance and sensitivity of normal organs and tumors 
to radiation is derived from external beam irradiation studies. Tolerance doses to 
external beam irradiation for normal organs are well described and used in treatment 
planning (69). These data cannot be simply extrapolated to RIT, since there is a 
noticeable difference between both types of irradiation. External beam irradiation is 
delivered at a high-dose rate of usually 60 Gy/h, whereas RIT irradiation is delivered 
at low-dose rates, ranging from 0.1 to 0.2 Gy/h (70,71). Moreover, for RIT it has been 
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more difficult to establish a dose-response relationship than for conventional external 
beam irradiation, since the dose calculations for RIT are subject to more uncertainties, 
for example as a consequence of much more heterogeneous dose delivery (72). RIT, 
however, has shown to be able to generate clinical responses at relatively low tumor 
radiation dose estimates as compared to conventional external beam irradiation. On 
the other hand, the estimated tumor doses show large variation between individuals 
within a RIT study as well as between different RIT studies. Much effort has been put 
in the individualization of RIT dose planning, in order to increase its accuracy and to 
allow the identification of patients who will benefit from RIT, but also to identify 
patients who might experience toxicity to normal organs as a result of RIT. As 
indicated previously, for this purpose, often a pretherapy or scouting procedure has 
been explored, to obtain imaging and dosimetry data. This can be done with the same 
radionuclide as planned for RIT like in studies with 131I-labeled MAbs. In this way, 
patients with non-Hodgkin’s lymphoma have been treated with 131I-labeled 
tositumomab at individualized therapeutic doses determined by a dosimetric study 
prior to RIT (73). The pretherapy study can also be performed with either a different 
or a chemically related radionuclide (matched pair). This has been done in 90Y-RIT 
studies with 111In-labeled MAbs for treatment planning (74-78), but also in RIT with 
186Re and 188Re-labeled MAbs, where a scouting procedure with a 99mTc-labeled MAb 
was performed (79-81). From the pretherapy study, the radioactivity dose that results 
in a specific radiation absorbed dose to a particular organ or tumor can be estimated. 
Thus, the pretherapy study is a guide to the maximum amount of radioactivity that can 
be safely administered (82).  
The most important dose limiting toxicity of RIT is bone marrow suppression, 
with a radiation dose limit to the bone marrow of 150-200 cGy. Radiation doses 
higher than 200 cGy usually lead to unacceptable toxicity, in general 
thrombocytopenia and leucocytopenia. Prediction of bone marrow toxicity with 
dosimetry, therefore, might improve the safety and efficacy of clinical RIT. Serial 
blood sampling in order to calculate the cumulated radioactivity in blood, together 
with the contribution of the whole body to the bone marrow dose, is currently 
accepted as the most accurate way to perform bone marrow dosimetry (83,84). With 
this approach, it is assumed that the bone marrow radioactivity levels are proportional 
to the blood activity levels (85). Although several studies have shown a good 
correlation between the bone marrow absorbed dose and the development of 
myelotoxicity, the blood-based bone marrow absorbed dose is not always a better 
predictor of myelotoxicity as compared to, for example, the total administered 
radioactivity dose or the whole body absorbed dose (86-89). Other, non-invasive 
approaches for bone marrow dosimetry are based on serial gamma camera imaging, 
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where the bone marrow dose is calculated using quantification of the cumulated 
radioactivity in the sacral and/or lumar spine area. Although this method in general 
does not show a better correlation with the development of myelotoxicity, it might be 
of value for accurate dosimetry in patients with bone marrow targeting as a result of 
tumor involvement or aselective trapping of the radionuclide (90-92). 
 
 
3.3 Radioimmunotherapy and hematological malignancies 
In the last decade, RIT was proven to be particularly effective in the treatment 
of hematological malignancies, especially non-Hodgkin’s lymphomas (NHL). High 
complete response rates and increased duration of response have been observed in 
several phase II and III trials with radiolabeled anti-CD20 MAbs like 90Y-
ibritumomab tiuxetan (93) and 131I-tositumomab (73,76,94,95), in patients with NHL 
refractory to chemotherapy. The results of these studies, as well as of RIT studies with 
other MAbs in patients with hematogical malignancies, have been reviewed by 
several authors (96-100). The success of 90Y-ibritumomab tiuxetan and 131I-
tositumomab is thought to be due to several factors. Both conjugates make use of an 
anti-CD20 MAb, which demonstrates intrinsic activity consisting of ADCC, CDC, 
and apoptosis induction upon binding to the target cell. These MAbs are particularly 
effective because of the good accessibility of lymphoma tumors and cells for MAbs 
and the high and homogeneous expression of the CD20 target antigen. A next 
dimension was added by coupling radionuclides to these MAbs, because of the 
intrinsic radiosensitivity of lymphoma. Enhanced efficacy of radiolabeled MAbs for 
treatment of NHL was demonstrated by a recent randomized trial in which RIT using 
90Y-ibritumomab tiuxetan in combination with unlabeled cMAb rituximab (Zevalin™ 
protocol (101)) was compared with immunotherapy with cMAb rituximab alone 
(Rituxan™). Ibritumomab is the murine form from which chimeric rituximab has 
been constructed. In this trial the overall response rate was in favor of 90Y-
ibritumomab tiuxetan: 80 % versus 56 %, respectively (75). In addition, 90Y-
ibritumomab tiuxetan treatment resulted in an overall response rate of 74 % in 
rituximab-refractory patients (102). 
 
 
3.4 Radioimmunotherapy and solid tumors 
Most RIT studies in patients with solid tumors have been performed with a 
single intravenous administration of 131I- or 90Y-labeled MAbs in phase I and II trials. 
An overview of these studies is given in Table 4. Other routes of administration for 
RIT are intralesional, intrathecal, intra-arterial, intravesical, and intraperitoneal. These 
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techniques for locoregional treatment have been explored to a lesser extent than the 
intravenous route, and in most cases for selected tumor types. 
  Phase I and II studies, in general, have been conducted in a limited number of 
patients with recurrent or metastatic disease, after earlier standard treatment. These 
patients have been treated at escalating radiation dose steps, in order to determine the 
maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) organ. This is 
the primary goal of phase I trials, which implies that most patients are treated at 
suboptimal radiation dose levels. 
Most experience in RIT of solid tumors has been acquired from studies with 
gastrointestinal and colorectal cancer patients. These trials have been performed 
mainly with 131I-labeled MAbs, directed against TAG-72 and carcinoembryonic 
antigen (CEA) (34,105,107-110,115-117). Murine MAb CC49, directed against the 
TAG-72 antigen, has been evaluated when labeled with 131I, 177Lu, and 90Y. 
Immunogenicity of mMAb CC49 was relatively high, with development of HAMA in 
75 to 100 % of the patients. Clinical response rates ranged from 17 to 25 % 
(116,117,119,127). The anti-CEA mMAb NP-4, has shown high tumor-absorbed 
doses in studies with 131I-NP-4 F(ab’)2 and 131I-NP-4 IgG, up to 12.9 and 218 
cGy/mCi, and clinical responses in 46 and 34 % of the patients, respectively. 
Development of HAMA, however, was observed in 83 and 94 % of the patients 
(34,107). 188Re-mMAb MN-14, also directed against the CEA-antigen, elicited 
HAMA responses in 80 % of the patients, and no clinical responses were observed 
(121). Its humanized counterpart (hMAb MN-14) was evaluated when labeled with 
131I and demonstrated high tumor-absorbed doses of 24.2 ± 22.6 cGy/mCi, but no 
clinical reponses in patients with mostly advanced and large metastatic lesions (109). 
More encouraging results were observed for 131I-hMAb MN-14 in patients with small-
volume disease of metastatic colorectal cancer. A total of 30 patients were treated 
with 60 mCi/m2, and the overall response rate was 58 % in 19 evaluable patients 
(108). Another anti-CEA MAb, 186Re-NR-CO-02 F(ab’)2, showed tumor-absorbed 
doses up to 18.6 cGy/mCi, and responses in 39 % of the patients (120). 131I-mMAb 
A5B7 F(ab’)2 and intact IgG, also directed against the CEA antigen, showed low 
tumor-absorbed doses of 1.1 to 1.5 cGy/mCi, and clinical responses in 10-11 % of the 
patients (105). Further trials in patients with colorectal cancer have been carried out 
with MAbs directed against other antigens or pancarcinoma MAbs. 131I-mMAb A33 
showed development of HAMA in 100 % of the patients, and a 15 % responses rate 
(103). A mixed response in one patient and stabilization of disease in 12 out of 20 
evaluable patients were observed for 125I-mMAb A33 (128). Pancarcinoma antibodies 
mMAb NR-LU-10 and its chimeric counterpart NR-LU-13 showed HAMA and 
HACA development in 100 % and 75 % of the patients, respectively. No objective 
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clinical responses were seen in studies with 186Re-labeled mMAb NR-LU-10 and 
cMAb NR-LU-13 in patients with colorectal, lung, and ovarian cancer (42,120). 
In breast cancer patients, phase I RIT studies have been performed using 
MAbs directed against the breast mucine MUC-1, and the L6, Lewisy, and TAG-72 
antigens (77,104,119,122,123). High tumor doses up to 3700 cGy were achieved with 
131I-labeled cMAb L6, showing partial responses in 5 out of 10 patients treated (104). 
A study with 90Y-labeled mMAb BrE-3, directed against the MUC-1 antigen, showed 
tumor doses ranging from 39 to 167 cGy, and only observation of mixed responses 
(123). 
Patients with medullary thyroid carcinoma have been treated with anti-CEA 
MAbs NP-4 and MN-14 F(ab’)2, labeled with 131I (34,106,107). 131I-MN-14 F(ab’)2 
elicited HAMA responses in 53 % of the patients, but high tumor-absorbed doses of 
23.7 ± 27.5 cGy/mCi were observed, with stabilization of disease in 92 % of the 
patients (106). 90Y-cMAb T84.66, a pancarcinoma MAb, was also evaluated in 
patients with medullary thyroid carcinoma, and showed clinical responses in 23 % of 
the patients, and an immune reponse in 59 % of the patients (126). 
RIT in patients with ovarian cancer has been evaluated for intravenous and 
intraperitoneal administration. Studies on intravenous administration have shown 
some responses and stabilization of disease (112,120,129). No immunogenicity was 
observed in 3 patients treated with 131I-cMAb MOv-18, and a mean tumor-absorbed 
dose of 27 cGy/mCi was observed (112). A mean tumor-absorbed dose of 8.0 
cGy/mCi was found for 131I-mMAb MN-14, but immunogenicity was 100 % (111). 
186Re-mMAb NR-LU-10, a pancarcinoma MAb, was evaluated in patients with 
ovarian cancer and other malignancies, and showed no clinical responses and 100 % 





Table 4.   Results of clinical phase I/II radioimmunotherapy studies in patients with solid tumors. Conjugates contained β-emitting 





























(%) (mCi) (h) (cGy) (cGy/mCi) (cGy) (cGy/mCi) (%)  
I-131 A33 A33 murine CRC 100 30-94 b 3/20 MR 15 (103) 
I-131               
   
   
              
        
                
 
      
              
              
L6 L6 chimeric BRC 80 20-70 b 120-3700 5/10 PR 50 (104) 
I-131 CEA A5B7 F(ab’)2 CRC  82-148 38    1.5 ± 1.9 1/9 CR 11 (105) 
I-131 CEA MN-14 F(ab’)2 MTC 53 99-206 20 140-220  202-18268 23.7 ± 27.5 11/12 SD 92 (106) 
I-131 CEA NP-4 F(ab’)2 CRC, NSCLC,
PA, MTC 
83 68-254 15 55-450 511-6476 12.9 6/13 SD 46 (107) 
I-131 CEA MN-14 humanized CRC 60 b  180 ± 80 3.0 ± 1.3   3/19 PR 
8/19 MR 
58 (108) 
I-131 CEA MN-14 humanized GI, CRC  58-107   2.2 ± 2.4  24.2 ± 22.6 0/17 0 (109) 
I-131 CEA A5B7 murine CRC  26-74 29    1.1 ± 2.1 1/10 10 (105) 
I-131 CEA F023C5 murine CRC 50-80 b 0.54 185 (max) 1/10 CR
2/10 PR 
30 (110) 
I-131 CEA MN-14 murine OV 100 52-91 39 41-249 2.3 ± 0.7  8.0 ± 5.8 1/14 CR 
1/14 MR 
14 (111) 
I-131 CEA NP-4 murine CRC, NSCLC,
PA, MTC, BRC 




I-131 folate MOv-18 chimeric OV 0 75-82  187-243 2.8 ± 0.3 600-3800 27.5 ± 22 3/3 SD 100 (112) 
I-131 G250 G250 chimeric RE 8 82-150 69 (β) 1/8 SD
1/8 PR 
25 (113) 
I-131 G250 G250 murine RE 100 50-200 22 17/33 SD 52 (114) 
             
               
  
 
I-131              TAG-72 B72.3 chimeric CRC 58 34-67 2.3-5.9 4/12 SD 33 (115) 
I-131              
              
       
              
      
     
     
       
             
                
 
              
             
TAG-72 CC49 murine CRC 92 75 b 60-117 19-667 3/15 SD 20 (116) 
I-131 TAG-72 CC49 murine CRC 100 45-228 39 6/24 SD 25 (117) 
I-131 TAG-72 CC49 murine PR 100 75 b    208-1083 3.4 ± 3.1 10/14 71 c (118) 
Lu-177 TAG-72 CC49 murine CRC, NSCLC,
BRC 
100 16-45 67 (β) 4.0-5.0 2/9 SD 22 (119) 
Re-186 CEA NR-CO-02 F(ab’)2 NSCLC,
CRC, GI 
86 25-336 14  0.4 ± 0.1  0.4-18.6 1/31 PR 
11/31 SD 
39 (120) 
Re-186 pan NR-LU-10 murine NSCLC, CRC,
OV, RE 
100 45-260 26  0.6 ± 0.2  0.4-17.7 0/15 0 (120) 
Re-186 pan NR-LU-13 chimeric CRC, NSCLC,
BRC, GI 
75 42-129 35  1.3 ± 0.3  0.9-7.5 2/9 SD 22 (42) 
Re-188 CEA MN-14 murine CRC 80 21-161 8  3.6 ± 1.6  16.2 ± 10.7 0/11 0 (121) 
Y-90 Lewisy B3 murine GI, BRC,
NSCLC 
 
100 5-25 77 (β)  4.8 ± 1.6  7.7-65.1 6/24 SD 25 (122) 
Y-90 MUC-1 BrE-3 murine BRC 83 9-17 87 (β) 442-1887 39-167 3/6 MR 50 (123) 
Y-90 adeno m-170 murine PR 70 5-20 b 59-327 4.1-8.9 10-93 7/17 SD 41 c (124) 
Y-90 7E11-
C3.5 
CYT-356 murine PR 8 3-29 48    16.2 ± 21.9 0/10 0 (125) 
Y-90 pan T84.66 chimeric CRC, NSCLC,
MTC 
 
59 8-43 - 5.3-171 0.5-4.6 66-1670 8.7-52.2 3/22 SD
2/22 MR 
23 (126) 
Y-90 TAG-72 CC49 murine GI 75 17-38 47 (β) 50-120 2.5 180-3000 35 2/12 SD 17 (127) 
 
a Monoexponential blood half-life; in some cases only the T1/2 β is provided in the study, which is indicated (β). 
b Injected dose range in mCi/m2. c Only relief of pain was observed as clinical response. 
Abbreviations: BM, bone marrow; CRC, colorectal cancer; BRC, breast cancer; MTC, medullary thyroid cancer; NSCLC, non-small cell lung cancer; 
GI, gastrointestinal cancer; PA, pancreatic cancer; OV, ovarian cancer; RE, renal cancer; PR, prostate cancer; CEA, carcinoembryonic antigen; MUC-
1, breast mucin; CR, complete response; PR, partial response; SD, stable disease; MR, mixed or minor response; pan, pancarcinoma. 
  
General Introduction 
RIT was also evaluated in patients with prostate cancer with 131I-mMAb CC49, 90Y-
mMAb CYT-356, and 90Y-mMAb m-170. The only clinical responses observed comprised 
relief of pain, and development of HAMA occurred in 100 and 70 % of the patients for 
mMAb CC49 and m-170, respectively, and in 8% of the patients treated with mMAb CYT-
356 (118,124,125,130). Modest anti-tumor effects were observed for 131I-mMAb CC49, 
whengiven one week after administration of interferon-γ for upregulation of the TAG-72 
target antigen (130). No clinical responses were observed in prostate cancer patients treated 
with 90Y-mMAb CYT-356 (125).  
Phase I/II trials with murine and chimeric MAb G250 have been conducted in patients 
with renal cell carcinoma, leading to stabilization of disease in 17 of 33 patients treated with 
131I-mMAb G250 (114). Immunogenicity was 100 % for mMAb G250, whereas this was 
reduced to 8 % for its chimeric counterpart (113). Moreover, the blood half-life of cMAb 
G250 was considerably prolonged as compared to mMAb G250 (113). 
Besides intravenous also intraperitoneal RIT has been studied in ovarian cancer 
patients. This might be a more effective approach, especially in a small-volume or residual 
disease setting. Complete and partial responses, as well as prolonged survival were found in 
several intraperitoneal RIT studies with 131I, 90Y, 186Re and 177Lu-labeled MAbs (131-134). A 
multicentre, randomized, prospective phase III study of adjuvant therapy with anti MUC-1 
MAb Pemtumomab (HMFG1), labeled with 90Y, is currently conducted in patients with 
ovarian cancer. Evidence for a marked long-term survival benefit in patients receiving 
intraperitoneal 90Y-Pemtumomab when in remission after surgery and chemotherapy has been 
observed in earlier phase II trials (135,136). 
Intrathecal RIT has been given to patients with meningeal spread of primitive 
neurectodermal tumors, medulloblastoma, and leukemia. An advantage as compared to 
external beam irradiation, where the administered dose is limited by the radiation to the 
normal brain tissue, is the local application in the cerebrospinal fluid. For this group of 
patients, intrathecal RIT bypasses the problem of poor access to tumor antigens, which is the 
case for intravenously administered MAbs. Stabilization of disease was observed in 42 % of 
patients with leptomeningeal metastases of glioblastoma multiforme after treatment with 131I-
mMAb 81C6 (anti-tenascin) (137). 
Intralesional RIT has been mainly applied for the treatment of malignant gliomas, with 
MAbs directed against the tenascin antigen, labeled with 131I or 90Y. Since malignant gliomas 
tend to spread by local invasion rather than by metastases, intralesional RIT might be an 
interesting approach for this type of cancer. Several studies with intralesional RIT have shown 
delivery of substantially higher radiation doses of 300 and 600 Gy for 131I- and 90Y-labeled 
MAbs than with other routes of administration (138). Direct injection of 131I-mMAb 81C6 
into surgically created resection cavities in patients with primary malignant gliomas resulted 
in an average absorbed dose of 41 Gy to the surgical cavity (139).  Improved survival and 
high response rates have been observed in several studies with direct injection of radiolabeled 
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MAbs in patients with malignant gliomas (138-140). Intra-arterial and intravenous RIT has 
also been explored in patients with malignant gliomas with 125I-labeled anti-epidermal growth 
factor receptor MAb 425, showing improved survival in both groups (141,142). 
Intravesical RIT with 67Cu-MAb C595 and 125I-HMFG1, which are both directed 
against the MUC-1 antigen, has been explored for treatment of superficial urinary bladder 
cancer in biodistribution studies (143,144). To date, however, no clinical phase I RIT studies 
have been carried out. 
Despite the encouraging results of RIT in patients with hematogical malignancies, 
such results have not been achieved as yet for solid tumors. In the majority of studies 
summarized in Table 4, tumor-absorbed dose estimates have been at most 20 to 30 Gy, and 
most clinical responses observed are stabilization of disease and minor or mixed responses, 
often of a short duration. Bone marrow toxicity has been dose limiting in all studies. 
However, encouraging results have been observed in patients with small tumor lesions or 
patients with (minimal) residual disease (34,110,135,136,145) and the first phase III trials in 




4.  Strategies to improve radioimmunotherapy 
 
 The opportunities to enhance the therapeutic efficacy of RIT in solid tumors have to be 
based on improvement of the ratio between tumor and bone marrow absorbed dose. Strategies 
to increase the tumor-absorbed dose and/or to decrease bone marrow toxicity have been 
explored by various approaches. Factors influencing bone marrow toxicity are the radiation 
absorbed dose to the bone marrow, the baseline platelet or white blood cell count, the 
presence of bone or bone marrow metastases, and prior chemotherapy before RIT (87,146-
150). Strategies to circumvent bone marrow toxicity have been explored with the use of 
autologous blood or bone marrow progenitor cell transplantation. These techniques include 
bone marrow transplantation and leucapheresis. Both have been successfully applied in RIT of 
patients with hematological malignancies, especially in patients with non-Hodgkin’s 
lymphoma. Increased complete response rates of longer duration and prolonged survival have 
been achieved with RIT in patients with non-Hodgkin’s lymphoma (94,95,151-155). In these 
studies higher radiation doses to tumor burden were delivered, while bone marrow toxicity 
was limited. Secondary dose limiting toxicities of normal organs were gastrointestinal and 
cardiopulmonary toxicity. RIT supported by autologous blood stem cell transplantation has 
been performed in patients with solid tumors, but only in a few studies. Table 5 summarizes 
results of phase I and II trials with autologous blood stem cell transplantation. Most studies 
have been conducted in patients with breast cancer using 131I- or 90Y-labeled MAbs (156-160), 
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but also in patients with colorectal (161,162), gastrointestinal (163), and medullary thyroid 
cancer (164). Substantially higher tumor-absorbed doses ranging from 10 to 70 Gy were 
achieved in these studies, leading to partial responses and stabilization of disease in a 
considerable number of patients. 
Another approach to increase the tumor to bone marrow ratio is pretargeted RIT. In 
this technique, the radionuclide is administered separately from the tumor-targeting MAb. The 
aim of pretargeted RIT is to obtain higher and more selective accumulation of radioactivity in 
tumor, and to reduce toxicity resulting from circulating radiation in blood. It is a multistep 
procedure, where at first a non-radiolabeled MAb that targets the tumor antigen, coupled to 
streptavidin or avidin, is administered. A so-called clearing agent is given to achieve complete 
removal of this first MAb from the circulation. Radiolabeled biotin, with an extremely strong 
affinity for streptavidin and avidin, is then administered. Several modification of this biotin-
streptavidin principle have been developed and have been reviewed recently (165). Evidence 
for higher tumor-absorbed doses and higher tumor to bone marrow ratios was observed in 
preclinical and clinical biodistribution studies with the biotin-streptavidin technique (166-
168). 
A different technique of pretargeted RIT involves the use of bispecific MAbs. These 
have mostly been modified with recombinant DNA techniques to allow targeting of two 
different antigens, one at the tumor site, and the other to a radiolabeled bivalent hapten. After 
the bispecific MAb has accumulated in the tumor, the radiolabeled bivalent hapten is 
administered. The latter is able to bind selectively to the second arms of two bispecific MAbs. 
This double binding at the tumor site is a more avid binding than the single binding with 
circulation bispecific MAb. Therefore, circulation bispecific MAb does not disturb tumor 
targeting with the bivalent hapten, and no clearance of the bispecific MAbs from the 
circulation is necessary with this variant of pretargeted RIT. This is an advantage as compared 
to RIT with the biotin-streptavidin technique. It simplifies the procedure, because a clearing 
step in pretargeted RIT requires careful dosing and timing of the clearing agent. Overdosing 
of the clearing agent, for example, may block the binding sites in the tumor and may thus 
reduce tumor targeting. Another disadvantage of the streptavidin-biotin pretargeted RIT is the 
presence of endogenous biotin and the development of human-anti-streptavidin responses, 
which can impede further administrations. Dosimetric analysis of pretargeted RIT with 
bispecific MAbs have shown evidence for high tumor-absorbed doses and high tumor to bone 

























          
         
(mCi/m2) (cGy) (cGy) (%)
I-131 L6 L6 BRC 150 85-141 11,200 1/3 SD 33 (156) 
I-131        
         
        
       
         
      





CRC 75 ` 393-1,327 4/14 SD 29 (161) 
















Y-90 mucin M170 BRC 20-34 133-205 4600 2 PR
1 SD
100 (158) 
Y-90 MUC-1 BrE-3 BRC 15-20 1,050-
1,680 
 
4/8 PR 50 (159) 





Abbreviations: BRC, breast cancer; CRC, colorectal cancer; GI, gastrointestinal cancer; MTC, medullary thyroid cancer; PR, partial 
response; CR, complete response; SD, stable disease; MR, mixed or minor response. 
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To date, few clinical RIT studies have been performed with these two 
pretargeting RIT strategies. Encouraging results have been observed in biotin-
streptavidin pretargeted RIT studies in patients with high-grade gliomas, where 
streptavidin conjugated anti-tenascin MAb BC4 was pretargeted for binding of 90Y-
labeled biotin. This resulted in tumor regression in 12/48 patients and prolonged 
survival in comparison with control patients (171,172). Murine MAb NR-LU-10 was 
evaluated in studies with patients with metastatic colon cancer (173,174). A five times 
higher radiation dose could be administered if pretargeted streptavidin-mMAb NR-
LU-10 was used for binding of 90Y-labeled biotin, resulting in tumor-absorbed dose of 
4000 - 6000 cGy (174). 
Evaluation of pretargeted RIT in NHL patients with 90Y-labeled biotin 
pretargeted by anti-CD20 cMAb C2B8 revealed higher tumor to whole body ratios 
(38:1) and complete responses in phase I and II studies (175,176). Clinical phase I and 
II studies of pretargeted RIT with bispecific MAbs have been performed, 
demonstrating antitumor effects in patients with medullary thyroid cancer and non-
small cell lung cancer (177-179). A chimeric bispecific MAb, composed of hMAb 
MN14 and mMAb 734, was evaluated in patients with CEA-expressing tumors, 
showing tumor doses ranging from 0.4 to 22.4 cGy/mCi (179). Bispecific MAb F6-
m734 and 131I-labeled bivalent hapten showed a tumor to bone marrow ratio of 29.6 ± 
35.3, as well as relief of pain and minor tumor responses in 26 patients with 
medullary thyroid cancer (177). In non-small lung cancer, bispecific anti-CEA MAb 
mediated targeting of an 131I-labeled bivalent hapten and resulted in partial responses 
in two patients and one stabilization of disease, with tumor doses ranging from 2.6 to 
32.2 cGy/mCi (178).  
Multiple administrations of antibodies or fractionated RIT can be performed to 
increase the tumor-absorbed dose, but is often hampered by the immunogenicity of 
MAbs. Development of chimeric and humanized MAbs have allowed multiple 
administration treatment regimens and higher total tumor-absorbed doses 
(104,180,181). Administration of immunosuppressive agents like cyclosporin A has 
also been explored to suppress the development of HAMA, but could not completely 
avoid a HAMA response and can lead to toxicity in patients (156,182,183). 
Another way to increase the tumor-absorbed dose is by combining RIT with 
external beam irradiation. This has been performed in patients with colorectal cancer 
with metastatic disease to the liver, where RIT was combined with external beam 
radiotherapy to the liver (184). Combined RIT and external beam radiotherapy has 
been proposed for HNSCC by Maraveyas et al., who reconstructed a theoretical 
phantom of the larynx to obtain dosimetric data. They were able to calculate dose-
absorbed fractions for different radionuclides coupled to mMAb HMFG1, and 
demonstrated an increased tumor to mucosa ratio if external beam radiotherapy was 
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combined with RIT (185). A disadvantage of the combined approach is that the 
synergistic effect can only be given to a limited area. Occult metastatic or minimal 
residual disease cannot be effectively treated in this way. 
 
 
5. Monoclonal antibodies for radioimmunotherapy of HNSCC 
 
In the past, at least 30 MAbs directed against HNSCC have been described in 
literature, as extensively reviewed by Börjesson et al.(186). These MAbs can be 
divided in three main categories. The first group of MAbs is predominantly reactive 
with squamous cell carcinoma and much less with other tumor types. A general 
restriction of this group of MAbs is their reactivity with normal squamous epithelia. A 
second group of MAbs, also known as pancarcinoma MAbs, are not only directed 
against HNSCC, but also against other tumor types. To this group belong e.g. MAbs 
directed against CEA, EGFR, and the epithelial cell adhesion molecule (EpCam). A 
general shortcoming of these MAbs is their heterogeneous binding pattern with 
HNSCC, and their reactivity with several normal tissues. Most recently, a third group 
of MAbs became available. These MAbs do not bind to tumor cells themselves but to 
stromal cells or components involved in angionesis. Their clinical development, 
however, is at its infancy. Also for this category of MAbs, cross-reactivity with 
normal tissues might form a limitation. 
Many of the MAbs described in literature are poorly characterized with respect 
to their reactivity profile, and only a few have been administered to HNSCC patients 
for radioimmunoscintigraphy (RIS) and biodistribution assessment. What is more, 
none of these MAbs had been evaluated in clinical RIT studies at the time this PhD 
study was started. Despite promising preclinical results, it may appear at an early 
stage of clinical studies, that the Mabs studied are not suitable for RIT. It is also 
possible that a MAb, though not selective enough for RIT, holds promise for other 
therapeutic approaches. This latter seems to be the case with MAbs directed against 
EGFR. 
Extensive clinical RIS and biodistribution studies have been conducted with 
the mMAbs E48, U36 and BIWA 1, which are preferentially reactive with squamous 
cell carcinomas. MAb E48 is directed against a HNSCC-associated antigen belonging 
to the human Ly-6 antigen family (Ly-6D), while the epitope recognized by U36 has 
been mapped to the v6 domain of CD44 (187). At a later stage a second mMAb 
directed against CD44v6 became available called BIWA1. This mMAb binds to a 
different epitope than MAb U36, and with a 35-fold higher affinity (33). From clinical 
trials it was learned that mMAbs E48, U36, and BIWA1 are equally well suited for 
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detection of antigen-positive primary tumors and lymph node metastases of HNSCC, 
while biodistribution appeared similar (35,188,189). Extensive immunohistochemical 
analyses revealed selective reactivity of mMAb E48 with only normal and malignant 
squamous and transitional epithelia, while mMAbs U36 and BIWA 1 appeared also 
reactive with a variety of adenocarcinomas such as of the breast, colon, lungs, and 
stomach (190,191). This broader expression of the CD44v6 target antigen made 
mMAbs U36 and BIWA 1 first choice for further development to clinical RIT. The 
restricted expression pattern of the MAb E48-defined antigen Ly-6D, however, made 
this antigen the better marker for detection of circulating squamous cells in blood and 
bone marrow by reverse transcriptase polymerase chain reaction (RT-PCR) (192). 
CD44v6 appeared unsuitable for the latter approach due to its minor expression on a 
small subset of white blood cells. 
 
 
6. Selection of HNSCC patients for radioimmunotherapy 
 
The future role for RIT in treatment of HNSCC is thought to be a systemic 
adjuvant therapy. Therefore, identification of patients at risk for development of 
recurrent disease is of major importance. As stated earlier, the most important 
prognostic indicator for relapse of HNSCC, either locoregionally or at distant sites, is 
the presence of metastatic spread to lymph nodes in the neck (11-16,19). Among 
strategies used for other solid tumors to select patients at risk for development of 
recurrent disease is detection of micrometastatic cells in tissue samples such as 
surgical margins, regional lymph nodes, and bone marrow of patients (193,194). 
These micrometastatic cells can be detected by immunocytochemistry and molecular 
methods, notably polymerase chain reaction (PCR). Both techniques mainly have 
used tissue specific marker antigens such as cytokeratins, since these are abundantly 
expressed in the majority of epithelial tumors and homogeneously among the cells of 
these tumors. The clinical relevance has been illustrated especially for breast and 
colorectal cancer patients, in whom the presence of micrometastases in regional 
lymph nodes or in bone marrow correlates with poor prognosis (194-199). 
Detection of single tumor cells in bone marrow of HNSCC patients proved 
feasible with immunocytochemistry techniques using monoclonal antibodies directed 
against cytokeratins (200,201). The presence of these cells at the time of primary 
treatment appeared to indicate a higher risk for development of both local recurrences 
and distant metastases, as well as a shorter disease-free survival time (200,202,203). 
In lymph nodes of HNSCC patients with histologically tumor-negative lymph nodes, 
detection of micrometastatic cells using reverse transcriptase PCR (RT-PCR) on the 
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HNSCC-associated antigen E48 was associated with a distinctly poor cause-specific 
survival (204). This RT-PCR assay is also able to detect E48 RNA transcripts in 
blood and bone marrow, and showed evidence for the presence of micrometastatic 
cells in bone marrow in 35% of HNSCC patients, whereas non-cancer controls were 
all negative (192). The early detection of micrometastatic cells in bone marrow of 
HNSCC patients could contribute to a more accurate staging and identification of 
patients at risk for development of recurrent disease, particularly at distant sites. 
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7. Aim of the study 
 
The primary aim of this thesis was to investigate the feasibility of RIT with 
CD44v6 targeting MAbs in HNSCC patients. Besides that, the value of E48 RT-PCR 
on bone marrow aspirates for detection of micrometastatic cells was determined in 
order to identify patients at risk for development of recurrent HNSCC. In chapter 2, 
the results of a phase I radiation dose-escalation study with 186Re-cMAb U36 in 
HNSCC patients are described. Evaluation of a pretherapy study with 99mTc-cMAb 
U36 to predict the pharmacokinetics and myelotoxicity of 186Re-cMAb U36 RIT is 
reported in chapter 3. In order to explore further radiation dose escalation with 186Re-
cMAb U36, a study with autologous peripheral blood stem cell support was 
performed (chapter 4). To deal with the problem of immunogenicity, the humanized 
anti-CD44v6 MAb (hMAb BIWA 4) was evaluated in a biodistribution study with 
patients treated for primary HNSCC, of which the results are described in chapter 5. 
Finally, chapter 6 evaluates the suitability of the E48 RT-PCR assay for detection of 
micrometastatic cells in bone marrow aspirates of patients treated for primary 
HNSCC to select patients who are at risk of developing recurrent disease, particularly 
at distant sites. 
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 A phase I therapy study was conducted to determine the safety, maximum 
tolerated dose (MTD), pharmacokinetics, dosimetry, immunogenicity, and therapeutic 
potential of 186Re-labeled anti-CD44v6 chimeric monoclonal antibody U36 (cMAb 
U36) in patients with squamous cell carcinoma of the head and neck (HNSCC). The 
potential of a diagnostic study with 99mTc-cMAb U36 to predict the biodistribution of 
186Re-cMAb U36 was evaluated. 
Thirteen patients with recurrent or metastatic HNSCC were given 20 mCi (750 
MBq) 99mTc-labeled cMAb U36 (2 mg), followed one week later by a single dose of 
186Re-cMAb U36 (12 or 52 mg) in radiation dose escalating steps of 11, 27, and 41 
mCi/m2 (0.4, 1.0, and 1.5 GBq/m2). After each administration planar and SPECT 
images were obtained, and pharmacokinetics and development of human-anti-murine 
as well as anti-chimeric MAb responses were determined. Radiation absorbed doses 
to tumor, bone marrow, and organs were calculated. 
Administrations were well tolerated and excellent targeting of tumor lesions 
was seen in all patients. Dose limiting myelotoxicity (thrombocytopenia being most 
prominent) was the only toxicity observed, resulting in grade 4 myelotoxicity in two 
patients treated with 41 mCi/m2. The MTD was established at 27 mCi/m2, at which a 
transient grade 3 thrombocytopenia was seen in one patient. One patient showed 
stable disease for 6 mo after treatment at the MTD. The two patients with dose 
limiting myelotoxicity both showed a marked reduction in tumor size. The reduction 
was of short duration and, therefore, not considered an objective response. Tumor 
absorbed doses at MTD ranged from 3.0 to 18.1 Gy. Bone marrow doses ranged from 
20 to 112 cGy (mean: 1.9 ± 0.6 cGy/mCi or 51 ± 16 cGy/GBq) and correlated with 
platelet nadir (r = 0.8, P < 0.01). Pharmacokinetics varied between patients treated at 
the same dose level, and were accurately predicted by the diagnostic procedure. Five 
patients experienced a human-anti-chimeric antibody response, one of which was a 
human-anti-mouse antibody response. 
This study shows that 186Re-cMAb U36 can be safely administered, with dose-
limiting myelotoxicity at 41 mCi/m2. The use of cMAb U36 instead of its murine 
counterpart did no decrease the induction of human antibody responses. The 
availability of a 99mTc-labeled diagnostic study that can predict the pharmacokinetics 
of 186Re-cMAb U36 offers the possibility of using such a study for selection of a safe 
RIT dose. 
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Introduction 
 
 Squamous cell carcinoma of the head and neck (HNSCC) accounts for about 
5% of all newly diagnosed malignancies in North-Western Europe and the United 
States and the world wide incidence is 500,000 cases each year (1). Despite 
improvements in locoregional treatment modalities by surgery and radiotherapy for 
stages III and IV (70%), the high failure rate, either locally or at distant sites, is still 
high. An effective adjuvant systemic treatment is therefore needed to improve 
survival in this patient group. 
Among the novel approaches for selective treatment is the use of monoclonal 
antibodies (MAbs), conjugated with radionuclides. In the last decade, successful 
treatment with radioimmunotherapy (RIT) of hematological malignancies refractory 
to chemotherapy has been reported (2,3). However, for solid tumors such results have 
not yet been reached, although some studies have reported encouraging results with 
RIT of small metastatic lesions or as adjuvant treatment (4-8). To date, most clinical 
RIT studies have been performed with 131I. However, the low percentage (33%) of 
therapeutic ß-emission of 131I is suboptimal and its abundant γ-emission can cause 
unnecessary radiation burden for medical personnel and relatives, requiring extensive 
radiation safety measures. Rhenium-186 (186Re) is considered to be a better candidate, 
since almost all decay (91%) is by therapeutic ß-emission with an ideal energy for 
eradicating minimal residual disease: a maximum ß-energy of 1.07 MeV, and 90% of 
it delivered within 1.8 mm of a point source (9,10). The 9% γ-emission has excellent 
imaging properties for scintigraphy and dosimetry, and results in minimal radiation 
exposure of medical personnel. Its physical half-life of 3.7 days is considered 
compatible with the time needed for intact MAbs to achieve optimal tumor to non-
tumor ratios. To date, few studies have been performed with 186Re-labeled MAbs (11-
13). 
Murine MAb U36 (mMAb U36) has been extensively studied in patients with 
primary HNSCC and lymph node metastases undergoing surgery (14,15). Tumor 
uptake values up to 43% of the injected dose per kg (%ID/kg) tumor were reached, 
with a mean value of 20.4 %ID/kg two days after administration (14). 
Immunohistochemistry has shown reactivity with 99% of primary HNSCC and a 
homogenous reactivity pattern with 96% of these tumors, making the antibody an 
ideal candidate for targeting nearly all HNSCC (16). The antigen recognized by MAb 
U36 is the v6 domain of the CD44 glycoprotein (17). The development of human-
anti-mouse (HAMA) responses in patients treated with mMAb U36 could hamper its 
use for multiple treatment RIT, and a chimeric MAb U36 (cMAb U36) was therefore 
constructed. 
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This phase I radiation dose escalation trial with 186Re-labeled cMAb U36 was 
performed on HNSCC patients to determine safety, dose limiting toxicity, and 
maximum tolerated dose. The pharmacokinetics, biodistribution, immunogenicity, 
imaging, dosimetry, and therapeutic effects were studied to evaluate its potential for 
adjuvant treatment of HNSCC. The feasibility of a scouting study with 99mTc-labeled 




Materials and methods 
 
Patients eligibility 
Patients with clinical evidence of recurrent HNSCC, either locally or at distant 
sites, refractory to conventional therapy or for whom no curative options were 
available, were candidates. A histologically confirmed HNSCC in the past was 
required for inclusion. Other eligibility criteria were: age between 18-80 y, a 
Karnofsky performance status of at least 60, and a life expectancy of at least 3 mo. An 
interval of at least 6 wk from the last chemotherapy and/or radiotherapy was required, 
as well as good recovery after prior treatment. Patients were excluded if their white 
blood cell count was below 3,500/µL, platelets below 150,000/µL, serum creatinine 
concentration above 150 µmol/mL, or bilirubin level above 40 µmol/mL. Other 
exclusion criteria were pregnancy, administration of murine antibodies in the past, 
evidence of a life-threatening infection, allergic diathesis, or serious cardiac disease. 
The study was approved by the Institutional Review Board of the VU University 
Medical Center (Amsterdam, The Netherlands). All patients signed informed consent 




MAb U36 (Centocor B.V., Leiden, The Netherlands) was generated by 
immunizing BALB/c mice with viable cells of the HNSCC cell line UM-SCC-22B 
(18). The antigen recognized by MAb U36 is a 200 kDa glycoprotein located on the 
outer cell surface. Characterization of the target antigen by cDNA cloning and 
sequence analysis revealed that the antigen is identical to keratinocyte-specific CD44 
splice variant epican (17). By screening overlapping synthetic peptides the epitope 
appeared to be located in the v6 domain of CD44 (17). Expression of the v6-
containing CD44 variants has been observed in a variety of carcinomas, including 
head and neck, lung, skin, espohagus, and cervix, but also in adenocarcinomas of the 
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breast, colon, lung, and stomach (19,20). In patients with carcinoma of the breast and 
colon and with non-Hodgkin’s lymphoma, a correlation has been shown between an 
overexpression of CD44v6 and reduced survival (21-23). The CD44v6 overexpression 
is thought to confer metastatic potential to tumor cells (24). Screening of normal 
tissues revealed expression in skin keratinocytes, breast and prostate myoepithelium, 
and bronchial epithelium (18,20,25). 
In previous radioimmunoscintigraphy (RIS) studies, HAMA responses were 
observed in 37% of patients (15). Therefore, for reduction of immunogenicity, cMAb 
U36 was constructed, containing the murine-variable domains attached to the human 
γ1 heavy-chain and human κ light-chain constant regions by using recombinant DNA 
technology as described (26). 
 
Radiolabeling and quality controls 
All patients received both 99mTc-cMAb U36 and 186Re-cMAb U36. The final 
quality of each batch of radiolabeled cMAb U36 was tested (27). For coupling of 
99mTc and 186Re to cMAb U36 the same chelate S-benzoyl-mercaptoacetyltriglycine 
(MAG3) was used as described previously (27,28). Radionuclides as well as the 
chelate were obtained from Mallinckrodt Medical, Petten, The Netherlands. The mean 
specific activity of 186Re at the time of labeling was 358 ± 151 µCi/nmol (13.2 ± 5.6 
MBq/nmol). In short, after synthesis of 99mTc-MAG3 or 186Re-MAG3, an 
esterification with tetrafluorophenol (TFP) was performed. Subsequently, the ester 
was purified and conjugated to cMAb U36. Radiolabeled cMAb U36 was purified on 
a PD10 column with 0.9% NaCl as eluent for the 99mTc-cMAb U36 conjugates and 
0.9% NaCl with 5 mg/mL ascorbic acid (pH 5) for the 186Re-cMAb U36 conjugates. 
Finally, the conjugates were filter sterilized. The 186Re-MAG3:cMAb U36 ratio was 
always lower than 4. The radiochemical purity of the conjugates was more than 93% 
(mean, 97%), as assessed by high-performance liquid chromatography (HPLC), and 
thin-layer chromatography (TLC) of the final product. Each radiolabeled cMAb U36 
preparation was assayed for immunoreactivity by measuring binding to 0.1% 
paraformaldehyde fixed cells of the HNSCC cell line UM-SCC-11B as described 
before (27). The immunoreactive fraction of both 99mTc- and 186Re-cMAb U36, as 
determined by a modified Lineweaver Burk plot, ranged from 77 to 100% (mean: 
96%) for all preparations. 
 
 
Prestudy screening and radiological assessment 
The patients’ history and physical condition were examined, and routine 
laboratory analyses were performed, including serum electrolytes, hepatic enzymes, 
thyroid and renal function, and urine. Complete blood cell and platelet counts, an 
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electrocardiogram, and chest radiograph were obtained. CT or MRI scans were 
obtained as previously described (15). 
Tumor volume was assessed by an experienced radiologist drawing regions of 
interest (ROIs) on consecutive CT or MRI slices with the use of a VoxelQ system 
(Picker International Highlands Heights, OH), which enables 3-dimensional 
reconstruction and automated volume calculation. Volumes of tumor recurrences or 
metastases were determined in cubic centimeters and used for tumor dosimetry and 
evaluation of efficacy of RIT. Because of the use of a gantry tilt in some of the CT 
studies, 3-dimensional reconstruction and automatic volume calculation was not 
always possible. In these cases, the sum of individual ROI surfaces and slice 
thicknesses was used for tumor volume estimation, and corrected for the degree of 
gantry tilt. 
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Study design 
All patients underwent a scouting study prior to RIT with 2 mg of 99mTc-
cMAb U36 (20 mCi/750MBq) to evaluate whether such procedure could predict the 
biodistribution of cMAb U36. A complete pretreatment assessment was performed 
before this study and blood samples were taken for pharmacokinetic analyses. 
Irrespective of the outcome of the RIS study, RIT was given within one week in 
escalating dose steps of 186Re-cMAb U36. Two patients (patients no. 1 and no. 2) 
received 12 mg cMAb U36, labeled with 11 mCi/m2 of 186Re. All other patients 
received 52 mg cMAb U36, labeled with escalating radiation doses. The dose levels 
were 11, 27, 41 mCi/m2 (0.4, 1.0, 1.5 GBq/m2), and were planned to rise with 
escalating steps of 14 mCi/m2 (0.5 GBq/m2). Vital functions (blood pressure, pulse 
rate, breathing rate, and temperature) were assessed before administration; after 20, 




Patients were admitted for 21 h in a special treatment room at the Department 
of Nuclear Medicine. Thereafter, they stayed for an additional 3 days in a single 
room. Dose rates (in µSv/hr) were measured directly after administration, and after 21 
and 72 h at distances of 50 and 100 cm, with a gamma radiation dose rate counter 
(Berthold LB 123, Ortec, Oak Ridge, TN). The patients were discharged 4 days after 
administration of 186Re-cMAb U36, and the set of pretreatment laboratory analyses 
was repeated weekly for at least 6 wk. The severity of toxicities was graded according 
to the National Cancer Institute Common Toxicity Criteria. The maximum tolerated 
dose (MTD) was defined as the dose level at which a grade 4 hematological or grade 
3 nonhematological toxicity developed in not more than 1 out of 6 patients. A 
complete response was defined as disappearance of all measurable disease by physical 
examination or radiographic criteria for a duration of at least 4 wk. A partial response 
was defined as a reduction of at least 50% in the sum of the products of the 
perpendicular diameters of all index lesions for at least 4 wk and no new lesions. 
Stable disease was defined as a 50% reduction or a 25% or smaller increase in the sum 
of the perpendicular diameter products and no new lesions. This state had to persist 
for a minimum of 3 mo. Progression was defined as an unequivocal increase in size 




 The same acquisitions were made for RIS with 99mTc-cMAb U36 as for RIS 
with 186Re-cMAb U36. In the 99mTc-RIS procedure, simultaneously acquired planar 
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anterior and posterior whole-body scans were obtained within 1 h after administration 
of the radioimmunoconjugate and after 21 h. For the 186Re procedure, scans were 
obtained after 72 and 144 h and, if feasible, for patients up to 2 wk. For all 
scintigraphic studies, a large field-of-view gamma camera (Dual Head Genesys 
Imaging System, ADAC Laboratories, Milpitas, CA) equipped with low-energy high-
resolution parallel-hole collimators and connected to a computer system (Pegasys, 
ADAC Laboratories, Milpitas, CA) was used. Use of the same collimator for 99mTc-
cMAb U36 as for 186Re-cMAb U36 was expected to result in good image resolution. 
The low percentage of high-energy gamma photons of 186Re (0.05% > 600 KeV) was 
not expected to require the use of a medium-energy collimator, as was done in other 
studies (29,30). Camera quality-control measures were taken at each imaging time 
point. With the aliquot retained from the radioimmunoconjugate preparation for 
injection, a weighed dilution of the injected patient dose was prepared as standard and 
measured simultaneously during imaging on all whole-body scans. Lateral, anterior, 
and posterior planar images and SPECT images of the region of tumor recurrence, 
that is, the thorax or head and neck region, were acquired at 21 h for 99mTc-RIS and 
21, 72, and 144 h after administration in case of 186Re-RIS. Acquisition parameters for 
planar and SPECT imaging were as previously described (14). In short, studies were 
performed with 360 degrees rotation, 64 steps, and postfiltering with Hanning filter 
(cut-off at 1 cycle/cm). Imaging results were interpreted by an experienced examiner, 




 Blood samples were taken from the opposite antecubital vein at 5, 10, 30 min, 
and at 1, 2, 4, 16, and 21 h after injection of 99mTc- as well as 186Re-cMAb U36. For 
186Re-cMAb U36, additional samples were taken at 72 and 144 h after injection. 
Whole blood and plasma samples were counted in a multiwell gamma counter (1470 
Wizard, Wallac, Turku, Finland) and radioactivity levels were expressed as 
percentage of the injected dose per kg (%ID/kg). Corrections were made for 
background and decay; the %ID/kg was determined by comparison with an aliquot 
retained from the conjugate preparation for injection. For 186Re-cMAb U36, an area 
under the time-activity concentration curve (AUC) to infinity was calculated using a 
curve-fitting program (Multifit, Groningen, The Netherlands) to generate 
monoexponential or biexponential clearance curves. To compare the pharmacokinetic 
behavior of both radioimmunoconjugates for each individual patient, AUCs from 0 to 
25 h after injection were calculated. The biologic half-life was calculated as t1/2, or 
t1/2α and t1/2ß for monoexponential or biexponential clearance, respectively, of the 
radioimmunoconjugate, depending on its best fit. HPLC was performed on plasma 
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samples to assess the percentages of radiolabeled free cMAb U36 (retention time: 
15.9 ± 0.2 min) and complexed cMAb U36 (retention time: 11.1 ± 1.1 min), 




A biological whole-body half-life (t1/2 wb) was calculated using least square 
fitting of the curve for whole-body time versus %ID. Extrapolation was done from the 
latest time points to infinity. The conjugate view counting technique was used for 
quantification of activity in the organs, and the initial whole-body counts were 
regarded as representing 100% of the injected dose. On all whole-body scans, regions 
of interest (ROIs) were drawn around the following organs: liver, lungs, spleen, and 
left kidney. For dosimetry of the lungs, a smaller ROI was drawn in the right lung to 
reduce the contribution of scatter originating from the cardiac blood-pool and liver. 
Total lung counts were obtained by correction of the counts per pixel of the smaller 
ROI for the total lung size. A background ROI was drawn in the lower left quadrant 
of the abdomen, and 75% and 50% of the counts was used for background correction 
of activity in the spleen and kidney, respectively (31). For lung and liver, no 
background correction was performed. An effective attenuation factor was derived 
from phantom studies by Breitz et al., who obtained fractions of counts transmitted to 
examine the attenuation for 186Re (29). The background subtracted counts from each 
organ were multiplied by this attenuation factor. Correction for counting efficiency of 
the gamma camera was done using an imaged standard with 186Re. The %ID was 
calculated for each organ at each imaging time point, and the effective AUC for the 
whole-body as well as for all organs was used to obtain residence times in a 
spreadsheet software program (Lotus 1-2-3, release 5, Lotus Development 
Corporation, Cambridge, MA). Residence times were implemented in MIRDOSE 3 
software (Oak Ridge Associated Universities, Oak Ridge, TN), to obtain S values and 
the total absorbed radiation dose per injected dose (cGy/mCi and cGy/GBq) to organs 
and the whole-body. 
Using the whole blood time-activity concentration curve for 186Re-cMAb U36, 
AUCs to infinity were calculated for bone marrow dosimetry. Patient-specific bone 
marrow dosimetry was performed according to Shen et al. (32). This method also 
considers the contribution of other organs and the whole-body. The concentration of 
intact MAbs in bone marrow is regarded 0.2-0.4 times that in circulating blood, and 
this bone marrow-to-blood ratio was determined using the patients’ hematocrit and 
bone marrow extracellular fluid fraction (33). A comparable clearance from blood and 
bone marrow was assumed, as well as a uniform distribution throughout the bone 
marrow.  
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A ROI for the tumor was drawn on the anterior whole-body scan made at 72 h 
after injection and then copied to anterior scans acquired at other time points. Another 
ROI was drawn for tumor background correction on the contralateral side of the neck. 
The relative tumor-to-neck diameter, as assessed with CT or MRI, was used for 
background correction according to Buijs et al. (31). Background-subtracted counts 
were corrected for attenuation depending on tumor depth derived from CT or MRI 
results and the effective attenuation factor (29). Tumor volume was measured to 
obtain S values for tumor nodules in MIRDOSE 3 software. The tumor absorbed dose 
estimates were obtained after implementation of the residence times using MIRDOSE 
3 software. For each evaluable patient, the ratio of tumor absorbed dose to bone 
marrow was determined. 
 
 
Human anti-cMAb U36 response 
 To evaluate the immunogenicity of cMAb U36, a human-anti-chimeric 
antibody (anti-isotypic, HACA) assay was performed. To evaluate whether there were 
responses against the murine part (anti-idiotypic, HAMA), a second assay was 
included. Human antibody response was tested in patients’ sera before administration 
of 99mTc- and 186Re-cMAb U36, and 1 and 6 wk after the start of the RIT. For the 
detection of HAMA, an enzyme-linked immunosorbent assay (ELISA) with mMAb 
U36 was used as described previously (15). In short, ELISA plates were coated with 
goat polyclonal anti-mouse IgG, followed by mMAb U36 solution. Prediluted patient 
serum samples were added, and for detection, rabbit polyclonal anti-human IgG 
conjugated with horseradish peroxidase (HRP) followed by o-phenylenediamine was 
used. The sensitivity of the HAMA assay was at a titer of 50. A HAMA titer of 3 
times this limit (> 150) was arbitrarily considered positive. 
The concentration of HACA was measured by coating a microtitre plate 
(Costar, Europe Ltd, Badhoevedorp, The Netherlands) with cMAb U36 IgG, 2 µg per 
well, in phosphate buffered saline (PBS), pH 7.2, and incubating overnight at room 
temperature. After the contents were discarded, the plate was blocked with 200 µL 
assay buffer per well (1% volume in volume newborn calf serum [BioWhittaker, 
Verviers, Belgium] in PBS with 0.02% Tween 20 [Sigma, Zwijndrecht, The 
Netherlands]), by incubating at 37° C for 1 h. The wells were then washed with 200 
µL wash buffer per well (PBS with 0.05% Tween 20). Thereafter, 100-µL of standard 
dilutions of rabbit anti-human IgG (A0424 DAKO, Glostrup, Denmark) in assay 
buffer and diluted patients’ serum (1:10 in assay buffer) were pipetted into the wells 
and incubated on an orbital shaker at 400 rpm for 1 h at room temperature. The rabbit 
anti-human IgG was used to construct a calibration curve. The wells were washed, 
and after the addition of 100 µL biotinylated cMAb U36 in assay buffer (1 µg per 
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well), the plate was incubated as in the previous step. After washing, the wells were 
incubated with 100 µL (10 ng per well) poly-HRP-conjugated streptavidin (CLB, 
Amsterdam, the Netherlands) in assay buffer for 20 min and 400 rpm at room 
temperature. The wells were then washed, and HRP activity was determined by 
adding 100 µL tetramethylbenzidine substrate solution per well, (100 mg/L 
tetramethylbenzidine in 0.1 mol/L sodium acetate and citric acid buffer [pH 4.0]) and 
incubated for 30 min in the dark at room temperature. The reaction was stopped with 
50 µL 2N H2SO4 per well, and the absorption was measured at 450 nm in a 
microtiterplate reader. The sensitivity of the HACA assay was at a concentration of 
0.2 mg/L. The intra-assay coefficient of variation (CV), as calculated from duplicate 
measurements in serum samples with test results greater than the detection limit, was 
6.5%. A HACA test value three times this limit, > 0.6 mg/L, was arbitrarily 
considered positive. 
Statistical analysis 
All mean values reported represent arithmic means with corresponding SD. 
Associations between variables were calculated with SPSS 7.5 software (SPSS Inc., 
Chicago, IL) using Pearson correlation tests. Two-sided significance levels were 




Thirteen patients (ten men, three women; age range 47-68 y; mean age 57 y) 
entered this study. Their characteristics are shown in Table 1. 
 
 
Safety and non-hematological toxicity 
 All administrations of 99mTc- and 186Re-cMAb U36 were well tolerated by 
patients and no signs of acute adverse events were observed. No relevant changes 
occurred in physical parameters during the first few days after administration, and no 
changes in blood parameters indicated toxicity of organs such as the liver or kidneys. 
Although in some patients accumulation of radioactivity in feces was visible by 
scintigraphy, no symptoms of gastrointestinal radiation toxicity were observed. Two 
weeks after 186Re-cMAb U36 administration, bilateral erysipelas developed in the 
face of patient 2, and was effectively treated with antibiotics. Patient 5 died two days 
after administration of 186Re-cMAb U36, most likely because of cardiopulmonary 
insufficiency or a myocardial infarction. In this patient, scintigraphy 21 h after 
administration of 99mTc-cMAb U36 showed relatively high uptake in the lungs, but 
this was not observed on images obtained after 186Re-cMAb U36 injection. This 
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apparant difference was considered to be related to the difference in MAb doses used 
in RIS and RIT. No other signs indicating a possible relationship between antibody 
administration and death were noticed, but the possibility of a relationship could not 
be excluded. 
Mean radiation dose rates at 1 m distance from the patients treated at the 
highest dose level were 3.2 µSv/h directly after injection, and 1.6 µSv/h at discharge 3 
days after injection. These dose rates would result in cumulative doses far below the 
annual limit of 2 mSv considered acceptable for medical personnel and family 
members. 
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Table 1. Patient and Tumor Characteristics. 
 
Patient Sex Age Site of Disease Prior Treatment 
no.  (y)  Radiotherapy Chemotherapy 
1 M 53 oropharynx yes MTX 
2 F 54 posterior pharyngeal wall yes none 
3 M 54 oropharynx yes none 
4 M 47 oropharynx no none 
5 M 56 piriform sinus left and 
right parapharyngeal area 
yes Cis+5-FU 
6 M 66 larynx and cystic lesion 
neck (right side) 
yes Cis+Gem/ MTX 
7 F 56 oropharynx, both sides yes none 
8 M 58 hypopharynx yes none 
9 M 67 neck recurrence, left side yes none 
10 M 68 oropharynx, right axilla 
metastasis 
yes none 
11 M 52 larynx yes none 
12 M 52 floor of mouth/ submental 
recurrence 
yes Cis+Gem 
13 F 59 esophagus yes none 
 
Abbrevations: M, male; F, female; MTX, methotrexate; Cis, cisplatin; 5-FU, fluorouracil; Gem, 
gemcitabine. 
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(mCi/m2) (mCi) (cGy/mCi) (cGy)
1           11 13 1.3 46 230 0 3.4 1 2.3 0
2           
           
           
           
           
           
           
           
           
           
           
           
11 16 0.9 25* NA NA NA NA NA NA
3 11 19 1.2 30 200 0 6.1 0 5.2 0
4 11 19 1.3 20 285 0 5.7 0 4.1 0
5 27 43 0.8 73* NA NA NA NA NA NA
6 27 57 0.8 109 37 3 3.6 1 2.1 0
7 27 44 NA 91 206 0 5.3 0 4.5 0
8 27 46 1.4 77 97 1 4.7 0 3.7 0
9 27 46 1.1 110 190 0 7.6 0 6.2 0
10 27 48 1.1 100 126 0 4.9 0 3.4 0
11 41 80 1.0 104 118 0 4.3 0 3.2 0
12 41 59 0.3 107 24 4 0.6 4 0.1 4
13 41 58 1.1 112 22 4 2.3 2 1.8 1
           
 
Abbrevations: NA, not available; wbc, white blood cell count.*Patients 2 and 5 did not complete follow-up for evaluation of hematological toxicity and are therefore not 
included for analysis of correlation between the bone marrow dose and development of hematological toxicity.
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Hematological toxicity 
The bone marrow appeared to be the dose-limiting organ. Myelotoxicity consisted 
mainly of thrombocytopenia, with a nadir 4 wk after RIT. At the lowest dose level -11 
mCi/m2- no clinically relevant hematologic toxicity was seen, whereas at the next dose level -
27 mCi/m2- only mild toxicity was observed (Table 2). In one patient at this dose level 
(patient 6) grade 3 thrombocytopenia and grade 1 leucocytopenia developed, and the patient 
recovered from both conditions within 1 wk. He had been treated 14 mo before RIT with two 
courses of cisplatin and gemcitabine, and had received a weekly dose of 60 mg methotrexate 
for 20 wk 6 mo before RIT. Of three patients treated with 41 mCi/m2, grade 4 
thrombocytopenia developed in two. One of these two patients (patient 13), who had never 
been treated with chemotherapy, showed recovery within 1 wk from a grade 4 
thrombocytopenia and grade 2 leucocytopenia. The other patient (patient 12) had previously 
experienced myelotoxicity before as a result of 3 courses of cisplatin and gemcitabine, given 6 
mo before entry in the RIT study, but hematological parameters had recovered to baseline. In 
that patient, grade 4 thrombocytopenia and leucocytopenia developed 4 wk after 
administration of 186Re-cMAb U36, and he died from an opportunistic lung infection shortly 
thereafter. Autopsy confirmed bilateral bronchopneumonitis with signs of an adult respiratory 
distress syndrome resulting from pneumonia caused by a mixture of S. Pneumoniae, E. Coli, 
and P. Aeruginosa. Although the bone marrow was greatly aplastic, some erythropoietic 




Whole-body scans obtained directly after administration of 186Re-cMAb U36 showed 
mainly blood-pool activity, which was decreasing over time but clearly present up to 72 h 
after injection in most patients. Representative whole-body scans are shown in Figure 1. At 
later time intervals, a homogeneous distribution was observed in the lungs, liver, spleen, and 
kidneys, except for increased uptake at tumor sites. In general, no selective accumulation at 
nontumor sites was visible, except in feces and urinebladder. In one patient, a relatively high 
accumulation was seen in the liver at 21 h after injection. This patient (patient 2) also had a 
relative rapid clearance of 186Re-cMAb U36 from the blood. 
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Figure 1. Whole-body scans of patient 4 acquired 1 h after administration of 186Re-cMAb U36, and after 
21, 72, and 144 h and 2 wk. Immediately after injection, the most prominent activity is in blood-pool. This 
activity remains high up to 72 h after injection. Relative uptake of radioimmunoconjugate in tumor in the 
right oropharynx increases over time. Tumor becomes better delineated as background activity decreases. 
 
 
Scintigraphy after administration of 99mTc- and 186Re-cMAb U36 showed a similar 
biodistribution including comparable uptake at tumor sites in the head and neck (Figure 2). 
Planar and SPECT imaging at later time intervals with 186Re-cMAb U36 showed improved 
delineation of small lesions and distant metastases. These concerned mainly lung metastases, 
of which visualization was hampered by the presence of blood-pool activity, requiring 
imaging at later intervals (Figure 3). Because of the small size of some lung metastases, not 
all detected with CT could be detected with planar imaging or SPECT of the chest. Prolonged 
high blood-pool activity in one patient (patient 13) disturbed the visualization of a tumor in 
the distal esophagus, because the tumor was directly posterior to the heart. A palpable, 
cytologically proven, 2x4 cm metastasis in the right axilla of patient 10 was not detected by 
scintigraphy during RIT. High uptake in the lungs was seen in patient 5 on whole-body scans 
obtained at 21 h after administration of 99mTc-cMAb U36. Imaging at 21 h after 
administration of 186Re-cMAb U36 did not show this high uptake. Patient 7 showed increased 
uptake in a decubitus lesion on her left shoulder. 
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Figure 2. Comparison of planar imaging of head and neck region of patient 1 acquired 21 h after 
administration of 99mTc-cMAb U36 (left) and 186Re-cMAb U36 (right). Accumulation of radiolabeled 





       
 
Figure 3. CT scan and planar anterior gamma camera scan of patient 7 obtained 144 h after 
administration of 186Re-cMAb U36 show targeting of a lung metastasis located in upper lobe of left lung. 
Accumulation of 186Re-cMAb U36 is also visible on both sides of oropharynx, where recurrent tumor is 
present. 
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Pharmacokinetics 
HPLC analysis of the conjugates for injection showed a monomeric peak, with more 
than 97% of the radioactivity bound to cMAb U36. In plasma samples taken after 
administration of 186Re-cMAb U36, HPLC analysis identified monomeric radiolabeled cMAb 
U36 (retention time: 15.9 ± 0.2 min) and a second small peak corresponding to less than 5% 
of the total radioactivity, representing complexed cMAb U36 (retention time: 11.1 ± 1.1 min). 
Therefore, all radioactivity in plasma was assumed to be monomeric radiolabeled cMAb U36, 
and pharmacokinetic analysis was based on these data. For 186Re-cMAb U36, in most patients 
a biexponential whole-blood disappearance could be described with a mean rapid distribution-
phase half-life (t1/2α) of 7.2 ± 5.1 h, followed by a slower elimination phase half-life (t1/2ß) of 
80.0 ± 36.6 h. Accurate assessment of these parameters for 99mTc-cMAb U36 was hampered 
by the limited number of measurements at times later than 21 h after injection. The effective 
AUCs to infinity to be used for bone marrow dosimetry of 186Re-cMAb U36 ranged from 125 
to 666 mCi x h/L (4.6 to 24.6 GBq x h/L). Biological AUCs for both 99mTc- and 186Re-cMAb 
U36, as determined up to 25 h after injection, showed variability between patients but, if 
compared for individual patients, showed a strong correlation (r = 0.94, P < 0.01), as is 
demonstrated in Figure 4. 
 
 
Human anti-cMAb U36 response 
HACA and HAMA immune responses were evaluable for all patients except patient 5. 
Five of the twelve evaluable patients showed a HACA response (Table 3). In three of these 
patients elevated HACA levels were observed within 1 wk after the 99mTc-cMAb U36 study 
procedure, before the start of 186Re-cMAb U36 RIT. One of these patients (patient 6) already 
showed detectable HACA levels before cMAb U36 administration. He had never before been 
exposed to mMAbs or cMAbs in the past. In three patients with an immune response, the 
highest HACA levels were found 1 wk after the start of RIT. One of the patients with a 
HACA response also showed elevated HAMA titers, indicating that only in this patient 




Table 3. Human-anti-cMAb U36 Antibody Response* 
 




HAMA titer HACA  HAMA titer HACA  HAMA titer HACA  HAMA titer HACA  
(mg) (mg/L) (mg/L) (mg/L) (mg/L)
1     2+12 <50 <0.2 <50 1.50 <50 2.05 <50 0.33
2     2+12 <50 <0.2 <50 1.30 113 5.73 ND ND
3 2+52 <50 <0.2 <50 <0.2 52 <0.2 55 <0.2
4 2+52 ND ND <50 <0.2 <50 <0.2 110 <0.2
5 2+52 <50 <0.2 <50 <0.2 ND ND ND ND
6 2+52 <50 0.7 <50 1.21 87 5.29 133 2.46 
7        2+52 <50 <0.2 <50 <0.2 <50 <0.2 510 1.76 
8          
          
          
          
       
2+52 <50 <0.2 <50 <0.2 <50 <0.2 <50 <0.2
9 2+52 <50 <0.2 67 <0.2 <50 <0.2 119 <0.2
10 2+52 <50 <0.2 <50 <0.2 <50 <0.2 <50 <0.2
11 2+52 <50 <0.2 <50 <0.2 <50 <0.2 147 <0.2
12 2+52 <50 <0.2 <50 <0.2 136 1.88 94 1.32 
13          2+52 <50 <0.2 <50 <0.2 <50 <0.2 <50 <0.2
          
     
     
          
           
          




* HAMA titers and HACA levels were measured before administration of 2 mg of 99mTc-labeled cMAb U36 for RIS and within 1 wk when patients received 12 or 52 mg 
186Re-labeled cMAb U36 for RIT. After the start of RIT, HAMA and HACA responses were measured at 1 and 6 wk. Underlined values represent positive responses. 
  
 









absorbed dose*  
Tumor 
absorbed dose  
Response  Follow-up
(mCi) (cm3) (Gy) (cGy/mCi) (mo)
1 13 34 2.0 15.7 stable lung metastases 4 
2       
       
       
       
       
       
       
       
16 80 1.8 11.4 progression 1
3 19 37 4.1 21.4 progression 4
4 19 81 6.7 34.4 progression 3
5 43 40 3.0 6.9 na na
6 57 nd nd nd progression 5
7 44 32 nd nd stable lung metastases 3 
8 46 28 3.5 7.6 stable disease for 6 mo 8 
9 46 14 18.1 39.4 progression 4
10 48 74 4.5 9.2 progression 3
11 80 80 16.7 20.8 progression 6
12 59 135 8.3 14.2 reduction of tumor mass 1 
13 58 98 nd nd reduction of tumor mass 2 
       
 
Abbrevations: na, not available; nd, not done. * Ten patients were evaluable for tumor dosimetry. The site of origin of the tumors is indicated in Table 1. Only volumes of 
visualized tumor lesions are included, dosimetry of lung metastases was not possible.
  
























Figure 4. Relationship between the AUC (expressed as %ID x h) determined for 0-25 h after 
injection for individual patients, both for 99mTc-cMAb U36 (horizontal axis) and for 186Re-cMAb 
U36 (vertical axis). Although relatively large variations are seen between patients, 
pharmacokinetic behaviour of the two conjugates seems similar for individual patients 




Assuming a homogeneous distribution, absorbed dose to the whole-body could 
be estimated for twelve patients (Table 2). One patient (patient 7) was not able to 
complete the series of whole-body images, and planar serial regional imaging was 
done. The whole-body absorbed self-dose was 1.0 ± 0.2 cGy/mCi (27.0 ± 5.4 
cGy/GBq). The mean biological whole-body half-life was 344 ± 164 h. For liver, 
lungs, spleen, and kidneys, calculated absorbed dose estimates to organs were 4.9, 
7.4, 5.1 and 5.0 cGy/mCi (132.4, 200.0, 137.8, and 135.1 cGy/GBq), respectively. 
Bone marrow doses, determined from the whole-blood time-186Re activity 
concentration curve, ranged from 20 to 112 cGy. The mean radiation dose to the bone 
marrow was 1.9 ± 0.6 cGy/mCi (51.4 ± 16.2 cGy/GBq). The most frequently 
observed myelotoxicity, that is, the decrease in number of platelets, correlated with 
 72
Limited Blood Sampling in Pretherapy Study for Radioimmunotherapy  
the bone marrow dose (r = 0.8 [P < 0.01] for platelet nadir and r = 0.6 [P < 0.05] for 
the percentage decrease from baseline platelet counts) (Figure 5). A significant 
correlation was found between the bone marrow dose and the decrease of 
granulocytes (r = 0.7 [P < 0.05] for the percentage decrease, and r = 0.6 [P < 0.05] for 
the granulocytes nadir). No significant correlation was found for bone marrow dose 

































Figure 5. Relationship between bone marrow dose (cGy) derived from whole-blood time-activity 
concentration curve for 186Re-cMAb U36 and percentage decrease from baseline platelet count 
(correlation r = 0.6, P < 0.05). 
 
 
Tumor dosimetry was possible for ten patients (Table 4). The volumes of these 
lesions ranged from 14 to 135 cm3. The ROI method on whole-body scans revealed 
the highest tumor uptake values at 72 h after injection, with a mean uptake of 18.6 ± 
9.1 %ID/kg. The mean tumor absorbed dose was 18.0 ± 11.0 cGy/mCi (486.5 ± 297.3 
cGy/GBq), with tumor doses ranging from 3.0 to 18.1 Gy at the MTD. For the ten 
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patients evaluable for tumor dosimetry, the ratio between tumor absorbed dose and 
bone marrow absorbed dose was 11.2 ± 8.7. 
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Tumor response 
One patient (patient 8), treated at the dose level of 27 mCi/m2, had stable 
disease for 6 mo as assessed with CT. At the highest dose level -41 mCi/m2-, obvious 
tumor shrinkage was observed in two patients. A marked reduction in size of a tumor 
in the esophagus (patient 13) was observed 3 wk after administration of 186Re-cMAb 
U36 (Figure 6). This tumor partly compressed a stent placed in the esophagus, and 
after RIT a 60% decrease in tumor size was observed simultaneously with relaxation 
of the stent. Another patient (patient 11) showed a reduction in size of a bulky tumor 
recurrence located submentally and of a lymph node metastasis on the right side of the 
neck. These two antitumor effects were observed in the 41 mCi/m2 group and did not 
meet criteria for an objective response because of a short duration. In other patients, 
who experienced disease progression under previous treatment, RIT stabilized the 
growth of some of the lesions. These stabilizations did not meet the criteria for 
objective response and included small lung metastases (patients 1 and 7), that seemed 





     
 
 
Figure 6. CT scan (left) of patient 13 shows large tumor originating from esophagus compressing 
stent that was placed for palliation 12 mo before RIT. CT scan (right)  of same patient 3 wk after 
administration of 58 mCi (2.15 GBq) 186Re-labeled cMAb U36. Sixty percent decrease in tumor 
size was observed as well as relaxation of stent. 
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Discussion 
 
RIT with 186Re-cMAb U36 seems to be safe, and no side-effects were 
observed in this phase I study besides dose-limiting myelosuppression at the 186Re 
dose level of 41 mCi/m2. The MTD of 27 mCi/m2 as found for 186Re-cMAb U36 is 
considerably lower than has been described for other 186Re-labeled MAbs in dose-
finding studies. For mMAb NR-LU-10, the MTD was established at 90 mCi/m2 (3.3 
GBq/m2), while for cMAb NR-LU-13, the MTD was found to be 60 mCi/m2 (2.2 
GBq/m2) (11,13). This difference can be explained by the longer circulating half-life 
in blood of cMAb U36, compared with the two other radioimmunoconjugates. The 
mean t1/2ß of cMAb U36 was 80.0 h, while for NR-LU-10 and NR-LU-13 a mean t1/2ß 
of 26.5 and 36.5 h, respectively, was found. MAb U36 does not bind to the cellular 
fraction of the bone marrow, and no patients with bone metastases participated in this 
study, nor did RIS reveal increased radioactivity uptake in the bone marrow. 
Myelotoxicity consisted mainly of thrombocytopenia, with a nadir 4 wk after 
administration of 186Re-cMAb U36. Grade 4 thrombocytopenia was observed at the 
highest dose level -41 mCi/m - for two patients, whereas grade 3 thrombocytopenia 
developed in one of five evaluable patients at the MTD level. Leucocytopenia of a 
grade higher than 3 was seen only at the 41 mCi/m2 dose level. The development of 
thrombocytopenia could be related to the bone marrow dose, calculated from the 
whole blood time-186Re activity curve. 
2
Because cMAb U36 clearance differed considerably between patients in the 
same dose group and resulted in thrombocytopenia of variable severity, an 
individualized radiation dose selection for cMAb U36 RIT candidates seems 
mandatory. In this study, we evaluated the possibility of using 99mTc-cMAb U36 for 
prediction of the 186Re-cMAb U36 biodistribution. To limit antigen occupation in the 
tumor because of such pretherapy studies, 99mTc-cMAb U36 was administered at a 
much lower antibody dose than 186Re-cMAb U36: 2 mg versus 52 mg. The overall 
biodistribution of the conjugates observed with RIS seemed to be the same at 21 h 
after injection, and comparable targeting of tumor lesions was seen (Figure 2). At 
later times, imaging with 99mTc-cMAb U36 is not feasible because of the short half-
life time of 99mTc, which is consistent with the findings of Breitz et al., who evaluated 
the use of 99mTc-labeled NR-CO-02 (Fab’)2 to predict 186Re dosimetry (29). 
Therefore, some distant metastases clearly delineated by 186Re-cMAb U36 RIS at later 
times could not be visualized reliably by 99mTc-cMAb U36 RIS. Despite the 
difference in antibody dose, the pharmacokinetic behavior of the 99mTc- and 186Re-
conjugates appeared to be similar during the first 25 h after injection. The physical 
half-life time compared to the biological half-life time of 99mTc-cMAb U36, however, 
 76
Limited Blood Sampling in Pretherapy Study for Radioimmunotherapy  
did not allow accurate prediction at later times. On the basis of these data, we think 
that prediction of radiation dose delivery to bone marrow, tumor and normal tissues in 
individual 186Re-cMAb U36 RIT candidates may be feasible, but that because of the 
short physical half-life of 99mTc, it is not the ideal radionuclide for use in such a 
pretherapy procedure. A better candidate may be 186Re itself. Data on radiation dose 
rates and bone marrow dosimetry from this study indicate that up to 10 mCi (370 
MBq) 186Re can be safely used as trace-labeled dose, thus allowing imaging and 
sampling for pharmacokinetics until 7 days after injection. An advantage of using 
186Re is that just one radioimmunoconjugate has to be developed for both pretherapy 
procedure and RIT. 
Besides the level of radiation dose delivery to the bone marrow, other factors 
may affect the severity of thrombocytopenia on RIT. For example, among the three 
patients in the 41 mCi/m2 group, patient 11 received a bone marrow dose similar to 
that received by patient 12 but showed more severe myelotoxicity (grade 4 
thrombocytopenia and granulocytopenia). This result was most likely related to past 
myelotoxic treatment. In addition, patient 13 suffered from severe myelotoxicity that 
could be explained neither by a history of myelosuppressive therapy nor by an 
increased MAb retention. This result indicates that although pretherapy procedures 
are used for individual bone marrow dosimetry, individual variation in development 
of myelotoxicity can be considerable. 
Previous immunohistochemical studies revealed that high CD44v6 expression 
in HNSCC tumors is similar to that as in normal squamous epithelia; therefore, we 
anticipated that acute local toxicity might become apparent in the oral mucosa (17-
19). However, despite the fact that most patients previously experienced mucositis 
after external beam irradiation, none of the patients experienced such toxicity during 
this RIT study, possibly because the target antigen is less accessible in normal mucosa 
than in HNSCC. Previous biodistribution studies in which tissue uptake of 
radiolabeled murine MAb U36 was assessed by biopsy of the surgical specimen 
revealed a 2.3 times lower uptake of the MAb in normal mucosa than in HNSCC 
tissue, at 2 and 7 days after injection (14,15). Moreover, for dosimetric calculations 
one must consider that a part of the disintegration energy dissipates outside the 
distribution volume of the tissue. Maraveyas et al. reconstructed a larynx phantom 
and concluded that, for 186Re, the absorbed fraction in normal mucosal linings will be 
about 1.6 times less than in HNSCC tissue, leading to a greater tumor versus mucosa 
dose advantage (34). 
In previous RIS studies with 99mTc-labeled mMAb U36, HAMA responses 
were observed in five of nine (56%) patients when using the same criteria for 
positivity as in this study (15). With the aim of reducing immunogenicity, cMAb U36 
was constructed. We found HACA responses directed against cMAb U36 in five of 
 77
Limited Blood Sampling in Pretherapy Study for Radioimmunotherapy  
twelve evaluable patients (42%), while in one of these patients (8%) antibodies 
directed against the murine variable region were found. Although a reduction in the 
development of HAMA has been achieved (from 56% to 8%) with cMAb U36, our 
data indicate that in four (maybe five) of these patients antibodies directed against 
epitopes residing in the human portion or in the murine-human fusion region of the 
cMAb had developed. 
Three patients already showed HACA before the start of RIT. In two of these 
patients, HACA responses were induced by administration of 2 mg 99mTc-cMAb U36, 
one week before the start of RIT, whereas in the third patient an elevated preimmune 
HACA level was found. In one of these patients (patient 2), a relatively rapid whole-
body and blood clearance of 186Re-cMAb U36 was observed, while RIS revealed 
relatively high accumulation of activity in the liver. This patient had the highest 
HACA level measured in the study, 5.73 mg/L. The HACA response may be 
responsible for the rapid blood clearance and liver accumulation of 186Re-cMAb U36 
in this patient. The fact that a rapid blood clearance was not observed for the other 
two patients with increased HACA levels at the start of RIT might have been caused 
by the lower HACA levels of these patients or the higher cMAb U36 dose (52 mg 
instead of 12 mg) they received for RIT. 
We have not analyzed the patients’ sera for human antibodies directed against 
the MAG3 chelate. However, one can conclude already, at this stage, that 
immunogenicity of cMAb U36 cannot be neglected when starting new studies with 
cMAb U36. This conclusion may be particularly true when considering pretherapy 
studies or repeated dosing.  
The observation of antitumor effects in patients with bulky disease offers 
opportunities for further development of RIT as an adjuvant treatment. Tumor uptake, 
as assessed by ROIs on scintigraphy, agreed with uptake values obtained previously 
with mMAb U36 (14,15). The calculated tumor absorbed doses ranged from 3.0 to 
18.0 Gy for the 27 mCi/m2 dose group, whereas the mean absorbed dose to the tumor 
was 18.0 cGy/mCi (486.5 cGy/GBq) for all evaluable patients. As shown in Table 4, 
these tumor doses appear sufficient for antitumor effects. That antitumor effects are 
caused by immune modulating effects is unlikely, because cMAb U36 was shown to 
lack antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent 
cytotoxicity (CDC)-mediating activity in vitro (15). RIT studies with 186Re-mMAb 
E48 in HNSCC-bearing nude mice revealed that with an accumulated dose in the 
range of 11 - 34 Gy, complete remissions of 18 - 50% could be achieved (35). Breitz 
et al. found a partial response lasting 7 mo on treatment of a colon cancer patient with 
two cycles of 186Re-labeled NR-LU-10. Tumor doses were 21 and 7 Gy for the two 
cycles (11). These data indicate that RIT with 186Re-cMAb U36 in its current form 
occasionally can cause antitumor effects. However, for complete tumor eradication 
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the radiation delivery to the lesions should be increased several times, as when 
applying RIT in an adjuvant setting for treatment of minimal residual disease. 
Recently, we reported on the relationship between HNSCC size and MAb 
accumulation (36). Data for this report were obtained from several RIS and 
biodistribution studies with the anti-HNSCC MAbs E48 and U36 in HNSCC patients. 
MAb uptake in small-volume tumors (1 cm3) was found to be approximately four 
times higher than uptake in large-volume tumors (> 50 cm3). No data are available for 
MAb uptake in tumor deposits smaller than 1 cm3, but we nevertheless think that the 
data presented in this article justify the evaluation of RIT with 186Re-cMAb U36 in an 
adjuvant setting.  
Several other strategies are followed at our institute to improve the efficacy of 
RIT. Most appealing may be strategies with higher doses of 186Re-cMAb U36 
combined with peripheral stem cell re-infusion or a combination of RIT with 
inhibitors of the epidermal growth factor receptor (EGFR). In the latter approach, RIT 
is combined with MAbs or chemical inhibitors capable to block EGFR. In a recent 
study, we showed that the anti-EGFR MAb 425 strongly enhanced the efficacy of RIT 
with 186Re-cMAb U36 in HNSCC-bearing nude mice (37). Taking into account that 
high expression of EFGR in most HNSCCs and its absence on bone marrow cells, this 





RIT with 186Re-cMAb U36 seems safe. The pharmacokinetics of 186Re-cMAb 
U36 can be predicted by 99mTc-cMAb U36, thus creating the possibility of such a 
procedure for selection of a safe RIT dose. However, such pretherapy procedure may 
induce a HACA reponse. This study shows that tumoricidal doses of 186Re-cMAb 
U36 can be reached in HNSCC patients with bulky disease. Avenues for RIT are thus 
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Abstract 
 
186Re-labeled chimeric monoclonal antibody U36 (cMAb U36) was recently 
evaluated in a phase I dose escalation study in head and neck cancer patients. All 
thirteen patients received 99mTc-cMAb U36 before 186Re-cMAb U36 
radioimmunotherapy. The aim of this study was to evaluate the suitability of multiple 
or limited blood sampling to predict clearance, bone marrow absorbed dose, and 
myelotoxicity of 186Re-cMAb U36. 
Population pharmacokinetics of 186Re-cMAb U36 were analysed with a 
nonparametric expectation algorithm (NPEM 2) and used for Bayesian analysis of 
individual patient data to predict cMAb U36 clearance. 
186Re-cMAb U36 clearance was most accurately predicted (r = 0.91, P < 0.001) with 
limited sampling for sample points 4 and 72 h after administration of 186Re-cMAb 
U36. These predictions were less accurate with 99mTc-cMAb U36 (r = 0.51, P = 
0.078, for multiple sampling; r = 0.47, P = 0.104 for sampling at 4 and 21 h after 
administration). Thrombocytopenia was found to be correlated with the bone marrow 
absorbed dose and was equally well predicted by limited blood sampling after 
administration of 99mTc-cMAb U36 (r = 0.81, P < 0.01) or 186Re-cMAb U36 (r = 
0.79, P < 0.01). 
In conclusion, limited sampling seems useful to predict pharmacokinetics and 
myelotoxicity of 186Re-cMAb U36. 
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Introduction 
 
Radiogenic damage to the bone marrow is the dose limiting toxicity in most of 
the radioimmunotherapy (RIT) studies conducted thus far, resulting in 
thrombocytopenia and leucocytopenia with a nadir at 4-6 wk after therapy. The bone 
marrow absorbed dose is often found to be related to the severeness of myelotoxicity 
(1). In a previous paper (2) we report on a phase I RIT trial in which 99mTc-labeled 
chimeric MAb U36 (cMAb U36) was administered one week before 186Re-cMAb U36 
to head and neck cancer patients. With these radioimmunoconjugates, an intrapatient 
consistency of pharmacokinetics was demonstrated for the decay-corrected areas 
under the curve (AUCs) up to 25 h after administration. Due to the short half-life of 
99mTc in comparison to 186Re, an accurate estimation of the total AUC based on 
individual patient data was not possible. In this study, a population-based model was 
used to compare the data on 99mTc-cMAb U36 and 186Re-cMAb U36 
pharmacokinetics obtained from the same group of patients. Subsequently, the 
potential of limited blood sampling to predict the pharmacokinetics of 186Re-cMAb 
U36 and the severity of myelotoxicity after RIT, was evaluated. 
 
 
Materials and methods 
 
Patients and study design 
The study was approved by the Institutional Review Board of the VU 
University Medical Center (Amsterdam, The Netherlands), and informed consent was 
obtained. Study design and methods including antibody production, radiolabeling, 
safety, imaging, and efficacy data of the trial have been reported previously (2). Prior 
to RIT, patients received 740 MBq 99mTc-labeled cMAb U36 (2 mg), followed one 
week later by a single dose of 186Re-cMAb U36 (12 or 52 mg) in radiation dose 
escalating steps of 0.4, 1.0, and 1.5 GBq/m2. Blood samples were collected at 5, 10, 
and 30 min, and 1, 2, 4, 16, and 21 h after injection in both studies, as well as at 72 h 
in the RIT study. Hematologic parameters were obtained on a weekly basis for at least 
6 wk, or until recovery of myelotoxicity was observed. 
 
 
Pharmacokinetic modeling, bone marrow dosimetry, and myelotoxicity  
Blood samples were counted in a multiwell gamma counter (1470 Wizard, 
Wallac, Turku, Finland), and compared to an aliquot retained from the conjugate 
preparation for injection. These results, together with patient age, sex, weight, body 
surface area, and serum creatinine, were analysed with a nonparametric expectation 
maximization algorithm (NPEM 2, USC-Pack, Los Angeles, CA) to reveal the 
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following mean pharmacokinetic parameters: initial volume of distribution (Vd), 
elimination constant rate (kelm), and transfer rate constants (k12 and k21) (3). The 
individual pharmacokinetic parameters were calculated with MW/Pharm (Mediware, 
Groningen, The Netherlands) using the population pharmacokinetic parameters as 
Bayesian forecast. Subsequently, the following analyses were performed:  
 
1. Bayesian clearance estimates of cMAb U36 were assessed, using blood 
activity concentration data of either 99mTc-cMAb U36 or 186Re-cMAb U36. For these 
estimates data of either all blood samples (“multiple sampling”) or combinations of 
two blood samples (“limited blood sampling”) were used. 
2. The obtained Bayesian clearance estimates were used to calculate the effective 
clearance according to the following equation:  Cl effective = Cl biological + Cl phys, where 
Cl effective and Cl biological are the effective and biological clearance of the 
radioimmunoconjugate, respectively, and Cl phys is the physical clearance of the 
radionuclide ( Vd x ln 2 / [half-life of 186Re] ; half-life of 186Re = 90.62 h. 
3. The actual effective clearance (i.e. non-Bayesian clearance) was assessed by 
fitting blood activity concentration data of all blood samples of an individual patient 
obtained after administration of 186Re-cMAb U36. 
4. Bayesian clearance estimates were compared with the actual non-Bayesian 
clearance. 
 
To calculate the total AUC in blood (AUC blood), and subsequently the bone marrow 
absorbed dose, the following equation was used: 
 
AUC BLOOD = ID / CL EFFECTIVE, 
 
where ID is the total injected therapy dose. This AUC blood, together with the total 
body radioactivity, was used for calculation of a patient-specific bone marrow dose 
according to the method of Shen et al. (4). The bone marrow absorbed dose estimates 
were compared with the development of myelotoxicity, that is, the nadir and the 




Statistical analysis  
All mean values reported represent arithmetic means with corresponding SDs. 
Associations between variables were calculated with SPSS 7.5 software (SPSS Inc., 
Chicago, IL) using Pearson correlation tests with P-values < 0.05 considered 
statistically significant. Multiple regression analysis was performed to find a possible 
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relationship between the covariates age, weight, body surface area, serum creatinine, 
injected dose, clearance, and bone marrow absorbed dose in predicting myelotoxicity 




Patient characteristics are shown in Table 1. The mean population parameters 
obtained with NPEM 2 were kelm : 0.013 h-1 ( ± 0.006), k12 : 0.024 h-1 ( ± 0.018), k21 : 
0.215 h-1 ( ± 0.146), and Vd : 0.074 L/kg ( ± 0.011). A mean cMAb U36 clearance of 
0.056 L/h (range 0.036 - 0.074 L/h) was found in the therapy study with 186Re-cMAb 
U36 using non-Bayesian analysis. The goodness of fit of the Bayesian and non-
Bayesian 186Re-cMAb U36 clearance was assessed (r = 0.99, P < 0.0001). 
 
Table 1.  Patient Characteristics 
Patien
t no. 





  (kg) (m2)  (mCi) (cGy) 
1 53/M 55 1.63 Yes 13 46 
2 54/F 48 1.50 None 16 25 
3 54/M 67 1.78 None 19 30 
4 47/M 57 1.78 None 19 20 
5 56/M 58 1.63 Yes 43 73 
6 66/M 86 2.03 Yes 57 109 
7 56/F 57 1.59 None 44 91 
8 58/M 61 1.76 None 46 77 
9 67/M 63 1.75 None 46 110 
10 68/M 69 1.86 None 48 100 
11 52/M 82 2.01 None 80 104 
12 52/M 47 1.46 Yes 59 107 
13 59/F 58 1.56 None 58 112 
 
Abbreviations: M, male; F, female; BSA, body surface area; BM, bone marrow. 
 
 
Bayesian analysis using data from all sample points in the 99mTc-cMAb U36 
study was not able to predict with statistical significance the actual 186Re-cMAb U36 
clearance for an individual patient (r = 0.51, P = 0.078). The optimal 99mTc-cMAb 
U36 sample pair for prediction was 4 and 21 h after administration (r = 0.47, P = 
0.104). 
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The combination of sample points at 4 and 72 h after administration of 186Re-
cMAb U36 appeared to be the optimal sample pair for prediction of the actual 
clearance of 186Re-cMAb U36 (r = 0.91, P < 0.001). 
Development of hematologic toxicity was evaluable for eleven out of thirteen 
patients, since two patients did not complete the follow-up for evaluation of 
myelotoxicity. Correlations between myelotoxicity and bone marrow absorbed dose 
estimates are given in Table 2. The most severe toxicity, that is, thrombocytopenia, 
was shown to be correlated with the bone marrow dose calculated from the actual 
186Re-cMAb U36 clearance: r = 0.80, P < 0.01, and r = 0.66, P < 0.05, for platelet 
nadir and percentage decrease, respectively. If the bone marrow dose was calculated 
from the Bayesian estimate of 186Re-cMAb U36 clearance obtained from the 99mTc-
cMAb U36 study, and normalized with respect to the injected dose of 186Re-cMAb 
U36 RIT, these correlations appeared to be similar. The relationship between the 
predicted bone marrow doses and development of thrombocytopenia is illustrated in 
Figure 1. 
Multiple regression analysis did not show any significant influence of the 
covariates age, weight, body surface area, or serum creatinine on 186Re-cMAb U36 
clearance. The Pearson correlation coefficients for platelets nadir and the different 
bone marrow dose estimates using multiple and limited sampling were all higher than 
for total injected dose (Table 2). The individual bone marrow dose estimate was thus 
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Figure 1. Relationship between bone marrow absorbed dose estimates and 
development of thrombocytopenia after 186Re-cMAb U36 radioimmunotherapy. 
Bone marrow absorbed dose estimate was calculated using Bayesian analysis of 
limited blood sampling at 4 and 72 h after administration of 186Re-cMAb U36. 
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Table 2. Pearson Correlation Tests for the Prediction of Myelotoxicity. 
 
Platelet nadir Platelet decrease (%)
White Blood Cell 
Nadir 






 r           P r P r P r P r P r P
186Re-cMAb U36, 
non-Bayesian 












0.81 < 0.01 0.67 < 0.05 0.45 0.16 0.55 0.08 0.57 0.07 0.61 < 0.05 
 
Pearson correlation tests to measure correlation between bone marrow absorbed dose estimates and myelotoxicity. Bone marrow absorbed dose was calculated 
using all blood samples (multiple sampling) and two blood samples (limited sampling) obtained after administration of 99mTc- and 186Re-cMAb U36. 
 
Radioimmunotherapy with Whole Blood Support 
Discussion 
 
The bone marrow absorbed dose, determined from the blood time-activity 
curve, is often a good predictor of myelotoxicity (1). For patient-specific dose 
planning, accurate bone marrow absorbed dose estimation might require frequent 
sampling, which is a burden for patients, especially when performed in an outpatient 
setting. In the present study, prediction of 186Re-cMAb U36 clearance proved to be 
feasible when only two instead of all blood samples were selected for Bayesian 
analysis. This prediction was optimal for the sample pair at 4 and 72 h after 
administration of 186Re-cMAb U36. All patients underwent a preceding pretherapy 
study with 99mTc-cMAb U36, but unfortunately, the prediction of 186Re-cMAb U36 
clearance from this pretherapy study using Bayesian analysis of multiple or limited 
blood samples was less accurate.  
Pharmacokinetics of 99mTc-cMAb U36 and 186Re-cMAb U36 could be 
different as a result of development of human-anti-chimeric antibody (HACA) 
responses, which were found in five of thirteen patients (2), of which three had an 
onset in the week between the 99mTc- and 186Re-cMAb U36 administrations. Because 
HACA titers were low (< 1.50 mg/L) and the amount of administered 186Re-cMAb 
U36 relatively high (50 mg), the effect of HACA on186Re-cMAb U36 
pharmacokinetics, however, is expected to be small. Presence of antigen at nontumor 
sites and different antibody doses used for pretherapy and therapy studies (as was the 
case in the present study) can also explain variation in pharmacokinetics. Previous 
biodistribution studies with MAb U36, however, showed consistency of 
pharmacokinetics irrespective of the antibody was administered at a dose of 2, 12 or 
52 mg (5). 
Another explanation for the different pharmacokinetics might be that the short 
half-life of 99mTc makes the pretherapy procedure with 99mTc-cMAb U36 of limited 
value. The short half-life of 99mTc does not allow sampling later than approximately 
25 h after administration. Therefore, 99mTc-cMAb U36 might allow accurate 
prediction of the early part of the 186Re-cMAb U36 clearance, but not of the late part. 
Indeed, biological AUCs for 99mTc- and 186Re-cMAb U36, as determined up to just 25 
h after injection, showed a very strong correlation (r = 0.94; P < 0.01), confirming 
intrapatient consistency of pharmacokinetics. 
Taking the aforementioned information into account we hypothesized that 
186Re-cMAb U36 might be a better candidate for such a pretherapy procedure. 186Re 
allows sampling at later time points, resulting in a more reliable prediction of cMAb 
U36 clearance, which was confirmed in this study: 186Re-cMAb U36 clearance was 
accurately predicted (r = 0.91, P < 0.001) with limited sampling at 4 and 72 h after 
administration. However, these sampling points were selected from the therapy data, 
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and not from a preceding diagnostic study. Whether the same accuracy can be found 





This study shows that limited sampling during a pretherapy procedure is a 
realistic option to predict the 186Re-cMAb U36 clearance during RIT. Development of 
myelotoxicity after 186Re-cMAb U36 RIT correlated well with the derived bone 
marrow dose estimates. 186Re-cMAb U36 seems to be better qualified for such a 
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Abstract 
 
 In an earlier phase I radioimmunotherapy (RIT) study with 186Re-labeled 
chimeric MAb U36 (cMAb U36) in patients with refractory head and neck squamous 
cell carcinoma (HNSCC), the maximum tolerated dose (MTD) was established at 27 
mCi/m2 (1.0 GBq/m2), at which bone marrow doses ranged from 0.7 to 1.1 Gy. In the 
present study, further dose escalation in RIT was evaluated using a facile method of 
re-infusion of granulocyte colony-stimulating factor (G-CSF) stimulated unprocessed 
whole blood. 
Nine patients with recurrent or metastatic HNSCC were treated at radiation 
dose levels of 27, 41, and 54 mCi/m2 (1.0, 1.5, and 2.0 GBq/m2). Before RIT, G-CSF 
(10 µg/kg/day) was administered subcutaneously at home during 5 days. On day 6, 
just prior to administration of 186Re-cMAb U36, 1 L of whole blood was harvested 
and kept unprocessed at 4˚ C, until re-infusion after 72 h. Blood samples were taken 
for analysis of pharmacokinetics and bone marrow dosimetry. Patients were evaluated 
for myelotoxicity and tumor response. 
Blood harvesting, RIT, and re-infusion of whole blood were well tolerated by 
all patients. G-CSF stimulation resulted in a mean of 0.41 x 106 CD34+ cells/kg 
(range: 0.15-0.83 x 106 cells/kg) and a mean committed colony-forming units 
granulocyte-macrophage (CFU-GM) count of 5.62 x 104/kg (range: 0.62-13.37 x 
104/kg). The mean biological half-life of 186Re-cMAb U36 in blood was 72.6 ± 16.0 h, 
and bone marrow doses ranged from 2.1 – 2.8 Gy at the highest dose level. 
Myelotoxicity exceeding grade 3 was not observed. Stable disease was observed in 
five of nine patients, ranging from 3 to 5 mo, and was still ongoing in one of these 
patients.  
In conclusion, this study indicates that a doubling of the MTD and bone 
marrow absorbed dose of 186Re-cMAb U36 can be achieved using re-infusion of G-
CSF-stimulated unprocessed whole blood. 
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Introduction 
 
 Radiolabeled monoclonal antibodies (MAbs) can be used for selective 
delivery of radiation to tumor sites. For selective treatment of head and neck 
squamous cell carcinoma (HNSCC), radioimmunotherapy (RIT) might be an 
interesting approach as an adjuvant therapy, because there is still a high failure rate, 
either locally or at distant sites, after locoregional treatment of HNSCC with surgery 
and/or radiotherapy. In patients with hematological malignancies RIT has shown 
efficacy, resulting in improved remission and response rates (1,2). In most of the RIT 
trials conducted thus far, radiogenic damage to the bone marrow has been dose 
limiting, resulting in thrombocytopenia and granulocytopenia occurring with a nadir 
of 4 to 6 wk after RIT. Autologous transplantation of bone marrow or separated 
growth factor-mobilized blood stem cells can reduce myelotoxicity and allowed dose 
escalation of RIT (3-5). Stem cell transplantation in patients with relapsed B-cell 
lymphomas treated with high-dose RIT allowed bone marrow absorbed doses as high 
as 6.4 Gy, before cardiopulmonary dose-limiting toxicity was observed (6). 
Both transplantation of bone marrow and filtered blood stem cells require 
equipment and laboratory facilities for separation and cryopreservation, while both 
techniques are laborious and expensive. In comparison, granulocyte colony-
stimulating factor (G-CSF) stimulated unprocessed whole blood might be an 
alternative source of blood stem cells. Re-infusion of G-CSF-stimulated whole blood 
is a straightforward and safe procedure, and can be performed in a routine clinical 
setting at low cost (7,8). The G-CSF stimulated whole blood can be stored for at least 
72 h at 4° C, without significant loss of viability of the blood stem cells (9,10). While 
up to 90% of the CD34+ population shows early apoptotic changes after 
cryopreservation (11), only 5-10% apoptotic changes were found in CD34+ 
population in whole blood transplants after 72 h storage (12). In multicyclic 
chemotherapy regimens of short duration this procedure allowed dose intensification 
in patients with small-cell lung cancer (7,13). Moreover, myeloablative chemotherapy 
with whole blood rescue for patients with high-risk lymphoma and multiple myeloma 
was proven to be feasible (8,14,15). To our knowledge, this whole blood procedure 
has never been applied in RIT studies. 
Because the time interval between RIT and the development of myelotoxicity is 
4-6 wk, re-infusion of G-CSF stimulated whole blood is a realistic option to reduce 
myelotoxicity of RIT, because it allows the re-infused blood stem cells to home and 
proliferate in the bone marrow before myelotoxicity becomes manifest. A prerequisite 
for this approach is that most of the radioactivity has disappeared from blood and 
bone marrow at the time of re-infusion. In an earlier phase I study, 186Re-cMAb U36 
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was evaluated in patients with refractory HNSCC (16). The maximum tolerated dose 
(MTD, at which a grade 4 hematological or grade 3 non-hematological toxicity 
developed in not more than one of six patients) was found to be 27 mCi/m2 (1.0 
GBq/m2), with a maximum tolerated bone marrow dose of 0.9 ± 0.2 Gy. Dose limiting 
grade 4 myelotoxicity occurred in two of three patients treated with 41 mCi/m2 (1.5 
GBq/m2). The effective half-life of 186Re-cMAb U36 in blood was 37 h, meaning that 
after 72 h, 25% of the injected radioactivity was still present in the blood. This 
effective half-life is related to both the biological half-life of the MAb and the 
physical half-life of the radionuclide, according to the equation [ 1/T1/2 effective = 
1/T1/2 biological + 1/T1/2 physical ]. In the current study, we evaluated whether re-
infusion of G-CSF stimulated unprocessed whole blood after 72 h allows dose 
escalation of 186Re-cMAb U36 RIT. 
 
 
Materials and methods 
 
Nine patients (five men and four women; age range, 48-71 y) were included in 
this study. Their characteristics are listed in Table 1. All patients had clinical evidence 
of relapsed HNSCC, either locoregionally or at distant sites, for which no curative 
options were available. A histologically confirmed HNSCC in the past was required 
for inclusion. Other eligibility criteria were described in an earlier report on a phase I 
dose escalation study without blood stem cell support (16). The study was approved 
by the Institutional Review Board of the VU University Medical Center (Amsterdam, 
The Netherlands). All patients gave written informed consent after thorough 
explanation of the study. 
The antigen recognized by MAb U36 (Centocor B.V., Leiden, The Netherlands)  
is the keratinocyte-specific CD44 splice variant epican. The epitope is located in the 
v6 domain of CD44 (17). CD44v6 is expressed by squamous cell carcinomas of the 
head and neck, lung, skin, esophagus, and cervix, and also by adenocarcinomas of the 
breast, colon, lung, and stomach (18,19). Antibody production, radiolabeling, and 
quality controls have been described in detail (16).The radiochemical purity of 186Re-
cMAb U36 ranged from  95 to 97 % as assessed by thin layer chromatography (TLC) 
of the final product. The immunoreactive fraction of 186Re-cMAb U36 ranged from 
89.0 – 93.8 %. 
To mobilize blood stem cells, G-CSF (Filgrastim, Neupogen®, Amgen, 
Thousand Oaks, CA) at a dosage of 10 µg/kg for 5 days was administered 
subcutaneously at home. On day 6, just prior to RIT, two phlebotomies of 500 mL 
each were performed via an antecubital vein within 2-3 h. Patients were carefully 
monitored for blood pressure and heart rate during the procedure, and infusion of 500 
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mL 0.65 % saline was performed after each phlebotomy. Blood was collected in two 
2,3-ethyl, hexyl-phtalate plasticized transfer bags (Nederlands Productie 
Laboratorium voor Bloedtransfusieapparatuur en Infusievloeistoffen BV, Emmer-
Compascuum, The Netherlands) containing 70 mL of CPD as anticoagulant. After 
collection the bags were sealed, and stored unprocessed and unshaken at 4°C in a 
temperature-controlled refrigerator. Re-infusion of the unprocessed whole blood was 
performed after 72 h. The number of cells expressing the CD34 antigen and the 
committed colony-forming units granulocyte-macrophage (CFU-GM) in stored whole 
blood were assessed from a sample taken just prior to re-infusion (10). 
Just after collection of G-CSF-stimulated whole blood 50 mg of 186Re-cMAb 
U36 was administered intravenously in 5 minutes. Blood samples were collected from 
the opposite antecubital vein and counted in a multiwell gamma counter (1470 
Wizard; Wallac, Turku, Finland) for pharmacokinetic analyses and patient-specific 
bone marrow dosimetry according to Shen et al. (20). This method takes the 
contribution of other organs and the whole-body into account. The dose levels were 
1.0, 1.5, and 2.0 GBq/m2 body surface area, and 3 patients were treated at each dose 
level. Vital functions (blood pressure, pulse rate, breathing rate, and temperature) 
were assessed before administration, and after 20, 40, 60, 120, and 240 min. Patients 
were admitted for 21 h in a special treatment room at the department of nuclear 
medicine. Thereafter, they stayed in a single room at the otolaryngology/head and 
neck surgery ward until re-infusion. Scintigraphic imaging studies were performed 
with a large field-of-view gamma camera (Dual Head Genesys Imaging System; 
ADAC Laboratories, Milpitas, CA). Whole-body, and lateral, anterior, and posterior 
planar images and SPECT of the head and neck region were obtained in all patients. 
Patients were discharged after the re-infusion was completed. 
Hematological parameters were obtained at least weekly until recovery of 
myelotoxicity was observed. The severity of toxicity was graded according to the 
National Cancer Institute Common Toxicity Criteria (21). Data on bone marrow 
dosimetry and development of myelotoxicity were compared to those from patients 
treated in an earlier study of 186Re-cMAb U36 without the use of whole blood re-
infusion (16). Physical examination and CT or MR imaging were performed every 4 
wk for evaluation of response. Stable disease was defined as a 50% reduction or a 
25% or smaller increase in the sum of the perpendicular diameter products and no 
new lesions, which had to persist for at least 3 mo. Progression was defined as an 
unequivocal increase in size (>25%) of any lesion or the appearance of a new lesion. 
All mean values reported represent ranges, arithmetic means, and corresponding 
SD. 
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 (y)   (x 109/L) (x 106/kg) (x 104/kg) 
1 60/F neck recurrence, lung, and 
liver metastases of 
laryngeal carcinoma 
SURG/XRT 35.6 0.28 6.33 
2 48/M bone metastases of 
pharyngeal carcinoma 
SURG/XRT 44.4 0.17 0.62 
3 58/M local recurrence, lung 
metastases of piriform 
sinus carcinoma 
CHEM/XRT 44.5 0.30 1.52 
4 58/M neck recurrence, lung, and 
liver metastases of 
supraglottic laryngeal 
carcinoma 
SURG/XRT 36.6 0.15 3.28 
5 54/F neck recurrence, lung 
metastases of tonsillar 
carcinoma 
SURG/XRT 26.6 0.26 6.74 
6 57/M neck recurrence, lung 
metastases after neck 
lymph node metastases of 
unknown primary tumor 
SURG/XRT 71.6 0.68 2.35 
7 71/F cutaneous metastases after 
neck lymph node 
metastases of unknown 
primary tumor 
SURG/XRT 48.8 0.66 13.37 
8 67/F local recurrence of 
tonsillar carcinoma 
XRT 38.4 0.38 5.34 
9 64/M lung metastases of 
piriform sinus carcinoma 
XRT/SURG 59.2 0.83 10.99 
 
Abbreviations: SURG, surgery; XRT, radiotherapy; CHEM, chemotherapy (cisplatin and 5-FU); WBC, 
white blood cell; CFU-GM, colony-forming units granulocyte macrophage. WBC count was assessed 
just prior to RIT, CD34+ and CFU-GM were assessed in stored whole blood just prior to re-infusion. 
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Results 
 
G-CSF treatment for blood stem cell mobilization did not cause side-effects in 
any of the patients. The mean white blood cell count after G-CSF stimulation was 
45.1 x 109/L (range: 26.6 – 71.6 x 109/L) (Table 1). Whole blood harvesting did not 
lead to significant hypotension in patients, and administration of 186Re-cMAb U36, as 
well as re-infusion of whole blood, was well tolerated by all patients, without 
occurence of acute side-effects. Scintigraphy showed selective targeting of tumor 
lesions in all patients, and no accumulation at nontumor sites, except for presence of 
radioactivity in feces and urine (Figure 1). The mean number of CD34+ cells 
harvested after G-CSF stimulation was 0.41 x 106 cells/kg body weight (range: 0.15-
0.83 x 106 cells/kg), and a mean CFU-GM count of 5.62 x 104/kg was found (range: 
0.62-13.37 x 104/kg) (Table 1). Pharmacokinetic analysis revealed a mean biological 
half-life of 72.6 ± 16.0 h for 186Re-cMAb U36 in blood. Bone marrow doses ranged 
from 0.8 to 2.8 Gy, with a mean bone marrow dose of 0.64 ± 0.13 Gy/GBq (Table 2). 
The nadir of platelets was observed 4-5 wk after administration of 186Re-cMAb 
U36, and the nadir of white blood cells and granulocytes was observed after 5-6 wk.  
In none of the patients a platelet count of less than 20 x 109/L was observed. For three 
patients, platelets were below 50 x 109/L for 5 to 21 days (Table 2). The granulocyte 
nadir was below 1.0 x 109/L in four patients lasting for 2, 4, 7, and 11 days, 
respectively. Three patients required transfusion of packed red blood cells for low 
hemoglobin levels, which was regarded as grade 3 toxicity. In one of these patients 
(patient 1) the transfusion was performed because of low hemoglobin level shortly 
after re-infusion of the unprocessed whole blood, which was therefore most likely the 
result of hemolysis rather than radiation-induced. Patient 4 was given 3 packed red 
blood cells as well as a single transfusion of platelets, because of a sudden low 
hemoglobin level (4.5 mmol/L) at 4 wk after RIT, which was attributed to a gastro-
intestinal bleeding, caused by concomitant use of corticosteroids and nonsteroidal 
anti-inflammatory drugs. At the time of the transfusion there was a grade 3 
thrombocytopenia, which showed recovery within 5 days. The other patient (patient 
6) was given two transfusions of 3 packed red blood cells for hemoglobin levels of 5.2 
and 5.5 mmol/L at 3.5 and 4 wk after RIT, respectively. He suffered from cachexia 
and frequent bleeding as a result of tumor progression. 
Overall, myelotoxicity exceeding grade 3 was not observed (Table 2), and non-
hematological toxicity consisted of a grade 2 mucositis in one patient (patient 5). Less 
severe myelotoxicity was observed as compared with patients treated at the highest 
dose levels in the previous phase I study without the use of re-infusion of G-CSF-
stimulated whole blood (Table 3) (16). None of the patients who received up to 54 
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mCi/m2 developed more than grade 3 myelotoxicity. The MTD in the previous study 
was established at 27 mCi/m2, with grade 4 myelotoxicity in two of three patients 
receiving 41 mCi/m2. Introduction of this procedure allowed increase of the maximum 
tolerated bone marrow doses from 0.9 ± 0.2 Gy to 2.5 ± 0.4 Gy, and an increase of the 
MTD from 27 mCi/m2 to at least 54 mCi/m2 (Table 3). 
Stable disease was observed in five patients, ranging from 3-5 mo, and still 
ongoing in one patient (patient 9). No partial or complete responses were seen. 
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Figure 1. Whole body scan (patient 8) acquired at 72 h after administration of 186Re-cMAb U36. At the 
site of recurrence in the left oropharynx, accumulation of 186Re-cMAb U36 is clearly visible. Except for 
blood pool activity, a more or less homogeneous distribution of 186Re-cMAb U36 is seen for the 






Table 2.  Dose levels, BM dosimetry, myelotoxicity, and response after 186Re-cMAb U36 RIT with re-infusion of G-CSF-stimulated 







BM dose Platelet 
nadir 
Platelets 




















(x 109/L) (no. of days) 
 
(mo)
1 27 46 1.0 144  8.9 6.2  1 x 2 PD  
2            
            
   
            
            
            
            
27 38 0.8 206 5.4 4.6 PD
3 27 59 1.0 201 4.5 3.1 SD 3
4 41 78 1.8 25 5 2.0 1.4  1 x 3a PD
5 41 70 1.7 67 1.7 0.8 11 SD 5
6 41 76 1.7 59  1.7 2.0  2 x 3 PD  
7 54 81 2.6 21 21 1.5 0.9 4 SD 3
8 54 92 2.8 33 13 1.6 0.9 2 SD 4
9 54 97 2.1 60 2.0 0.8 7 SD > 5b 
 
Abbreviations: BM, bone marrow; pRBC, packed red blood cells; PD, progressive disease; SD, stable disease; aPatient 4 also received a 





Table 3  Comparison of mean bone marrow (BM) dose and maximum hematological toxicity grade after RIT with 186Re-cMAb U36 in 
patients treated without re-infusion of G-CSF-stimulated whole blood and patients treated with re-infusion of G-CSF-stimulated whole 
blooda 
 
Patients treated without whole blood support  Patients treated with whole blood support 
Activity 
level 






Mean BM dose Maximum hematogical 
toxicity grade 
(mCi/m2)       (Gy)  (mCi/m2) (Gy)
11 4 0.3 ± 0.1 1  11 - - - 
27 6 0.9 ± 0.2 3  27 3 0.9 ± 0.1 0 
41 3 1.1 ± 0.04 4  41 3 1.7 ± 0.1 3 
54 - - -  54 3 2.5 ± 0.4 3 
 
aPatients treated without re-infusion of G-CSF-stimulated whole blood (left, previous phase I trial described in reference 16), versus patients 
treated with re-infusion of G-CSF-stimulated whole blood in the current study (right). The number of patients treated at each dose level is 
indicated, as well as the mean bone marrow dose per dose level and corresponding SD. 




In this study, re-infusion of G-CSF-stimulated unprocessed whole blood was 
used for dose intensification of RIT with 186Re-cMAb U36. As in chemotherapy, 
myelotoxicity, in general, is dose-limiting in RIT studies. Whereas after 
chemotherapy myelotoxicity becomes manifest within a few days, the nadir of 
platelets and granulocytes after RIT occurs at 4-6 wk. This might allow blood stem 
cells, if re-infused at a timepoint at which an acceptable low radiation level is present 
in blood, to home and proliferate in the bone marrow before myelotoxicity becomes 
manifest, thereby reducing the severity of myelotoxicity. 
 At the current stage of development, re-infusion of G-CSF-stimulated whole 
blood should be performed not more than 72 h after harvesting in order to guarantee 
the viability of the blood stem cells (9,10). The effective half-life of 186Re-cMAb U36 
is 37 h (16), which means that at the time of re-infusion radiation damage to 
circulating blood stem cells can still occur.  
This preliminary phase I study showed improved potential of RIT with 186Re-
cMAb U36 in comparison with a previous study where no re-infusion of G-CSF-
stimulated unprocessed whole blood was performed. In the current study, patients 
tolerated higher total injected doses, and higher doses delivered to the bone marrow 
were tolerated. Stable disease was more frequently observed in the present study. In 
total, five of nine patients showed stable disease, and all three patients treated at the 
highest dose level showed stable disease. In the previous study only one of thirteen 
patients showed stable disease. The only responder had been treated at the highest 
dose level. The observation of stabilization of disease in patients treated in the current 
study offers opportunities for further development of RIT in an adjuvant setting, since 
antibody uptake in small-volume tumors is found to be higher than uptake in large 
tumors (22,23). 
An aspect for further improvement is the storage time of whole blood, which is 
currently limited to 72 h. To increase the clinical applicability, as for RIT with 
radiolabeled MAbs with a relatively long effective half-life in blood, this storage time 
should be extended. Encouraging results with new storage mediums have shown 
preservation of clonogenic capacity of blood stem cells in whole blood for at least 7 
days (24), which could allow re-infusion at a later, more suitable time-point after RIT, 
at which remaining radiation levels in blood have been further decreased. For 
leucopheresis or bone marrow transplantation, this problem of storage time does not 
play a role. However, both procedures require filtration techniques, cryopreservation, 
and expensive laboratory facilities. Re-infusion of G-CSF-stimulated unprocessed 




 In conclusion, this study showed that a doubling of the MTD of 186Re-cMAb 
U36 could be achieved using re-infusion of G-CSF-stimulated unprocessed whole 
blood. Our results indicated that bone marrow doses up to 2.8 Gy could be reached 
without development of dose-limiting myelotoxicity or nonhematological toxicity. In 
five of nine patients with recurrent disease for whom no curative options were 
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Previous studies have shown the potential of murine and chimeric anti-
CD44v6 monoclonal antibodies (MAbs) for radioimmunotherapy (RIT) of head and 
neck squamous cell carcinoma (HNSCC). A limitation of these MAbs, however, 
appeared to be their immunogenicity. Therefore, humanized monoclonal antibody 
BIWA 4 (bivatuzumab), with an intermediate affinity for CD44v6, was recently 
selected. As a prelude to RIT, we evaluated the safety, tumor-targeting potential, 
pharmacokinetics, and immunogenicity of technetium-99m-labeled BIWA 4 in 
patients undergoing operations for primary HNSCC in this study. 
Ten patients were treated at BIWA 4 dose levels of 25 mg (n=3), 50 mg (n=4), 
and 100 mg (n=3). Patients received 2 mg of 750 MBq 99mTc-BIWA 4, together with 
23, 48, and 98 mg unlabeled BIWA 4, respectively. Radioimmunoscintigraphy (RIS) 
was performed within 1 h and after 21 h, and patients underwent surgery at 48 h after 
injection. Biodistribution of 99mTc-BIWA 4 was evaluated by radioactivity 
measurements in blood, bone marrow, and in biopsies of the surgical specimen 
obtained 48 h after injection. BIWA 4 concentration in blood was assessed by ELISA 
and high performance liquid chromatography and related to soluble CD44v6 levels in 
serum samples. The development of human-anti-human antibody (HAHA) responses 
was determined. 
Administration of 99mTc-BIWA 4 was well tolerated by all patients and no 
HAHA responses were observed. A mean t1/2 in plasma of 54.8 ± 11.5, 76.1 ± 21.8, 
and 68.5 ± 21.2 h was found for the 25, 50, and 100 mg dose group, respectively. No 
complex formation of BIWA 4 with soluble CD44v6 in blood was observed. RIS 
showed targeting of primary tumors and lymph node metastases in eight of ten and 
one of five patients, respectively. The highest tumor uptake and tumor to nontumor 
ratios were observed for the 50 mg dose group. Tumor uptake was 12.9 ± 5.9, 26.2 ± 
3.1, and 15.4 ± 1.9 % of the injected dose (ID)/kg for the 25, 50, and 100 mg dose 
group, respectively, while the tumor to bone marrow ratios for these groups were 1.7 
± 0.5, 3.2 ± 1.1, and 2.0 ± 0.6, respectively. 
Conclusion:  99mTc-BIWA 4 can safely be administered to patients with 
HNSCC, with absence of detectable HAHA responses. The 50 mg dose level showed 
the highest tumor uptake and tumor to nontumor ratios. These findings support the use 
of BIWA 4 for RIT studies with HNSCC. 




Squamous cell carcinoma of the head and neck (HNSCC) accounts for 
approximately 5% of all newly diagnosed malignancies in Northwestern Europe and 
the United States, and the worldwide incidence is 500,000 cases each year (1). 
Despite improvements in locoregional treatment by surgery and radiotherapy for 
advanced stages III and IV (70%), the failure rate, either locally or at distant sites, is 
still high. An effective systemic adjuvant treatment, therefore, is needed to improve 
survival in this patient group. Among the novel approaches for selective treatment is 
the use of monoclonal antibodies (MAbs) conjugated with radionuclides. 
Radioimmunotherapy (RIT) has shown efficacy in treatment of hematological 
malignancies (2,3).  
These successes have motivated us to apply RIT in HNSCC. In the selection of 
a suitable target antigen in HNSCC, CD44 splice variants containing the v6 domain 
appeared to be the most promising thus far (4,5). The CD44 protein family consists of 
isoforms, encoded by standard exons and up to nine alternatively spliced variant 
exons (v2-v10), which are expressed in a tissue-specific way. Soluble v6-containing 
CD44 (sCD44v6) fragments have been detected in the blood of cancer patients, as 
well as of healthy individuals (6). 
In the past decade, the development of CD44v6-directed RIT in HNSCC has 
shown encouraging progress. For this purpose two murine MAbs (mMAbs) became 
available designated U36 and BIWA 1. Although both MAbs target the same CD44v6 
antigen, BIWA 1 binds to a different epitope with 35-fold higher affinity (7). At a 
later stage, a chimeric derivative of U36 (cMAb U36) also became available. 
Extensive evaluation of mMAb U36, cMAb U36 and BIWA 1 in HNSCC patients 
revealed selective tumor targeting and high tumor uptake (8-10). 
Although not the primary aim in phase I studies, promising antitumor effects 
were observed in clinical phase I RIT studies (11,12). Unfortunately, BIWA 1 showed 
complex formation with sCD44v6 present in the blood and heterogeneous uptake 
throughout the tumor (10). These phenomena might be related to the high affinity of 
this MAb. In addition, for all three MAbs a high incidence of human-anti-mouse or 
human-anti-chimeric antibody responses (HAMA and HACA, respectively) was 
observed.  
Formation of HAMA or HACA should be eliminated to prevent allergic 
reactions and rapid clearance of the radioimmunoconjugate, especially when multiple 
administrations of the radioimmunoconjugate are anticipated. The engineering of 
humanized MAbs (hMAbs), being almost completely human apart from a small part 
of the antigen-binding sites became the next approach to deal with this problem. 
  
 
Several studies showed decreased immunogenicity of hMAbs in comparison with 
their murine counterparts (13-15). 
The high immunogenicity of the previously tested MAbs led us to construct 
two humanized derivatives of BIWA 1, designated BIWA 4 and BIWA 8. Together 
with mMAb U36 and BIWA 1, these new antibodies were evaluated for 
biodistribution and efficacy in RIT using nude mice bearing HNSCC xenografts. 
Remarkably, the lower-affinity MAbs showed a superior tumor targeting capacity in 
HNSCC-bearing nude mice (7). For this reason the intermediate affinity hMAb BIWA 
4 rather than the high affinity hMAb BIWA 8 was selected as candidate for further 
clinical development. 
As prelude to RIT, in the present study 99mTc-BIWA 4 was evaluated for its 
safety, biodistribution, pharmacokinetics, and immunogenicity in patients who 
underwent surgery for primary HNSCC. These parameters were evaluated at three 




Patients and methods 
 
Patient eligibility 
 Ten patients with histologically proven HNSCC were included in this study, 
while a biopsy of their primary tumor had to show expression of CD44v6 in at least 
50% of the cells (semiquantitatively determined). Their characteristics are shown in 
Table 1. Patients who participated were planned to undergo resection of the primary 
tumor and unilateral or bilateral neck dissection. Other eligibility criteria were age 
between 18 and 80 years, and a Karnofsky performance status of 70 or greater. 
Exclusion criteria were a life-threatening infection, allergic diathesis, serious cardiac 
disease, alimentary or contact allergy, severe atopy or allergy, pregnancy, and 
chemotherapy or radiotherapy within four weeks prior to inclusion. Patients were 
excluded if their white blood cell count was less than 3500/µL, if platelets were lower 
than 150,000/µL, if the serum creatinine concentration was greater than 150 µmol/mL, 
or the bilirubin level was greater than 40 µmol/mL. The study was approved by the 
Institutional Review Board of the VU University Medical Center (Amsterdam, The 
Netherlands). All patients gave signed informed consent after receiving a thorough 
written and oral explanation of the study. 
 
 
   
 
BIWA 4 (bivatuzumab) and CD44v6 
 The parental MAb of BIWA 4, BIWA 1 (Boehringer Ingelheim, Vienna, 
Austria) was generated by immunizing BALB/c mice with glutathione S-transferase 
fusion protein containing the human CD44 domains v3-v10. The epitope recognized 
by BIWA 1 has been mapped to amino acids 360-370 in domain v6 of CD44 
(numbering according to Kugelman et al.) (16). Homogeneous expression of v6-
containing CD44 has been observed in squamous cell carcinoma of the head and neck, 
lung, skin, esophagus, and cervix, while heterogeneous expression was found in 
adenocarcinomas of the breast, colon, lung, pancreas, and stomach (5). In normal 
tissues, expression has been found in epithelial tissues as oral mucosa, skin, breast and 
prostate myoepithelium, and bronchial epithelium (17).  
 
 












of lymph node 
metastasis 
 (y)    (mg)   
1 37 M parotid gland T4N0 25 Yes NA 
2 45 M oropharynx, 
tonsillolingual 
sulcus 
T2N1 25 Yes* No 
3 55 F oral cavity, 
retromolar area 
T4N1 25 Yes Yes 
4 78 F oral cavity, buccal 
mucosa 
T3N1 50 Yes No 
5 38 M oral cavity, 
inferior alveolar 
process 
T4N0 50 No NA 
6 67 F larynx, 
supraglottis 
T4N2c 50 Yes No 
7 51 M oropharynx, tonsil T3N1 50 Yes No 
8 38 M oral cavity, lateral 
tongue 
T2N0 100 No NA 
9 72 F oral cavity, floor 
of mouth 
T2N0 100 Yes* NA 
10 66 F oropharynx, base 
of tongue 
T2N0 100 Yes* NA 
 
∗ Tumor or lymph node metastasis only detected by SPECT imaging. Abbreviations: 




 Generation, production, and characterization of BIWA 4 has been described 
previously (7). Humanized versions of the BIWA 1 heavy and light chain variable 
regions generated by complementarity-determining regions (CDR) grafting were 
cloned in front of the immunoglobulin constant regions of the above mentioned 
expression vectors, resulting in BIWA 4. Clinical grade BIWA 4 was supplied by 
Boehringer Ingelheim, Germany. 
It was anticipated that the optimal MAb dose for future RIT would be in the 
range of 25-100 mg. The most optimal dose should result in a high relative tumor 
uptake, high tumor to nontumor ratios, and a homogeneous MAb distribution 
throughout the tumor. With respect to the latter, an increased MAb dose will result in 
a more homogeneous distribution (8,10). Three patients were intended to be treated at 
each dose level of 25, 50, and 100 mg, respectively. Since no BIWA 4 tumor uptake 
data were obtained in one patient of the 50 mg dose group (patient 5), an extra patient 
was included at this dose level. All other data obtained from patient 5 were used for 
analysis. 
   
 
Radiolabeling and quality controls 
 Radiolabeling of BIWA 4 with 99mTc was performed using the chelate S-
benzoyl-mercaptoacetyltriglycine (MAG3) as described previously (18). Both 99mTc 
and the chelate were obtained from Mallinckrodt, Inc. (Petten, The Netherlands). In 
short, after synthesis of 99mTc-MAG3 an esterification with tetrafluorophenol was 
performed. Subsequently, the ester was purified and conjugated to BIWA 4. 
Radiolabeled BIWA 4 was purified on a PD10 column (Pharmacia-Biotech, Woerden, 
The Netherlands) with 0.9% NaCl as eluent. The conjugates were filter sterilized. 
Radiochemical purity of the conjugates was assessed by thin-layer chromatography 
(TLC) with a mean value of 98.4 % (range 96.9 – 99.1 %). The immunoreactive 
fraction of 99mTc-BIWA 4 was determined by linear extrapolation to conditions 
representing infinite antigen excess using a modified Lineweaver Burk plot (18). A 
mean immunoreactive fraction of 94.7 ± 5.6 % was found for eight of ten patients. For 




 Patients’ histories and physical conditions were examined, and routine 
laboratory analyses were performed, including serum electrolytes, hepatic enzymes, 
thyroid and renal functions, and urine. Complete blood cell and platelet counts, an 
electrocardiogram, and a chest radiograph were obtained. Before surgery, patients 
underwent imaging by CT or MRI, as well as a panendoscopy. BIWA 4 was 
administered intravenously in 5 min at a dose of 2 mg and 20 mCi (750 MBq) 99mTc-
BIWA 4, with 23, 48, or 98 mg unlabeled BIWA 4, respectively. Vital signs (blood 
pressure, pulse rate, breathing rate, and temperature) were recorded just prior to 
administration, and after 10, 60, and 120 min. Scintigraphy studies were performed 
using a large field-of-view gamma camera (Dual Head Genesys Imaging System, 
ADAC Laboratories, Milpitas, CA) equipped with a low-energy high-resolution 
parallel-hole collimator and connected to a computer system (Pegasys, ADAC 
Laboratories, Milpitas, CA). Camera quality control measures were taken at each 
imaging time. Planar anterior and posterior whole-body scans were obtained within 1 
h after administration of 99mTc-BIWA 4, and after 21 h. Lateral, anterior, and 
posterior planar images and SPECT images of the head and neck region were 
acquired at 21 h after administration. The results of the scintigraphy and CT/MRI 
studies were each scored by one experienced examiner. The two examiners were 
blinded to the results of other examinations and the histopathological outcome of the 
surgical specimen. Surgery was performed 48 h after administration of 99mTc-BIWA 
4. From the surgical specimen, biopsies were taken of tumor tissue, lymph node 
metastases, and various normal tissues (fat, muscle, skin). Blood, bone, and bone 
  
 
marrow were obtained immediately before surgery under general anesthesia. Tissue 
and blood samples were weighed, and the amount of 99mTc was measured in a 
gamma-well counter (1470 Wizzard; Wallac, Turku, Finland). Tumor to nontumor 
values were calculated using matched uptake values of one patient. After counting, 




 Blood samples were taken from the opposite antecubital vein preinfusion, and 
at 5, 10, and 30 min, and 1, 2, 4, 16, 24, 48, 72, and 144 h after administration. Urine 
was collected from 0-4, 4-8, 8-12, 12-24, 12-24, and 24-48 h after administration to 
determine excretion of radioactivity. Plasma samples were prepared for determination 
of the concentration of (immunoreactive) BIWA 4 by validated ELISA method, 
essentially as described previously (10). In addition, whole-blood and serum samples 
were prepared and counted together with the urine samples in a gamma-counter (1470 
Wizard; Wallac, Turku, Finland), and radioactivity levels were expressed as 
percentage of the injected dose per kg tissue (%ID/kg). Background activity and 
decay were corrected for and the %ID/kg was determined by comparison with an 
aliquot retained from the conjugate preparation for injection.  
Non-compartmental pharmacokinetic parameters were calculated using 
WinNonlin 3.1 Professional (Pharsight Corporation, Mountain View, CA). Size 
exclusion chromatography (silica-based gel filtration high-performance liquid-
chromatography, HPLC) was applied to assess the percentage of radiolabeled free 
BIWA 4 and complexed BIWA 4, essentially as described previously (10). Levels of 
sCD44v6 were assessed in serum samples obtained before administration of BIWA 4, 
and after 21, 48, and 144 h and at 6 wk. A commercially available sandwich type 
ELISA was used (Bender MedSystems, Vienna, Austria) (19). 
 
 
Human-anti-BIWA 4 response 
Evaluation of the immunogenicity of the BIWA 4 radioimmunoconjugate was 
conducted by determination of human-anti-hMAbs (HAHAs) in serum samples taken 
prior to administration of 99mTc-BIWA 4, and 1 and 6 wk after administration, using a 
validated bridging ELISA. In short, BIWA 4 antibodies labeled with the chelator 
MAG3 were immobilized onto microtiter plates. Antibodies to MAG3-BIWA 4 
present in the serum sample bound simultaneously to the solid phase and to 
biotinylated MAG3-BIWA 4 that was added at the same time in a fixed amount. 
Streptavidin coupled to horseradish peroxidase (Boehringer Mannheim, Germany) 
was used for signal generation by the peroxidase/tetramethyl-benzidine system. A 
   
 
serum sample was considered HAHA positive only, if all the following criteria were 
met: 1) The measured titer was above the lower limit of determination/quantification, 
2) The titer in the post-injection sample was at least two times higher than in the pre-
injection sample, 3) The sample could be serially diluted with a strong correlation 
between titer and dilution factor, 4) The titer could be blocked by addition of BIWA 




All mean values reported represent arithmetic means and corresponding 
standard deviations. Two-sided significance levels were calculated for all parameters, 





No serious adverse reactions to 99mTc-BIWA 4 were observed in any of the 
patients, and no clinically significant changes in vital signs and blood analyses were 
noted. One patient (patient 6) developed dyspnea 10 min after administration of 
99mTc-BIWA 4, which was treated with administration of oxygen and steroids. The 
dyspnea lasted for less than 2 min. No other signs indicating an immunological 
reaction (rash, fever, hypotension) were observed, and no positive HAHA titer was 
measured in the serum of this patient. The reaction was attributed to hyperventilation 
because of mental stress. However, a relation with administration of 99mTc-BIWA 4 
could not be excluded. Another patient (patient 1) required a reintervention directly 
after primary surgery because of bleeding from the wound. He recovered well, and no 
relation with the administration of 99mTc-BIWA 4 was suspected. Patient 10 
developed a thrombophlebitis of the external jugular vein 4 days after surgery. A 
reintervention was performed, and the patient was treated with antibiotics. A relation 
with the administration of 99mTc-BIWA 4 appeared unlikely. 
Imaging showed mainly blood-pool activity on whole-body scans made 
directly after administration of 99mTc-BIWA 4, which had decreased after 21 h, and 
showed a more or less homogeneous distribution for lungs, liver, spleen, and kidneys, 
and increased uptake at tumor sites. Planar imaging and SPECT at 21 h after 
administration showed uptake of 99mTc-BIWA 4 at the primary tumor site in eight of 
ten patients. In only one of five patients with histopathologically proven lymph node 
metastases in the neck, SPECT revealed focal uptake (Figure 1). No selective 
accumulation was observed at nontumor sites. In one of the patients (patient 5), the 
primary tumor in the inferior alveolar process was considered too small (< 5 mm) for 
  
 
detection and no tumor tissue could be obtained for biodistribution analysis. All other 
data obtained from patient 5 were used for analysis. An extra patient was included at 
the 50 mg BIWA 4 dose level. The other patient (patient 8), where scintigraphy could 
not detect the primary tumor, had a tongue carcinoma measuring 40 x 20 mm. 
Mobility of the tongue during scintigraphy might have influenced image quality, since 




Figure 1.  Coronal SPECT image at 21 h after administration of 99mTc-BIWA 4 
of patient with primary oral cavity carcinoma (left arrow) and neck lymph node 
metastasis in level II (right arrow) (patient 3). 
 
 
Pharmacokinetic analyses of BIWA 4 in plasma as assessed by ELISA showed 
a mean t1/2 of 54.8 ± 11.5, 76.1 ± 21.8, and 68.5 ± 21.2 h for the 25, 50, and 100 mg 
dose group, respectively. BIWA 4 concentrations as assessed by this ELISA method 
were consistent with radioactivity concentrations for samples collected untill 48 h 
after injection (data not shown). Due to the short half-life of 99mTc accurate 
measurements of radioactivity concentrations were not possible at later time points. 
For six patients with complete 48 h urine collections, the mean amount of 
radioactivity collected was 10% of the administered dose. Levels of sCD44v6 in 
   
 
serum did not change after administration of 99mTc-BIWA 4 for the three different 
BIWA 4 dose groups (Table 2). HPLC analysis did not reveal complex formation of 
BIWA 4 with sCD44v6. 
  
 
Table 2. Soluble CD44v6 in serum before and after administration of hMAb 
BIWA 4. 
 
hMAb BIWA 4 dose (mg) 25 50 100 
Time after administration (h)    
preadministration 203 ± 46 337 ± 73 174 ± 21 
21 223 ± 34 301 ± 76 179 ± 9 
48 200 ± 41 275 ± 82 157 ± 12 
144 188 ± 40 282 ± 104 182 ± 59 
6 wk 203 ± 32 310 ± 53 210 ± 18 
 
Levels of soluble CD44v6 in serum (mean values, in ng/mL) at different times before 
and after administration of 99mTc-hMAb BIWA 4 as assessed by ELISA. 
 
Uptake results of 99mTc-BIWA 4 in tumor and nontumor tissue biopsies are 
summarized in Table 3. The highest tumor uptake was observed in the 50 mg dose 
group, ranging from 22.6-28.1 %ID/kg. In this dose group the tumor to bone marrow 
ratio was 3.2 ± 1.1, whereas tumor to bone marrow ratios for the 25 mg and 100 mg 
dose group were 1.7 ± 0.5, and 2.0 ± 0.6, respectively (Table 4). 
None of the patients showed a HAHA response following administration of 
99mTc- BIWA 4. 
   
 
Table 3.  Uptake (%ID/kg) of 99mTc-BIWA 4 in biopsies obtained from surgical 
specimens at 48 h after administration. 
 
TISSUES 25 mg BIWA 4 50 mg BIWA 4 100 mg BIWA 4
Tumor 12.9 ± 5.9 26.2 ± 3.1 15.4 ± 1.9 
Mucosa 8.6 ± 1.7 10.6 ± 4.6 9.1 ± 3.2 
Positive lymph node 6.1 ± 3.2 7.6 ± 2.9 NA 
Normal lymph node 2.9 ± 2.8 1.6 ± 0.5 1.8 * 
Muscle 2.0 ± 0.4 1.4 ± 0.2 1.2 ± 0.3 
Fat 2.6 ± 0.4 1.9 ± 1.2 1.6 ± 0.4 
Bone 1.3 ± 0.8 1.6 ± 1.1 1.1 ± 0.1 
Glandular tissue 5.2 ± 2.3 4.9 ± 0.6 5.3 * 
Vein 2.6 ± 0.1 2.5 ± 1.2 2.9 * 
Blood 8.7 ± 1.9 8.9 ± 2.0 8.8 ± 1.7 
Total bone marrow aspiration 7.2 ± 1.5 8.5 ± 2.1 8.1 ± 1.9 
Supernatant bone marrow 
aspiration 
14.4 ± 2.2 13.5 ± 2.7 13.9 ± 1.1 
Sediment bone marrow 
aspiration 
3.6 ± 1.1 4.1 ± 1.9 5.7 ± 2.4 
 





Administrations of 99mTc-BIWA 4 were well tolerated by all patients and no 
adverse-effects related to BIWA 4 were noticed. Since none of the patients showed a 
HAHA response, it can be concluded that the immunogenicity of BIWA 4 is less than 
that of the parental murine BIWA 1, as well as that of both murine and chimeric MAb 
U36. These findings support the feasibility of a multiple administration regimen of 
BIWA 4 in future RIT studies, and might indicate a reduced risk of allergic reactions 
following administration. In the meantime, 18 patients more have been treated with 50 
mg radiolabeled BIWA 4 in 2 parallel radioimmunoscintigraphy-biodistribution 
studies with non-small-cell lung cancer and breast cancer patients (data not 
published). In none of these additional patients HAHA responses were observed. This 
result compares favourably with those found for cMAb U36 (40% HACAs) (11), and 





Table 4.  Tumor to nontumor ratios of 99mTc-BIWA 4 in biopsies obtained from 
surgical specimens 48 hours after administration. 
 
TISSUES 25 mg BIWA 4 50 mg BIWA 4 100 mg BIWA 4 
    
Mucosa 1.9 ± 0.3 3.1 ± 1.6 1.9 ± 0.7 
Normal lymph node 6.2 ± 3.9 18.0 ± 5.8 7.5 * 
Muscle 6.5 ± 2.7 19.8 ± 6.1 13.7 ± 3.2 
Fat 4.9 ± 2.0 23.2 ± 16.6 9.5 ± 0.8 
Bone 17.2 ± 16.3 11.6 * 13.7 ± 2.3 
Glandular tissue 3.4 ± 1.3 6.1 ± 0.9 2.5 * 
Vein 4.1 ± 2.5 12.6 ± 6.0 4.5 * 
Blood 1.4 ± 0.5 2.9 ± 0.9 1.8 ± 0.5 
Total bone marrow aspiration 1.7 ± 0.5 3.2 ± 1.1 2.0 ± 0.6 
Supernatant bone marrow 
aspiration 
0.9 ± 0.3 2.1 ± 0.7 1.1 ± 0.2 
Sediment bone marrow 
aspiration 
3.5 ± 1.1 7.2 ± 3.2 3.2 ± 1.6 
 
* Samples were available from only one patient. 
 
Humanization of other MAbs has been performed with variable success. For 
instance, hMAb M195 elicited no immune response in a study group of 14 patients 
compared with 37% HAMAs found with mMAb M195 (13,20). Furthermore, hMAb 
BrE-3 showed 14% HAHAs (14), compared with mMAb BrE-3, which showed 
immunogenicity in 47-83% of patients (21). On the other hand, hMAb A33, elicited 
HAHAs in 26 of 41 patients (15). Although significantly lower as compared to its 
parental mMAb A33, for which HAMAs were found in all treated patients (22), this 
example illustrates that humanization not always solves the problem of 
immunogenicity. 
Scintigraphy identified eight of ten primary tumors and lymph node metastases 
in only one of five patients. Size and localization of the primary tumors and lymph 
node metastases might have played a role in causing poor imaging results. Another 
explanation is that the short physical half-life of 99mTc is not well-matched with the 
relatively long plasma t1/2 of  BIWA 4, the latter causing a relatively high blood-pool 
activity at the time of imaging, hampering delineation of tumors and lymph node 
metastases. 
   
 
In an earlier biodistribution study with 2, 12, and 52 mg 99mTc-BIWA 1, levels 
of sCD44v6 in serum apparently fell during the first week after administration, and 
extensive complex formation of BIWA 1 with sCD44v6 was observed, especially at 
the 2 mg dose level. Moreover, a heterogeneous distribution of BIWA 1 throughout 
the tumor was observed (10). Both phenomena were attributed to the high affinity of 
BIWA 1 to CD44v6. In the current study, no changes in serum levels of sCD44v6 
were observed after administration for three different BIWA 4 dose levels. Moreover, 
no complex formation of BIWA 4 with sCD44v6 was observed. Consistent with the 
findings from previous biodistribution studies with nude mice bearing HNSCC 
xenografts (7), tumor uptake values of the intermediate affinity BIWA 4 were high, 
higher than for the high affinity BIWA 1, and similar to the uptake values of the low 
affinity mMAb U36. While tumor uptake at 48 h after administration was 26.2 ± 3.1 
%ID/kg for BIWA 4 at the 50 mg dose level, uptake of BIWA 1 and mMAb U36 at 
this dose level was 8.0 ± 2.8 %ID/kg and 20.4 ± 12.4 %ID/kg, respectively. 
Apparently, BIWA 4 has a higher avidity for membrane-bound v6-containing 
CD44 variants than for soluble CD44v6 variants. The high density of CD44v6 on 
tumor cell membranes may allow bivalent binding, whereas bivalent binding to 
soluble CD44v6 variants is not possible as each molecule contains only a single 
epitope. Furthermore, v6-containing CD44 variants present on tumor cell membranes 
may have better interaction with BIWA 4 than the variants present in the circulation 
because of conformational differences. Reduced affinity for binding to circulating 
antigen in comparison to immobilized antigen has also been described for other 
antibodies, including MAbs directed against carcinoembryonic antigen (23,24). 
In conclusion, this study shows that 99mTc-BIWA 4 can safely be administered, 
selectively targets HNSCC with high tumor uptake, and does not induce detectable 
HAHA responses after a single administration. The 50 mg dose seems to be optimal 
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Despite improvements in locoregional treatment of squamous cell carcinoma 
of the head and neck (HNSCC), local and distant failure rates remain high. A putative 
prognostic indicator in HNSCC and other epithelial malignancies, enabling more 
accurate staging and selection of patients for whom adjuvant therapy is recommended, 
is the presence of micrometastatic cells in bone marrow. The gene encoding the E48 
antigen is selectively expressed by HNSCC, and the detection of E48 transcripts in 
bone marrow by reverse transcriptase-polymerase chain reaction (RT-PCR), 
presumably represents the presence of micrometastatic cells. The purpose of this 
study was to determine the association between the presence of micrometastatic cells 
in bone marrow of HNSCC patients and clinical outcome. 
A total of 162 patients treated surgically for primary HNSCC underwent a 
single bone marrow aspiration from the upper iliac crest for detection of 
micrometastatic cells using E48 RT-PCR. In total 139 patients were evaluable. The 
major statistical endpoint were disease-free and distant metastases-free survival. 
E48 RT-PCR indicated the presence of bone marrow micrometastatic cells in 
56/139 (40%) of the patients. Presence of micrometastatic cells had no significant 
influence on disease-free survival or distant metastases-free survival for the whole 
group of patients (P = 0.1460 and P = 0.2912, respectively). For patients with ≥ 2 
lymph node metastases, however, the presence of micrometastatic cells was 
associated with a poor distant metastases-free survival (P = 0.0210). 
Conclusion: the presence of micrometastatic cells in bone marrow of HNSCC 
patients with ≥ 2 lymph node metastases is correlated with a poor distant metastases-
free survival. In this subgroup of HNSCC patients, the E48 RT-PCR can be a valuable 
tool to identify patients who are at increased risk for development of distant 
metastases, and therefore might benefit from adjuvant systemic therapy. 
 




Head and neck squamous cell carcinoma (HNSCC) represents ~95% of head 
and neck tumors. The estimated incidence worldwide in 2000 was approximately 
551,000 cases, and 217,000 died of the disease (1). About one third of the patients 
presents with early stage (I and II) disease, while two third of the patients present with 
advanced stage (III and IV) disease (2). Initial therapy of HNSCC is surgery and/or 
radiotherapy. While early stages I and II generally have a good prognosis, the more 
advanced stages have a high failure rate. Despite improvements in locoregional 
control for patients with advanced HNSCC, the overall survival rates have not 
significantly improved over the last 25 years, as the incidence of metastases at distant 
sites increased (3). 
In large series of patients, the development of distant metastases, generally` 
within two years after locoregional treatment, ranges between 5-25%, whereas in 
subgroups of patients with advanced disease the incidence of distant metastases can 
be much higher (4-9). The most important prognostic indicator for relapse of HNSCC, 
either locoregionally or at distant sites, is the presence of metastatic spread to lymph 
nodes in the neck. When multiple lymph node metastases are present, the incidence of 
distant metastases can be as high as 50% (4,6,7,9,10). 
The presence of small tumor deposits or even single metastatic tumor cells in 
bone marrow of patients with various types of epithelial cancers can be detected by 
immunocytochemistry and molecular methods, notably the polymerase chain reaction 
(PCR). Both techniques mainly use tissue-specific marker antigens such as 
cytokeratins, since these are abundantly expressed in the majority of epithelial tumors 
and homogeneously among the cells of these tumors (11). The clinical relevance of 
micrometastatic cells in bone marrow has been illustrated convincingly for breast and 
colorectal cancer patients, in whom their presence correlates with poor prognosis (11-
14). The early detection of these micrometastatic cells could thus contribute to a more 
accurate staging and the identification of patients who might benefit from adjuvant 
therapy. 
Detection of single tumor cells in bone marrow of HNSCC patients with 
immunocytochemical techniques using monoclonal antibodies directed against 
cytokeratins seems a feasible approach (15,16). These immunocytochemical methods 
are difficult to standardize, and many researchers use subjective morphological 
criteria to assign immunostained cells as cancer cells (17). RT-PCR methods are an 
alternative approach. For detection of micrometastatic cells in the bone marrow of 
HNSCC patients we exploited the E48 antigen. The gene encoding the E48 antigen is 
selectively expressed in HNSCC, and previously we showed that E48 RNA transcripts 
  
 
can be detected in bone marrow aspirates of 35% of HNSCC patients, suggesting the 
presence of micrometastatic cells, whereas samples of noncancer controls were 
negative (18). 
   
 
In this study, the clinical significance of micrometastatic cells in bone marrow 
as detected by E48 RT-PCR at initial work-up is assessed in HNSCC patients who 
were treated with primary surgery and postoperative radiotherapy and then followed 
for a median period of 49 months. 
 
 
Patients and methods 
 
Patients 
 From December 1995 to August 2000, a total of 162 patients underwent bone 
marrow aspiration just before primary surgical treatment for HNSCC. Eligible were 
patients with a primary HNSCC tumor scheduled for surgery and no history of 
malignancy in the past. Criteria for analysis were histological tumor-free margins and 
good quality RNA isolated from the bone marrow sample. Based on these criteria for 
analysis, a total of 23 patients were excluded (in 11 patients the surgical margins were 
not histogically tumor-free, and in 12 cases the RNA quality was poor). Classification 
and staging of the primary tumor was performed according to the TNM system of the 
International Union Against Cancer (Union Internationale Contre le Cancer, UICC) 
(19). Postoperative radiotherapy was given to patients depending on stage and 
histopathological evaluation. After primary treatment patients were followed regularly 
at the outpatient clinic. The study was approved by the Institutional Review Board of 
the VU University Medical Center (Amsterdam, The Netherlands), and all patients 
signed informed consent. 
 
 
Preparation of bone marrow samples and RNA isolation 
 Just prior to surgery, a bone marrow sample (2-5 ml) was obtained under 
general anaesthesia from the upper iliac crest by needle aspiration on one side and 
stored in heparin-treated tubes. Samples were diluted 1:1 in RPMI 1640. After 
centrifugation at 220 x g for 10 min, the erythrocytes in the pellet were lysed in 5 ml 
of lysis buffer containing 160 mM KHCO3, and 0.1 mM EDTA (pH 7.4) and 
incubated at 4° C for 15 min while the solution was mixed occasionally by inverting 
the tube. Nucleated cells were pelleted by centrifugation at 220 x g for 10 min, 
washed with 10 ml of RPMI 1640, and centrifuged at 220 x g for 5 min. Cells were 
resuspended in 1 ml of RPMI, transferred to a 1.5-ml microcentrifuge tube, and 
centrifuged at 12,000 x g for 1 min. The pellet was dissolved in 1.0 ml of RNAzol-B 
(Campro Scientific BV, Veenendaal, the Netherlands) and mixed. After the addition 
of 100 µl of chloroform, the sample was mixed vigorously for 15 s and put on ice for 
  
 
5 min. After centrifugation at 12,000 x g for 15 min at 4°C, the aqueous phase was 
transferred to another microcentrifuge tube, while the RNA was precipitated by 
addition of an equal volume of isopropanol, and stored until use at -20°C. Just before 
use, RNA was pelleted by centrifugation at 12,000 x g for 30 min at 4°C. The pellet 
was washed by vortexing in 70% ethanol, centrifuged at 12,000 x g for 5 min at 4°C, 
and dissolved in 25-100 µl of RNAse-free H2O and incubated at 65°C for 15 min. The 




E48 RT-PCR and quality assurance 
The standardized RT-PCR technique for detection of E48 RNA transcripts in 
bone marrow has been described previously (18). In short, 5 µg of total RNA was 
reverse transcribed in 20 µl and on 4 x 5 µl RT-product a PCR was performed 
(quadruplicate analysis). Amplimers were electrophorized on an agarose gel, blotted 
and hybridized with the E48 cDNA as a probe. A serial dilution of RNA from the E48 
expressing cell line UM-SCC-22A, ranging from 50, 15, 5, 1.5, to 0.5 pg, was run in 
parallel in each experiment for calibration, as described previously (20). All primers, 
probes and buffers were prepared in a laboratory that is isolated from sample 
preparation and PCR product analysis. RNA isolation, cDNA synthesis, and 
preparation of PCR reactions were performed in a pre-PCR laboratory. To prevent 
amplimer carryover contamination, all materials and reagents were transported in a 
one-way direction from the pre-PCR laboratories to the PCR laboratory. Sample-to-
sample carryover contamination was further avoided by using different pipet sets and 
filter tips (Greiner Bio-One, Kremsmünster, Austria). Preparations without RNA 
template were used as negative RT-PCR control. In addition, a blotting control was 
loaded on the agarose gels consisting of dilutions of EcoRI cut plasmid DNA 
containing the E48 cDNA (21). Autoradiography was standardized using the blotting 
control. An assay was considered reliable when at least one of four signals was seen at 
0.5 pg UM-SCC-22A RNA. A sample was considered positive when at least one of 
four PCR reactions was positive. RT-PCR amplification of β2-microglobulin 
transcripts was used as control for the quality of the RNA. These amplimers were 




   
 
Statistical analysis 
 Differences in frequency distributions of clinical characteristics were analyzed 
by either Student’s t-test or the Chi-square test (for two-by-two tables Fisher’s exact 
test). The major statistical endpoint of the prognostic study was the number of patients 
remaining free of recurrent disease and distant metastases using Kaplan-Meier life-
table analyses and log-rank tests (Mantel-Cox). Time to recurrence or death was 
measured from the date of primary surgery. Patients who developed a second primary 
tumor were censored for all outcomes at the incidence date of the second tumor, since 
development of recurrent disease in such case could not be related to the primary 
tumor alone. Delayed lymph node metastases that developed in an untreated neck 
during follow-up were not regarded as recurrence. Statistical analyses were performed 
with the statistical software package BMPD (22). Data summaries and graphical 
presentations were obtained using SPSS software (23). P values < 0.05 were 





 The E48 RT-PCR assay detected E48 transcripts in bone marrow aspirates of 
56 of 139 (40%) patients. No significant differences in frequency distributions 
between the clinical characteristics of patients were seen for the presence or absence 
of a positive E48 RT-PCR result (Table 1). Of all patients, 37% presented with stage I 
or II disease, whereas 63% were staged as III or IV. The primary tumors were staged 
pT1 (16%), pT2 (33%), pT3 (34%), and pT4 (17%). In 60 of 139 (43%) patients, 
lymph node metastases were detected by histopathological examination of the neck 
dissection specimen. Extranodal spread in one or more lymph node metastases was 
noticed in 46 of 60 (77%) patients with lymph node metastases.  
The median follow-up of patients was 49 months, ranging from 5 to 87 
months. An overview of the type of events during follow-up is given in Table 2. 
Recurrent disease occurred in 24 of 139 patients, of whom 8 had a local recurrence, 3 
patients developed regional recurrent disease, and 13 patients presented with distant 
metastases during follow-up. A second primary tumor was diagnosed in 14 patients. 
In 10 patients, who presented at initial diagnosis with a clinically negative neck and 
did not undergo elective neck dissection, lymph node metastases in the neck occurred 
during follow-up and they were treated with a delayed neck dissection. None of these 





Table 1. Clinical characteristics of 139 HNSCC patients, with presence or absence of occult 
micrometastatic cells as assessed by E48 RT-PCR on bone marrow aspirates. 
 





 No. No. % No. %  
       
All patients 139 83 60 56 40  
       
Mean age 58 58  57  0.5129 a 
Sexe       
 Male 94 56 60 38 40 1.000 b 
 Female 45 27 60 18 40  
Site       
 Oral cavity 84 47 56 37 44 0.1185 b 
 Oropharynx 37 23 62 14 38  
 Hypopharynx 11 10 91 1 9  
 Larynx 7 3 43 4 57  
T stage       
 pT1 22 15 68 7 32 0.6781 b 
 pT2 46 26 57 20 43  
 pT3 48 30 62 18 38  
 pT4 23 12 52 11 48  
N stage       
 ≤ pN2a 92 57 62 35 38 0.4699 c 
 ≥ pN2b 47 26 55 21 45  
Stage       
 I/II 52 31 60 21 40 1.000 c 
 III/IV 87 52 60 35 40  
Number of lymph node 
metastases 
      
 ≤ 1 92 57 62 35 38 0. 4699 c 
 ≥ 2 47 26 55 21 45  
Extranodal spread       
 Absent 57 40 70 17 30 0.1061 c 
 Present 46 25 54 21 46  
Postoperative radiotherapy       
 Yes 96 57 59 39 41 0.9040 b 
 No 43 26 60 17 40  
 
Differences between frequency distributions were calculated with aStudent’s T-test, bChi-square, 
cFisher’s exact test. 
   
 
Table 2. Events1 during follow-up and type of recurrent disease for HNSCC patients with or 
without micrometastatic cells in bone marrow as assessed by E48 RT-PCR at initial work-up. 
 
 E48 RT-PCR  
 Negative Positive Total 
Disease free 50 31 81 
Death other cause, no recurrent disease 7 3 10 
Delayed lymph node metastases  5 5 10 
Local recurrence 3 5 8 
Regional recurrence 2 1 3 
Distant metastases 6 7 13 
Second primary tumor 10 4 14 
Total 83 56 139 
 
1 only primary events during follow-up were used for analysis 
 
 
Presence of micrometastatic cells in bone marrow, as assessed by a positive 
E48 RT-PCR result, had no significant influence on disease-free survival (Figure 2) or 
distant metastases-free survival (P = 0.1460 and P = 0.2912, respectively). Standard 
risk factors like the presence of multiple lymph node metastases and extranodal 
spread showed a significantly higher risk for development of recurrent disease (P < 
0.0001). Based on the number of lymph node metastases, we were able to define a 
good (≤ 1 lymph node metastases) and a poor prognosis (≥ 2 lymph node metastases) 
group (Figure 3). For both groups, disease-free survival was not significantly 
associated with the presence of E48 transcripts in the bone marrow, although a trend 
is observed in the poor prognosis group (P = 0.7601 and P = 0.0908, for patients with 
≤ 1 lymph node metastasis versus patients with ≥ 2 lymph node metastases, 
respectively). For patients with ≤ 1 lymph node metastasis, no significant relation 
between a positive E48 RT-PCR result and distant metastases-free survival was found 
(P = 0.4215), but for patients with ≥ 2 lymph node metastases, a positive E48 RT-
PCR result was associated with a poor distant metastases-free survival (P = 0.0210). 
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Figure 1.  E48 RT-PCR of bone marrow samples of HNSCC patients. Upper panel: a serial 
dilution of RNA from the E48 expressing cell line UM-SCC-22A, ranging from 50, 15, 5, 1.5, to 
0.5 pg, was run in parallel in each experiment as positive control. Lower panel: preparations 
without RNA template were used as negative RT-PCR control. In addition, a blotting control was 
loaded on the agarose gels consisting of dilutions of EcoRI cut plasmid DNA containing the E48 
cDNA to standardize autoradiography. RT-PCR amplification of β2-microglobulin transcripts 
were used as control for the quality of the RNA. Four representative examples of bone marrow 
aspirates of HNSCC patients are depicted; samples P1 and P3 were scored as positive for 
micrometastatic cells in bone marrow. 
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Figure 2. Kaplan-Meier life-table analysis of the disease-free survival of HNSCC patients, 
according to the presence or absence of micrometastatic cells in bone marrow as assessed by E48 
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P < 0.0001 
Months after Surgery ± Radiotherapy 
 
Number of 
patients at risk 
   
≤ 1 LNM 92 77 36 7 
≥ 2 LNM 47 14 9 3 
 
 
Figure 3. Kaplan-Meier life-table analysis of the disease-free survival of HNSCC patients, related 
to the number of lymph node metastases (LNM) as assessed by histopathological analysis of the 
neck dissection specimen. The disease-free survival of patients with ≤ 1 LNM versus patients with 
≥ 2 LNM is significantly different (P < 0.0001). 
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Months after Surgery ± Radiotherapy 
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Figure 4. Kaplan-Meier life-table analysis of the disease-free (Figure 4A) and distant metastases-
free (Figure 4B) survival of HNSCC patients, related to the presence of micrometastatic cells in 
bone marrow as assessed by E48 RT-PCR at initial work-up and to the number of lymph node 
metastases (LNM) as assessed by histopathological analysis of the neck dissection specimen. 
Figure 4A: significant difference in disease-free survival was neither observed for patients with ≤ 
1 LNM nor for patients with ≥ 2 LNM (P = 0.7601 and P = 0.0908, respectively). Figure 4B: the 
presence of micrometastatic cells in bone marrow of patients with ≥ 2 LNM correlated with a 
poor distant metastases-free survival (P = 0.0210). No significant difference in distant metastases-
free survival was observed for patients with ≤ 1 LNM (P = 0.4215). Abbreviations: LNM, lymph 
node metastasis; DM, distant metastases. 




 The E48 antigen is selectively expressed on HNSCC, and no expression has 
been observed on bone marrow cells (21,24,25). An earlier study showed no positive 
E48 RT-PCR results in bone marrow aspirates of noncancer controls (18). Therefore, 
the findings of E48 RNA transcripts in bone marrow seems a strong indicator for the 
presence of HNSCC micrometastatic cells. In this study, a positive E48 RT-PCR 
result in bone marrow was associated with a poor distant metastases-free survival for 
patients with multiple lymph node metastases at the time of primary surgery. Patients 
with multiple lymph nodes are known to be at risk for development of recurrent 
disease, and the observations of this study indicate that selection of a high-risk 
subgroup of patients, based on E48 RT-PCR findings, is feasible. In this way, the 
assay could be a useful tool to identify patients for whom adjuvant systemic treatment 
is recommended. 
 From the 83 patients with a negative E48 RT-PCR result, a total of 11 patients 
developed recurrent disease: 3 local recurrences, 2 regional recurrences, and 6 distant 
metastases. Especially the development of distant metastases should be regarded as a 
false-negative result of the E48 RT-PCR assay. An explanation for false-negative 
findings might be the heterogeneous expression of the E48 antigen. In primary 
HNSCC, immunohistochemical data showed homogeneous expression of the E48 
antigen in 70% of primary tumors, and heterogeneous expression in an additional 
19% (26). No data are available on E48 expression by micrometastatic HNSCC cells. 
False-negative findings could also be explained by sampling errors as a results of the 
low number of micrometastatic cells in bone marrow of HNSCC patients. This 
phenomenon is well known from studies with other tumor types. In breast cancer 
patients, it has been demonstrated that collection of four bone marrow samples instead 
of one increases the rate of detection of micrometastatic cells (27). It is very likely 
that the number of micrometastatic cells is even lower for HNSCC than for breast 
cancer patients, thus requiring multiple bone marrow sampling at different sites. It is 
unlikely that the sensitivity of the E48 RT-PCR assay itself is responsible for false-
negative results. The level of sensitivity of the E48 RT-PCR has been assessed in 
seeding experiment with the HNSCC cell line UM-SCC-22A, and showed 
reproducible detection of a single tumor cell in a background of around 2 x 107 white 
blood cells (18,20). 
A low specificity of the E48 RT-PCR would make the assay less suitable for 
selection of patients for adjuvant therapy. In our study, positive E48 RT-PCR results 
were observed in 31 of 81 patients who did not develop recurrent disease despite a 
sufficient median duration of follow-up. An explanation might be that these positive 
  
 
E48 RT-PCR results indeed indicate the presence of micrometastatic cells, but that 
they represent non-proliferating or dormant metastatic tumor cells (11). Postoperative 
bone marrow sampling has been suggested for identification of persistent populations 
of micrometastatic cells that might be best equipped for metastasis outgrowth, but 
initial data do not support this (28). 
The E48 RT-PCR assay detected micrometastatic cells in bone marrow 
aspirates in 40% of the patients, which is in concordance with other reports using 
immunocytochemistry on bone marrow aspirates in HNSCC patients (15,16). In these 
studies, an association between the presence of cytokeratin-positive cells and clinical 
outcome of HNSCC patients was observed. In a recent report on a smaller number of 
HNSCC patients by Partridge et al., detection of micrometastatic cells in bone 
marrow with combined immunocytochemistry and E48 RT-PCR was associated with 
a higher risk for both local and distant relapse, as well as reduced survival (28). The 
E48 RT-PCR on bone marrow aspirates in their study was positive in just 9 of 36 
patients who underwent surgery for primary HNSCC, and recurrent disease occurred 
in 7 of these 9 patients, of whom 4 developed distant metastases. The concordance 
between immunocytochemistry and E48 RT-PCR was good, and each single test 
predicted development of distant metastases. 
We conclude that presence of micrometastatic cells in bone marrow of 
HNSCC patients with ≥ 2 lymph node metastases at the time of primary surgery is 
associated with a poor distant metastases-free survival. Nevertheless, the E48 RT-
PCR assay meets limitation to select HNSCC patients for adjuvant systemic treatment 
because of a suboptimal specificity and sensitivity. Increasing the number and time 
points (postoperatively) of bone marrow aspirates might be necessary to further 
improve the sensitivity and specificity of the assay to be of value for selection of 
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Summary, Discussion and Future Perspectives 
  
 
Squamous cell carcinoma is by far the most frequently occurring malignant 
tumor in the head and neck. More than 95% of head and neck squamous cell 
carcinoma (HNSCC) originate from the mucosal linings of the oral cavity, the 
pharynx, or the larynx. The estimated worldwide incidence of HNSCC in 2000 was 
more than 551,000 cases, and more than 217,000 deaths. Initial therapy of HNSCC 
consists of surgery and/or radiotherapy. 
In the introduction (Chapter 1) of this thesis, it is outlined that for advanced 
stages III and IV HNSCC the failure rate remains high (both locoregionally and at 
distant sites), despite improvements in locoregional control, as the incidence of distant 
metastases increased. The addition of (neo)adjuvant chemotherapy to the primary 
treatment of HNSCC has resulted in improved quality of life, particularly in terms of 
organ preservation, but not in a benefit in survival of these patients. An effective 
systemic adjuvant treatment is therefore needed in order to improve survival rates. 
Among novel therapeutic approaches is the use of monoclonal antibodies (MAbs), 
able to recognize specific structures on tumor cells and, when loaded with toxic 
agents, able to kill these tumor cells. Most MAbs available nowadays, have been 
generated by hybridoma technology and were murine from origin. One of the major 
limitations of using these murine MAbs (mMAbs) in patients is immunogenicity, 
which can impede repeated administrations of mMAbs for multi-cycle treatment 
strategies. Advances in DNA technology have allowed engineering of chimeric 
(mouse/human) and humanized MAbs, which are expected to have reduced 
immunogenicity as compared to their murine counterparts.  
Radioimmunotherapy (RIT) is targeted radiotherapy using tumor-selective 
MAbs labeled with radionuclides. In this way, systemically administered radiation can 
be selectively delivered to tumor sites irrespective their location in the body while 
sparing normal tissues. The most widely used radionuclides for RIT are 131I and 90Y. 
Based on its physical properties, rhenium-186 (186Re) might be another suitable 
candidate. For 186Re, the optimal tumor diameter for curability ranges between 7.0-
12.0 mm, making it an ideal radionuclide for RIT of small tumor lesions or as 
adjuvant treatment (1). Almost all decay (91%) is by therapeutic β-emission, and a 
modest (9%) part is by low-energy γ-emission, which has excellent imaging 
properties and can be used for confirmation of tumor targeting as well as for 
dosimetric purposes. Knowledge of dosimetry in tumor and normal tissues is essential 
for an appropriate planning of RIT. In a pretherapy or scouting procedure, dosimetry 
can be used for individualization and increased accuracy of RIT. Since the most 
important dose limiting toxicity of RIT is bone marrow suppression, prediction of 
bone marrow toxicity with a pretherapy study might improve safety as well as 
efficacy. 
   
 
In the last decade, RIT has proven to be particularly effective in the treatment 
of hematological malignancies, especially non-Hodgkin’s lymphomas (NHL). The 
success of RIT in this field is due to several factors, among which are the intrinsic 
activity of the MAbs under consideration consisting of ADCC, CDC, and apoptosis 
induction upon binding to the target cell, together with the good accessibility for 
MAbs, homogeneous expression of target antigens and the high intrinsic 
radiosensitivity of lymphoma tumors and cells. Despite the encouraging results of RIT 
in patients with hematological malignancies, however, for solid tumors such results 
have not been achieved as yet. In the majority of studies, tumor-absorbed dose 
estimates have been relatively low, with few clinical responses, and bone marrow 
being the dose limiting organ in all studies. Strategies to enhance the therapeutic 
efficacy of RIT in solid tumors have been based on increasing the tumor-absorbed 
dose or reducing bone marrow toxicity. The latter can be achieved with the use of 
autologous blood or bone marrow progenitor cell transplantation. 
For RIT in HNSCC patients, the v6 domain of CD44 splice variants (CD44v6) 
might be a promising target. From earlier clinical radioimmunoscintigraphy and 
biodistribution trials it was learned that the anti-CD44v6 MAbs U36 and BIWA are 
equally well suited for selective targeting of antigen-positive primary tumors and 
lymph node metastases. In view of the fact that the future role for RIT in HNSCC 
patients is thought to be a systemic adjuvant treatment, identification of patients at 
risk for development of recurrent disease is a cornerstone. Among strategies used for 
other solid tumors to select patients at risk is detection of micrometastatic cells in 
bone marrow. For HNSCC, the E48 antigen has been proposed as a suitable marker 
antigen for the detection of micrometastatic cells in bone marrow by RT-PCR (2). 
The primary aim of this thesis was to investigate the feasibility of RIT with 
CD44v6 targeting MAbs in HNSCC patients. Besides that, the value of E48 RT-PCR 
on bone marrow aspirates for detection of micrometastatic cells was determined in 
order to identify patients at highest risk for development of recurrent HNSCC, 
particularly at distant sites. 
In a phase I radiation dose-escalation study with 186Re-cMAb U36 in HNSCC 
patients (Chapter 2), it was demonstrated that 186Re-cMAb U36 can be safely 
administered with the MTD established at 27 mCi/m2 (1.0 GBq/m2), and dose limiting 
bone marrow toxicity at 41 mCi/m2 (1.5 GBq/m2). The extent of bone marrow toxicity 
correlated with the bone marrow absorbed dose as determined from blood 
pharmacokinetics of 186Re-cMAb U36. Although pharmacokinetics of 186Re-cMAb 
U36 varied between patients, these could be predicted by 99mTc-cMAb U36, which 
was administered as a diagnostic imaging study prior to RIT. Moreover, scintigraphy 
after administration of 99mTc- and 186Re-cMAb U36 showed a similar biodistribution, 
including comparable consistent and selective uptake at tumor sites. Due to the longer 
  
 
half-life of 186Re in comparison with 99mTc, improved delineation of small lesions and 
distant metastases was observed with 186Re-cMAb U36 at later time intervals. Despite 
the use of a chimeric MAb, induction of human antibody responses was observed in 
five of thirteen patients. In patients treated at the highest radiation dose levels anti-
tumor effects were observed. 
 The administered radioactivity dose in RIT can be fixed or to some level 
individualized, based on the patients' body weight or body surface area. More 
individualized treatment protocols make use of a pretherapy imaging study to confirm 
tumor targeting and/or to estimate the whole body or bone marrow absorbed dose. 
Although this approach might increase the accuracy and safety of RIT, it requires an 
extra study and is a burden for patients. For 186Re-cMAb U36 RIT, a pretherapy 
imaging study to confirm tumor targeting is of limited value, since consistent and 
selective uptake at tumor sites was observed in the phase I trial described above. 
Moreover, the U36 antigen is expressed homogeneously in practically all HNSCC 
tumors, making the need for confirmation of tumor targeting superfluous. On the 
contrary, pharmacokinetics of cMAb U36 do vary between patients and accurate 
prediction of the pharmacokinetics and, consequently, the bone marrow absorbed dose 
of 186Re-cMAb U36 RIT, can be useful. To achieve this, a pretherapy 
pharmacokinetic study with a limited number of blood samples is to be preferred. In 
Chapter 3 a study has been described on the prediction of the total 186Re-cMAb U36 
pharmacokinetics by a limited number of blood samples from the therapy (186Re-
cMAb U36) or pretherapy (99mTc-cMAb U36) study. Moreover, it was evaluated 
whether myelotoxicity could be predicted by a limited number of blood samples from 
the therapy or pretherapy study. Population pharmacokinetic analysis by using a non-
parametric expectation algorithm and Bayesian analysis of individual patient data 
allowed accurate prediction of the 186Re-cMAb U36 clearance by limited sampling at 
4 and 72 h after administration of 186Re-cMAb U36. This prediction was less accurate 
when the 4 and 21 h blood samples from the 99mTc-cMAb U36 pretherapy study were 
used. Moreover, the development of bone marrow toxicity was equally well predicted 
by limited blood sampling in the diagnostic study with 99mTc-cMAb U36, as well as in 
the 186Re-cMAb U36 RIT study. 186Re-cMAb U36 appeared to be a better candidate 
for a pretherapy study as compared to 99mTc-cMAb U36, due to the longer physical 
half-life of 186Re. As a consequence, a single type of radioimmunoconjugate can be 
used for both pretherapy study and RIT when individualized treatment planning is 
preferred. 
 In order to reduce bone marrow toxicity and to achieve a higher MTD of 
186Re-cMAb U36, transplantation of autologous blood progenitor cells was evaluated 
in another phase I trial with 186Re-cMAb U36 (Chapter 4). Bone marrow 
transplantation or leucapheresis are the most common procedures used in clinical RIT 
   
 
to achieve this goal. Another approach is re-infusion of granulocyte colony-
stimulating factor (G-CSF) stimulated unprocessed whole blood. This procedure can 
be performed in a routine clinical setting at low cost, since it does not require 
equipment and laboratory facilities for separation and cryopreservation of the blood 
progenitor cells. The approach of 186Re-cMAb U36 RIT supported by re-infusion of 
G-CSF stimulated unprocessed whole blood was used successfully, and resulted in 
reduced bone marrow toxicity, despite a higher bone marrow absorbed dose and a 
doubling of the MTD to 54 mCi/m2 (2.0 GBq/m2). In the majority of patients as well 
as in all patients treated at the MTD-level stabilization of disease was observed. 
A drawback of cMAb U36 is the induction of human antibody responses in a 
considerable number of patients, impeding multiple administrations. This problem can 
be circumvented by the use of humanized MAbs. The anti-CD44v6 humanized MAb 
BIWA 4 was therefore evaluated in a biodistribution study with ten patients who 
underwent surgery for primary HNSCC (Chapter 5). None of the patients showed a 
human antibody response on administration of 99mTc-BIWA 4, and tumor uptake 
values were similar as previously observed for cMAb U36. In the meantime, a phase I 
radiation dose-escalation study with 186Re-BIWA 4 in HNSCC patients has been 
carried out (3). A total of 20 patients were treated in this study, and 3 of them 
received multiple administrations. The MTD was established at 50 mCi/m2 (1.85 
GBq/m2) and stabilization of disease was observed in 3 of 6 patients treated at the 
MTD-level, and in only 2 of 20 patients induction of human antibody responses was 
observed.  
In order to select HNSCC patients who might benefit from adjuvant RIT, the 
prognostic value of the presence of micrometastatic cells in bone marrow of HNSCC 
patients as assessed by E48 RT-PCR on bone marrow aspirates taken was evaluated in 
Chapter 6. In 56 of 139 (40%) HNSCC patients treated with primary surgery bone 
marrow micrometastatic cells could be detected at initial work-up. A positive E48 
RT-PCR result was not associated with poor disease-free survival. For patients with 
multiple lymph node metastases at the time of primary treatment, however, a 
significant association was found with distant metastases-free survival. 
Thus far, it can be concluded that RIT with 186Re-cMAb U36 is safe and 
tumoricidal doses can be achieved in HNSCC patients. A phase II study at the MTD 
level could be the next step for evaluation of the potential of RIT for treatment of 
HNSCC in the future. Next, the efficacy of 186Re-cMAb U36 can be evaluated in a 
phase III clinical trial with a large group of patients. If re-infusion of G-CSF 
stimulated unprocessed whole blood is used in a phase II study, a higher radioactivity 
dose can be administered, which is an attractive option in terms of clinical responses 
to be expected. Although the procedure of re-infusion of G-CSF stimulated 
unprocessed whole blood is well tolerated by patients and can be performed at 
  
 
relatively low cost, it would make the study protocol more complicated. Alternatively, 
evaluation of 186Re-BIWA 4 in a phase II study can be regarded as next attractive step 
as well. 186Re-BIWA 4 has demonstrated antitumor effects in a phase I dose escalation 
RIT study and in contrast to cMAb U36 has shown minimal development of human 
antibody responses, which allows repeated administration of this MAb (3).  
Although for complete tumor eradication the radiation dose delivered to tumor 
lesions should be increased several times, the observation of antitumor effects in 
patients with bulky disease offers opportunities for further development of RIT as an 
adjuvant treatment for HNSCC. It has been demonstrated that the uptake of MAbs in 
small volume HNSCC tumors (1 mm3) is generally about four times higher than 
uptake in larger tumors (50 mm3) (4). Moreover, most promising results in RIT of 
solid tumors have been achieved in patients with small tumor lesions or minimal 
residual disease (5-7). Although not the primary aim of a phase I study, clinical 
responses were observed after RIT with 186Re-cMAb U36, and when re-infusion of G-
CSF stimulated unprocessed whole blood was used, delivery of a two times higher 
radiation dose to the tumor resulted in stabilization of disease in the majority of 
patients. Selection of HNSCC patients for systemic adjuvant therapy could be based 
on the extent of lymph node metastases in the neck, particularly on the number of 
lymph node metastases, since it has been shown that for these patients the incidence 
of distant metastases is increased (8). The risk for development of distant metastases 
in this subgroup of HNSCC patients is even higher when micrometastatic cells are 
present in bone marrow as assessed by E48 RT-PCR on bone marrow aspirates at 
initial work-up. Based on aforementioned data, and pending confirmation in a phase II 
clinical trial, we think that RIT might become a realistic option for adjuvant therapy 
of minimal residual HNSCC, of which the efficacy should be assessed in a large 
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Samenvatting, Discussie en Toekomst 
 
Het plaveiselcelcarcinoom is veruit het meest voorkomende maligne 
tumortype in het hoofd-halsgebied. Meer dan 95% van de hoofd-hals 
plaveiselcelcarcinomen (HHPCC) ontstaan in het slijmvlies van mondholte, keelholte 
en strottenhoofd. De geschatte wereldwijde incidentie van HHPCC in 2000 was meer 
dan 551.000 gevallen en meer dan 217.000 patiënten overleden aan de ziekte. Meestal 
wordt HHPCC in eerste instantie behandeld met chirurgie en/of radiotherapie. 
In de introductie (Hoofdstuk 1) van dit proefschrift wordt beschreven dat na 
behandeling van gevorderde HHPCC (stadia III en IV) een hoog percentage recidief 
ziekte optreedt, zowel locoregionale recidieven als metastasen op afstand. Ondanks 
verbeteringen in de locoregionale behandeling van HHPCC met radiotherapie en 
chirurgie is de overleving van patiënten de afgelopen 25 jaar nauwelijks verbeterd. 
Dit komt met name door een toename in de incidentie van metastasen op afstand. 
Toevoeging van chemotherapie aan initiële radiotherapie heeft weliswaar verbetering 
gebracht in de kwaliteit van leven met name middels zogenaamde “organ 
preservation”, maar tot op heden is geen verbetering in overleving bereikt.  
Het gebruik van monoklonale antilichamen (MAbs) vormt een nieuwe 
mogelijkheid voor therapie. MAbs zijn in staat om specifieke structuren op 
tumorcellen te herkennen en kunnen deze vernietigen als aan het MAb een toxische 
stof gekoppeld is. De meeste MAbs die heden beschikbaar zijn werden met behulp 
van de hybridoma techniek ontwikkeld en zijn van muizen origine. Eén van de 
belangrijkste nadelen van het gebruik van muizen MAbs is immunogeniciteit, hetgeen 
herhaalde toediening in de weg kan staan. Door het gebruik van moderne DNA 
technologie is het mogelijk gebleken om chimere (muis/mens) en humane MAbs te 
ontwikkelen, welke over het algemeen minder immunogeen zijn. 
Radioimmunotherapie (RIT) maakt gebruik van tumorselectieve MAbs 
waaraan radionucliden zijn gekoppeld. Aldus kan systemisch toegediende 
radioactiviteit selectief worden afgeleverd bij tumorcellen ongeacht hun lokalisatie in 
het lichaam. De meest gebruikte radionucliden voor RIT zijn 131I en 90Y. Rhenium-
186 (186Re) is op basis van zijn fysische eigenschappen een andere geschikte 
kandidaat. De optimale diameter van een tumor voor curatie met 186Re RIT bedraagt 
7.0-12.0 mm, hetgeen 186Re tot een ideaal radionuclide maakt voor RIT van kleine 
tumoren (1). Het grootste deel van de straling die vrijkomt bij verval van 186Re is β-
straling (91%) met daarnaast een klein gedeelte lage energie γ-straling (9%), dat 
ideale eigenschappen heeft voor beeldvorming middels scintigrafie en zo gebruikt kan 
worden om informatie te verkrijgen over tumoropname en dosisafgifte. Dosimetrie 
geeft inzicht in de afgifte van straling aan tumor en normale weefsels. Als een 
   
 
dergelijke diagnostische studie voorafgaand aan RIT wordt uitgevoerd spreekt men 
van een "pretherapie" of "scouting" studie. Pretherapie studies kunnen worden 
gebruikt voor zorgvuldige planning van RIT voor individuele patiënten. Omdat het 
beenmerg over het algemeen het orgaan is waar de meeste toxiciteit zal ontstaan 
(dosislimiterend orgaan), kan het voorspellen van de beenmergtoxiciteit met behulp 
van een pretherapie studie zowel de veiligheid als de effectiviteit verbeteren.   
RIT is de laatste 10 jaar het meest succesvol gebleken bij de behandeling van 
lymfomen, in het bijzonder non-Hodgkin’s lymfomen. Dit succes kan toegeschreven 
worden aan de intrinsieke activiteit van MAbs bestaande uit “antibody-dependent 
cellular cytotoxicity” (ADCC), “complement-dependent cytotoxicity” (CDC) en 
apoptose inductie na binding aan de tumorcel. Daarnaast spelen de goede 
toegankelijkheid van lymfomen voor MAbs, homogene expressie van de target 
antigenen en de intrinsieke gevoeligheid van lymfomen voor straling een belangrijke 
rol. RIT is helaas minder succesvol gebleken bij de behandeling van solide tumoren. 
In het merendeel van de studies was de stralingsdosis die aan de tumor afgegeven kon 
worden laag, met als gevolg dat het therapeutisch effect gering was. Strategieën om 
het therapeutisch effect bij solide tumoren te vergroten zijn gebaseerd op het verhogen 
van de stralingsdosis in de tumor en het verminderen ervan in het beenmerg. Dit 
laatste kan bereikt worden door gebruik te maken van beenmerg- of 
stamceltransplantatie. 
Een veelbelovend target antigeen voor RIT van HHPCC is het v6 domein van 
het CD44 membraan eiwit (CD44v6). Eerdere klinische radioimmunoscintigrafie en 
biodistributie studies hebben laten zien dat de anti-CD44v6 MAbs U36 en BIWA in 
gelijke mate selectieve ophoping in primaire HHPCC tumoren en lymfkliermetastasen 
vertonen. Vanwege het feit dat de toekomst van RIT waarschijnlijk vooral zal liggen 
in het gebruik als adjuvante systemische behandeling, is het van belang dat patiënten 
met het hoogste risico op het ontwikkelen van recidief ziekte vooraf geselecteerd 
kunnen worden. Eén van de manieren om patiënten met een verhoogd risico te 
identificeren is door het aantonen van tumorcellen in het beenmerg. Het zogenaamde 
E48 antigen kan van waarde zijn voor het opsporen van deze cellen omdat dit 
antigeen selectief tot expressie komt in HHPCC en gedetecteerd kan worden met de 
zogenaamde "reverse transcriptase polymerase chain reaction" (RT-PCR) techniek 
(2). 
  Het primaire doel van het onderzoek zoals beschreven in dit proefschrift was 
het evalueren van RIT met anti-CD44v6 MAbs bij HHPCC patiënten. Daarnaast werd 
de waarde van het opsporen van tumorcellen in het beenmerg van HHPCC patiënten 
middels E48 RT-PCR voor de bepaling van het risico op recidief ziekte, met name 
metastasen op afstand, onderzocht. 
  
 
In een fase I dosisescalatie RIT studie bij HHPCC patiënten (hoofdstuk 2) 
werd aangetoond dat 186Re-cMAb U36 veilig is. De maximaal tolereerbare dosis 
(MTD) werd vastgesteld op 27 mCi/m2 (1.0 GBq/m2) en dosislimiterende 
beenmergtoxiciteit werd waargenomen bij 41 mCi/m2 (1.5 GBq/m2). De mate van 
beenmergtoxiciteit bleek direct gecorreleerd te zijn aan de geabsorbeerde 
beenmergdosis, welke bepaald werd aan de hand van de farmacokinetiek van 186Re-
cMAb U36 in bloed. Er trad variatie op in farmacokinetiek van 186Re-cMAb U36 
tussen patiënten onderling, maar de individuele kinetiek kon worden voorspeld uit 
pretherapie studies met 99mTc-cMAb U36. Bovendien liet scintigrafie na toediening 
van 99mTc- en 186Re-cMAb U36 een vergelijkbare biodistributie zien, waaronder 
consistente en selectieve ophoping van deze conjugaten in de tumor. Tengevolge van 
de langere halfwaardetijd van 186Re ten opzichte van 99mTc, en daardoor de 
mogelijkheid voor beeldvorming op latere tijdstippen, werden met 186Re-cMAb U36 
kleine tumoren en afstandsmetastasen duidelijker afgebeeld. Ondanks het gebruik van 
een chimeer antilichaam werd toch nog bij vijf van de dertien patiënten een humane-
antichimeer-antilichaam reactie tegen cMAb U36 waargenomen. Bij patiënten die op 
het hoogste dosisniveau werden behandeld werd de tumorgroei tot stilstand gebracht. 
 De toegediende radioactiviteitdosis voor RIT kan een vaste dosis zijn, of een 
dosis die gebaseerd is op het gewicht of de lichaamsoppervlakte van de patiënt. Een 
meer geïndividualiseerde behandeling kan uitgevoerd worden met behulp van een 
pretherapie studie, waarbij de behandeldosis wordt vastgesteld op basis van middels 
beeldvorming waargenomen tumorophoping van het conjugaat en de stralingsafgifte 
op het totale lichaam of op het beenmerg. Ofschoon met zo'n pretherapie studie de 
RIT dosis nauwkeuriger bepaald kan worden, betekent het een extra onderzoek en dus 
een grotere belasting voor de patiënt. Een dergelijke pretherapie studie is in het geval 
van 186Re-cMAb U36 RIT niet echt noodzakelijk, omdat tot nu toe bij alle patiënten 
een consistente en selectieve tumor opname werd gezien. De consistente tumor 
opname heeft onder andere te maken met het feit dat het U36 antigeen in vrijwel alle 
HHPCC tumoren homogeen tot expressie wordt gebracht. De farmacokinetiek van 
186Re-cMAb U36 varieert daarentegen wel tussen patiënten onderling met als gevolg 
verschil in beenmergdosis. Daarom lijkt een pretherapie studie waarbij uitsluitend 
naar de farmacokinetiek wordt gekeken eventueel wel nuttig. Idealiter zou de 
farmacokinetiek van 186Re-cMAb U36 aan de hand van een beperkt aantal 
bloedmonsters in een pretherapie studie voorspeld moeten kunnen worden, waardoor 
de belasting voor de patiënt minimaal is. In hoofdstuk 3 wordt een studie beschreven, 
waarin werd getracht de totale 186Re-cMAb U36 farmacokinetiek te voorspellen aan 
de hand van een beperkt aantal bloedmonsters voor zowel de therapie (186Re-cMAb 
U36) als pretherapie studie (99mTc-cMAb U36). Tevens werd nagegaan in hoeverre de 
beenmergtoxiciteit met een beperkt aantal bloedmonsters uit de therapie of 
   
 
pretherapie studie betrouwbaar te voorspellen is. De 186Re-cMAb U36 
farmacokinetiek kon nauwkeurig voorspeld worden op basis van slechts twee 
bloedmonsters genomen op 4 en 72 uur na toediening van 186Re-cMAb U36, door het 
gebruik van een non-parametrisch verwachtingsalgoritme en analyse volgens Bayes. 
Deze voorspelling was minder nauwkeurig als hiervoor de 4 en 21 uur bloedmonsters 
van de 99mTc-cMAb U36 pretherapie studie genomen werden. De mate van 
beenmergtoxiciteit kon bovendien evengoed worden voorspeld door 99mTc-cMAb U36 
en 186Re-cMAb U36. 186Re-cMAb U36 bleek echter een betere kandidaat voor het 
voorspellen van de farmacokinetiek vanwege de langere halfwaardetijd van 186Re. Dit 
laatste betekent dat, indien individuele therapie voorspelling wenselijk wordt geacht, 
voor pretherapie studie en RIT een zelfde conjugaat gebruikt kan worden. 
  In een andere fase I studie met 186Re-cMAb U36 werd het gebruik van re-
infusie van "granulocyte colony-stimulating factor" (G-CSF) gestimuleerd autoloog 
volbloed geëvalueerd om zo de beenmergtoxiciteit te verminderen en de MTD te 
kunnen verhogen (Hoofdstuk 4). Voor dit doel wordt in het algemeen 
beenmergtransplantatie of leucaferese aangewend. Re-infusie van gestimuleerd 
autoloog volbloed is echter een interessant alternatief, omdat het in vrijwel ieder 
ziekenhuis toegepast kan worden en relatief goedkoop is. Omdat bij deze techniek 
geen beenmergstamcellen gezuiverd en opgeslagen worden, zijn geen dure 
laboratoriumfaciliteiten nodig. Ondersteuning van 186Re-cMAb U36 RIT door re-
infusie van G-CSF gestimuleerd autoloog volbloed bleek succesvol en de 
beenmergtoxiciteit kon aanzienlijk worden verminderd, waardoor een verdubbeling 
van de MTD tot 54 mCi/m2 (2.0 GBq/m2) kon worden bereikt. Bij de meerderheid van 
de patiënten, en bij alle patiënten die op het MTD niveau werden behandeld, werd 
stabilisatie van de ziekte waargenomen. 
Een nadeel van het gebruik van cMAb U36 is het optreden van humane-
antichimeer-antilichaam reacties in een aanzienlijk gedeelte van de patiënten, hetgeen 
herhaalde toediening van cMAb U36 in de weg staat. Deze beperking wordt over het 
algemeen minder waargenomen als gehumaniseerde MAbs gebruikt worden. BIWA 4 
is een gehumaniseerd anti-CD44v6 MAb dat werd geëvalueerd in een biodistributie 
studie met tien patiënten die werden geopereerd vanwege een primair HHPCC 
(Hoofdstuk 5). Er werden geen humane antilichaam reacties waargenomen na 
toediening van 99mTc-BIWA 4 en de opname van het MAb in tumor en normale 
weefsels bleek vergelijkbaar met die van cMAb U36. Inmiddels is ook een fase I RIT 
studie met 186Re-BIWA 4 in 20 HHPCC patiënten uitgevoerd (3), waarbij drie 
patiënten het BIWA 4 meer keren kregen toegediend. Humane antilichaam reacties 
traden slechts bij twee patiënten op. De MTD bleek 50 mCi/m2 (1.85 GBq/m2) te zijn 
en stabilisatie van de ziekte werd gezien in drie van de zes patiënten die werden 
behandeld op het niveau van de MTD.  
  
 
De waarde van het opsporen van tumorcellen in het beenmerg van HHPCC 
patiënten middels E48 RT-PCR voor de bepaling van het risico op recidief ziekte, met 
name metastasen op afstand, is beschreven in hoofdstuk 6. In 56 van de 139 (40%) 
patiënten die werden geopereerd vanwege een primair HHPCC konden preoperatief 
tumorcellen in het beenmerg worden gedetecteerd. Een positieve E48 RT-PCR test 
bleek niet gecorreleerd met ziekte-vrije overleving. Er werd wel een significant 
verband gevonden tussen een positieve E48 RT-PCR test en het optreden van 
metastasen op afstand voor patiënten die bij operatie twee of meer tumorpositieve 
lymfklieren in de hals hadden. 
Uit de studies beschreven in dit proefschrift kan worden geconcludeerd dat 
RIT met 186Re-cMAb U36 veilig is en dat bovendien klinische responsen werden 
waargenomen bij HHPCC patiënten. De volgende stap zou een fase II studie kunnen 
zijn waarin de effectiviteit wordt vastgesteld in een groter aantal patiënten, behandeld 
op het niveau van de MTD. Vervolgens kan de effectiviteit van 186Re-cMAb U36 als 
adjuvante therapie in een grote groep HHPCC patiënten (fase III) worden onderzocht. 
Door toepassing van re-infusie van G-CSF gestimuleerd autoloog volbloed in een fase 
II studie, kan een hogere MTD worden gebruikt en mag een beter klinisch resultaat 
worden verwacht. Ofschoon re-infusie van G-CSF gestimuleerd autoloog volbloed 
relatief eenvoudig is uit te voeren en de belasting voor patiënten aanvaardbaar is, zal 
het RIT studieschema uitgebreider worden. Als alternatieve fase II studie kan worden 
gedacht aan BIWA 4, dat als 186Re-BIWA 4 in een fase I studie stabilisatie van de 
ziekte tot gevolg had bij een aantal patiënten. Bovendien is BIWA 4 nauwelijks 
immunogeen gebleken in tegenstelling tot cMAb U36, hetgeen herhaalde 
toedieningen mogelijk maakt (3).  
Voor complete en langdurige responsen dient de stralingsafgifte op de tumor 
bij RIT nog enkele malen hoger te worden dan nu het geval is. Het feit dat antitumor 
effecten werden waargenomen in de beschreven studies is gunstig, omdat het hier 
over het algemeen patiënten betrof met grote tumoren of metastasen. Het is bekend 
dat opname van MAbs in kleine HHPCC tumoren (± 1 mm3) gemiddeld vier keer 
hoger is dan opname in grote tumoren (± 50 mm3) (4). Bovendien hebben RIT studies 
bij patiënten met solide tumoren de beste resultaten laten zien wanneer het patiënten 
betrof met kleine tumoren of minimale residuele ziekte (5-7). In de studie met re-
infusie van G-CSF gestimuleerd autoloog volbloed (hoofdstuk 4) werd aangetoond 
dat een verdubbeling van de stralingsafgifte aan de tumor resulteerde in stabilisatie 
van de ziekte in het merendeel van de patiënten. De selectie van patiënten voor 
adjuvante RIT kan gebaseerd zijn op klinische criteria zoals de aanwezigheid van 
multipele tumorpositieve lymfklieren in de hals, omdat deze patiënten een grote kans 
op recidief ziekte, in het bijzonder metastasen op afstand, hebben (8). Ofschoon de 
E48 RT-PCR test op beenmerg een subgroep van HHPCC patiënten kan aanwijzen 
   
 
met een verhoogd risico op het ontwikkelen van metastasen op afstand, lijkt verder 
onderzoek in de toekomst noodzakelijk om tot een test te komen die gebruikt kan 
worden voor de selectie van HHPCC patiënten voor wie adjuvante therapie in 
aanvulling op operatie en/of bestraling wenselijk is. Gebaseerd op de bovenstaande 
gegevens en in afwachting van de resultaten van een fase II studie, lijkt ons verdere 
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